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SUMMARY
1) The pharmacological actions of adenine and uracil nucleotides are reviewed. The 
current knowledge of purinoceptor subtypes involved in mediating the actions of 
these nucleotides and related analogues are summarised and their relevance in 
smooth muscle preparations discussed.
2) The receptor(s) mediating contraction at which adenosine 5'-triphosphate (ATP) 
and related analogues, and uridine 5-triphosphate (UTP) act was studied in the rat 
colon muscularis mucosae.
2a) ATP and adenosine have been shown to contract the rat colon muscularis 
mucosae, and the receptors at which they act have been classified as P2Y- and Aj- 
purinoceptors respectively. UTP also contracts this tissue, and desensitisation and 
antagonism by suramin was used to investigate the receptors by which it acts, in the 
light of suggestions that specific pyrimidinoceptors may exist for UTP, or that P21J- 
purinoceptors exist which are responsive to both ATP and UTP but not to some ATP 
analogues such as 2-methylthioadenosine 5 -triphosphate (2-MeSATP).
2b) ATP, UTP and adenosine each contracted the rat colon muscularis mucosae in a 
concentration-dependent manner over the concentration range 0.3-300pM, although 
maximal responses to ATP and UTP were not obtained. ATP was approximately four 
times as potent as UTP and approximately equipotent with adenosine although the 
maximal response to adenosine appeared to be less than to ATP or UTP.
2c) Desensitisation of the tissue with ATP (200jiM) given immediately before each 
concentration of the agonists reduced subsequent contractions induced by ATP itself
and also to UTP, but did not significantly reduce contractions induced by adenosine. 
Desensitisation of the tissue with UTP (200pM) also reduced contractions induced 
by ATP and UTP but not by adenosine, whereas desensitisation with adenosine 
(200|iM) reduced contractions induced by adenosine itself but not by ATP or UTP.
2d) Desensitisation of the tissue with 2-MeSATP (200jiM), which is a more potent 
agonist than ATP at P2Y-purinoceptors, greatly reduced the responses to ATP and to 
UTP, but had no effect on responses induced by adenosine. Attempts to desensitize 
the tissue with adenosine 5'-(a,p-methylene)triphosphonate (AMPCPP), which is a 
more potent agonist than ATP at P2x-purinoceptors but is less potent at P2Y- 
purinoceptors, were unsuccessful.
2e) The non-selective P2 antagonist suramin (lOOpM), inhibited contractions 
induced by both ATP and UTP to a similar extent, shifting their concentration- 
response curves to the right.
2f) ATP and UTP induced contractions were observed in neonatal (2 and 5 day old) 
and adult rat colon muscularis mucosae, and at each of these ages ATP and UTP 
showed a similar potency relative to each other.
2g) Equal antagonism of ATP and UTP by suramin suggests that ATP and UTP are 
acting at the same receptor in the rat colon muscularis mucosae. Furthermore, these 
results show that cross-desensitisation to ATP and UTP occurred and was specific 
for these agonists rather than being due to a general decrease in the ability of the 
muscle to contract. This further implies that ATP and UTP act at the same receptor, 
which does not support the existence of specific pyrimidinoceptors but which could 
be taken as evidence for the existence of a P2xj-purinoceptor on this tissue. However,
the ability of 2-MeSATP, which is inactive at the P2xj-purinoceptor, also selectively 
to desensitize this receptor indicates instead that ATP and UTP are both acting at a 
purinoceptor of the P2Y subtype in this tissue. An alternative explanation of this data 
could be heterologous desensitisation of both P2Y- and P2u-purinoceptors.
3) The receptors at which ATP and related analogues, and uridine 5'-triphosphate 
(UTP) act was studied in the rat whole duodenum.
3a) Previous studies have shown that the rat duodenum relaxes to adenosine and 
ATP via Pi - and P2Y-parinoceptors respectively, but in preliminary studies UTP was 
found to contract this tissue. Suramin and a number of nucleotides were therefore 
used to investigate this response further.
3b) 2-MeSATP, ATP, UTP, adenosine 5'-0-(3-thiotriphosphate) (ATP-y-S), 
adenosine 5-diphosphate (ADP), uridine 5'-diphosphate (UDP) and guanosine 5- 
triphosphate (GTP) each relaxed the duodenum, with an agonist potency order of 
2-MeSATP>ATP=ADP>AMPCPP=ATP-y-S»GTP»UTP=UDP, consistent with 
the presence of a P2Y-purinoceptor mediating relaxation.
3c) ATP-y-S, UTP and UDP each contracted the duodenum with an agonist potency 
order of ATP-y-S>UTP>UDP, although maximal responses to these agonists were 
not obtained at a concentration of 267|xM (ATP-y-S) and 300pM (UTP and UDP). 
No contractions were observed with any of the other agonists at concentrations of up 
to 300pM.
3d) Indomethacin (25pM) did not inhibit the contractions induced by UTP, 
indicating that they were not mediated via production of prostaglandins.
3e) Suramin (lOOpM and ImM) inhibited relaxations induced by ATP, shifting the 
concentration-response curve to the right, with the maximal response to ATP being 
decreased by the higher concentration of suramin (ImM). Suramin (ImM) inhibited 
relaxations induced by ATP-y-S, shifting the concentration-response curve to the 
right, and completely abolished contractions induced by ATP-y-S. In contrast, 
suramin (100[iM and ImM) had no effect on contractions induced by UTP. 
Contractions induced by UTP were, however, less sustained in the presence of 
suramin, which also affected the basal tone of some tissues when precontracted with 
carbachol (0.1 pM). In the presence of suramin (ImM), no contractions to ATP were 
observed.
3f) These results confirm that in the rat duodenum there is a P2Y-purinoceptor that 
mediates relaxation in response to a number of purine nucleotides, and at which the 
pyrimidine nucleotides UTP and UDP are almost inactive. There are also receptors at 
which UTP and ATP-y-S act to cause contraction. Suramin discriminates between 
the contractile effects of these two agonists, which may indicate the presence of a 
suramin-insensitive pyrimidinoceptor as well as a suramin-sensitive receptor for 
ATP-y-S. An alternative explanation is that the differential effects of suramin are via 
its action as an antagonist in addition to its action as an ectonucleotidase inhibitor.
4) In the rat colon the response to adenosine and to nucleotides on the longitudinal 
muscle and the muscularis mucosae are different, and it seemed likely that in the 
duodenum different receptors might also be located on the different muscle layers. 
The longitudinal muscle and the muscularis mucosae of the rat duodenum were thus 
investigated to determine which P2 receptors were present on each muscle layer, by 
the use of suramin and a number of nucleotides.
4a) 2-MeSATP, ATP, ATP-y-S and AMPCPP each relaxed the longitudinal muscle, 
with an agonist potency order of 2-MeSATP>ATP=ATP-y-S>AMPCPP, while UTP 
and UDP were not observed to elicit relaxation. This indicates the presence of a 
relaxant P2Y-purinoceptor on the longitudinal muscle. The longitudinal muscle did 
not contract to any of the agonists at concentrations of 300pM, apart from ATP-y-S 
which caused very weak contractions.
4b) ATP-y-S, adenosine 5'-(a,p-methylene)diphosphonate (AMPCP), AMPCPP, 
ATP, UTP, ADP, UDP and 2-MeSATP each contracted the muscularis mucosae with 
an agonist potency order of ATP-y-S>AMPCP>AMPCPP=ATP=UTP=ADP=UDP» 
2-MeSATP, although maximal responses were not obtained at concentrations of 
300pM. The muscularis mucosae did not relax to any of the agonists at 
concentrations of 300pM.
4c) Suramin (ImM) inhibited relaxations induced by ATP on the longitudinal 
muscle, shifting the relaxation concentration-response curve to the right. This further 
supports the presence of a P2Y-purinoceptor on this muscle layer. Suramin (ImM) 
inhibited contractions induced by AMPCPP, but not those induced by ATP, UTP or 
ATP-y-S in the muscularis mucosae. Desensitisation of the muscularis mucosae was 
seen with AMPCPP, but not with UTP or ATP-y-S, and no cross-desensitisation 
between AMPCPP and UTP or ATP-y-S was observed. This suggests there are two 
receptors which mediate contraction on the rat duodenum muscularis mucosae, one 
suramin-sensitive and the other suramin-insensitive.
4d) These results show that there is a P2Y"Purinoceptor which mediates relaxation in 
the rat duodenum longitudinal muscle. They also show that there is a contraction- 
mediating suramin-sensitive receptor on the rat duodenum muscularis mucosae
which is desensitized by AMPCPP, and thus is probably of the P2X subtype. In 
addition, there is a contraction-mediating suramin-insensitive receptor on the rat 
duodenum muscularis mucosae which is not desensitized by UTP or ATP-y-S, and at 
which ATP and UTP show equal potency, and is thus probably of the P2U subtype.
5) The rat duodenum has been shown to dephosphoiylate ATP rapidly via 
ectonucleotidases and adenosine deaminase. Degradation of nucleotides by the rat 
duodenum muscularis mucosae was therefore investigated to determine if inhibition 
by suramin of nucleotide degradation could explain differential antagonism by 
suramin of the nucleotides in the muscularis mucosae.
5a) ATP was rapidly degraded by the muscularis mucosae to ADP, adenosine 5'- 
monophosphate (AMP) and inosine, with no adenosine being detected. A similar rate 
of degradation was seen for UTP with UDP, uridine 5'-monophosphate (UMP) and 
uridine being formed and for 2-MeSATP with 2-methylthioadenosine 5'-diphosphate 
(2-MeSADP), 2-methylthioadenosine 5'-monophosphate (2-MeSAMP) and 
2-methylthioadenosine being formed. AMPCPP and ATP-y-S were both degraded 
more slowly than ATP, UTP and 2-MeSATP, AMPCPP being degraded to AMPCP, 
and ATP-y-S to ADP, AMP and inosine. Suramin (ImM), did not significantly affect 
the rate and pattern of degradation of these nucleotides, apart from AMPCPP which 
was degraded slightly more slowly in the presence of suramin.
5b) Buffer in which the muscularis mucosae had been incubated for 45 minutes also 
degraded ATP to ADP, AMP and inosine, and UTP to UDP, UMP and uridine but at 
a significantly slower rate, indicating that degradative enzymes were released into 
the buffer. In the presence of suramin (ImM) the rate of degradation of both ATP 
and UTP was significantly slower.
5c) The rat duodenum muscularis mucosae therefore contains ectonucleotidases and 
adenosine deaminase, which rapidly degrade nucleotides, although the inhibition by 
suramin of this degradation is unlikely to explain differential antagonism by suramin 
of the nucleotides in the muscularis mucosae.
6 ) The results of this thesis therefore show that UTP is active in both the rat colon 
and duodenum, and acts at P2 -purinoceptors like ATP, rather than at separate 
pyrimidinoceptors. In the rat colon muscularis mucosae contractions to ATP and 
UTP appear to be mediated by a common receptor which is probably of the P2Y 
subtype, whereas in the rat duodenum muscularis mucosae contractions are mediated 
by a P2u-purinoceptor. There is also a contraction-mediating P2x-purinoceptor in the 
rat duodenum muscularis mucosae. In contrast, the rat duodenum longitudinal 
muscle contains a relaxation-mediating P2Y-purinoceptor at which ATP but not UTP 
acts, and which therefore shows a differential location of the purinoceptors on the 
two muscle layers in relation to the response (contraction or relaxation) which each 
muscle layer is associated with. However, in the rat whole duodenum in which there 
are present both the opposing relaxation-mediating (longitudinal muscle) and 
contraction-mediating (muscularis mucosae) P2-purinoceptors, relaxant responses to 
ATP predominate (via the P2Y-purinoceptor), whilst UTP which predominantly acts 
at the P2U“Purinoceptor induces contraction.
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CHAPTER 1: INTRODUCTION
20
1.1. GENERAL INTRODUCTION
It has been recognised for many years that nucleotides such as adenosine 5- 
triphosphate (ATP) perform essential roles intracellularly which include energy 
metabolism, nucleic acid synthesis and enzyme regulation. The synthesis and 
conservation of ATP by cells involves complex mechanisms requiring the 
expenditure of metabolic energy (Arch & Newsholme, 1978; Traut, 1994), and thus 
the concept that ATP could be specifically released from cells to perform 
extracellular functions was until more recently a controversial area, but one which is 
now widely accepted. In fact adenine nucleosides and nucleotides have now been 
shown to exert physiological and pharmacological actions extracellularly on a wide 
range of cells and tissues which include the nervous, cardiovascular, respiratory, 
gastrointestinal, urinogenital and immune systems (Williams, 1987; White, 1988; 
Olsson & Pearson, 1990; Dubyak & El-Moatassim, 1993).
The first evidence to suggest an extracellular action of adenosine and adenine 
nucleotides came in 1929 from work by Druiy & Szent-Gyorgyi. Extracts from heart 
muscle, brain, kidney and spleen were intravenously injected into whole animals, 
and the resultant effects on the mammalian heart investigated. These extracts were 
observed to induce bradycardia and reduce the contractile force of the heart, and also 
to cause dilation of coronary vessels and lower arterial pressure (due in part to 
cardiac slowing and in part to general arterial dilation). Adenylic acid (adenosine 5- 
monophosphate; AMP) was extracted and identified as the active compound 
responsible for these effects. However, AMP readily undergoes dephosphorylation to 
adenosine, and adenosine extracted from yeast was also observed to produce 
identical effects when injected intravenously into whole animals (Druiy & Szent- 
Gyorgyi, 1929).
21
The physiological importance of adenosine was not realised until some decades later 
when it was proposed to be a metabolic regulator. It was suggested that under 
hypoxic conditions adenosine was released and acted to reduce metabolic demand 
and/or increase oxygen availability via reducing heart rate and inducing coronaiy 
vasodilation. This was based on the observations that the degradation products of 
adenosine, (inosine and hypoxanthine), were found in the perfusate of isolated cat 
heart and in the coronaiy sinus blood of dog heart that had been subjected to severe 
hypoxia (Berne, 1963). The physiological importance of adenosine was further 
strengthened in 1970 with the suggestion of a neuromodulatory role from work in 
guinea-pig cerebral cortex slices, in which adenosine was observed to increase cyclic 
adenosine 3’,5'-phosphate (cAMP) accumulation, and also that this adenosine- 
induced second-messenger response was blocked by methylxanthines (Sattin & Rail, 
1970).
The actions of adenosine are not confined to the cardiovascular system, but have also 
been implicated in the modulation of transmitter release in the central nervous 
system. Adenosine has been shown to inhibit the release of various neurotransmitters 
including acetylcholine, noradrenaline, dopamine, y-aminobutyric acid (GABA), 
5-hydroxytryptamine (5-HT), glutamate and aspartate (Fredholm & Hedqvist, 1980; 
Phillis & Wu, 1981; Stone, 1981; Williams, 1984; Fredholm, 1995a, b).
In the 1950’s, it was observed that vasodilation due to antidromic stimulation of 
sensory nerves supplying the rabbit ear arteiy was similar in time course to that 
caused by arterial injection of ATP (Holton & Holton, 1954). Further work showed 
that following antidromic stimulation of the great auricular nerve, which resulted in 
vasodilation of the rabbit ear vessels, there was release of ATP (Holton, 1959). 
However, the suggestion that ATP could possibly be a neurotransmitter was not
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widely accepted, and it was assumed that observations such as these could be 
explained within the classical framework of adrenergic and cholinergic transmitters.
The physiological importance of ATP emerged from the realisation that the 
autonomic nervous system did not comprise entirely of cholinergic and adrenergic 
nerves, and that ATP had a role as a neurotransmitter. In the 1960's it was observed 
that intramural nerve stimulation of the guinea-pig taenia caeci produced a relaxation 
that was resistant to blockade by the cholinergic neurone blocker atropine 
(Bumstock et a i, 1963) and the adrenergic neurone blocker guanethidine (Bumstock 
et al., 1964). It was soon recognised that nerve stimulation gave rise to responses that 
were resistant to both adrenergic and cholinergic antagonists in a large number of 
smooth muscle preparations, and thus these nerves were initially termed "non- 
adrenergic and non-cholinergic (NANC)" (Bumstock, 1969). Along with other 
observations, such as ATP produced either similar or identical responses in terms of 
type and time course as for the stimulation of NANC nerves in gastrointestinal and 
bladder preparations from a number of animals (Bumstock, 1972), led to the 
proposal that the active substance released from at least some NANC nerves was the 
purine nucleotide ATP, and the term "purinergic" was tentatively used for these 
NANC nerves, (Bumstock, 1971; 1972). In addition to ATP a number of other 
substances have also been shown to be putative neurotransmitters at NANC nerves, 
which include dopamine, 5-HT and substance P (Bumstock, 1981).
1.2. SOURCES AND FATE OF ADENOSINE
Adenosine can be produced by virtually any cell and does not appear to be stored in 
exocytotic vesicles, but rather is produced on demand much like the prostaglandins 
and leukotrienes. Intracellular concentrations of adenosine are normally very low but
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increase during periods of ischemia, hypoxia or high energy demand by the cell. 
Adenosine has an extracellular half life of a few seconds indicating a localised but 
wider sphere of action than a single synapse, and it has thus been suggested that 
adenosine acts as a local hormone rather than as a neurotransmitter or circulating 
hormone (Bruns, 1990).
There are two major routes for the synthesis of intracellular adenosine. This may be 
from the dephosphorylation of AMP by cytosolic 5-nucleotidase, with AMP being 
generated as a result of energy consuming reactions in which adenosine 
triphosphatases dephosphorylate ATP to adenosine 5'-diphosphate (ADP), which can 
then be converted to AMP by adenylate kinase. Alternatively adenosine may be 
formed from the catabolism of adenosylhomocysteine by adenosylhomocysteine 
hydrolase. Once formed adenosine can be utilized in several ways. It may be 
transported out of the cell and elicit physiological responses by acting at Pj- 
purinoceptors (see section 1.4.1.). Alternatively, it may be phosphoiylated back to 
AMP either by adenosine kinase or via the purine salvage pathway, or may undergo 
degradation to inosine, hypoxanthine and uric acid by adenosine deaminase, purine 
nucleoside phosphoiylase and xanthine dehydrogenase respectively. There are in 
addition a number of other minor pathways for the synthesis and utilisation of 
adenosine (Arch & Newsholme, 1978; Phillis & Wu, 1981; Henderson, 1985; Olsson 
& Pearson, 1990; Meghji, 1993).
Extracellular adenosine can also result from more than one source. It can result from 
the transport of intracellular adenosine across the cell membrane via a bidirectional 
nucleoside transport system due to facilitated diffusion, which occurs when 
intracellular concentrations of adenosine exceed extracellular concentrations. 
Similarly, this mechanism can function as an adenosine uptake mechanism whereby
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extracellular adenosine can enter cells when extracellular concentrations exceed 
intracellular concentrations. Dipyridamole and nitrobenzylthioinosine (NBTI) have 
been shown to be potent inhibitors of this nucleoside transport system, although they 
are not selective (Pearson & Gordon, 1985). Alternatively, via the metabolism of 
extracellular adenine nucleotides to AMP (see section 1.3.), adenosine may be 
formed by ecto-5-nucleotidase located on the outer face of the plasma membrane 
which converts this extracellular AMP to adenosine (Arch & Newsholme, 1978; 
Meghji, 1993).
In addition to a cytosolic form of adenosine deaminase, it has been shown in rat 
brain and small intestines (Franco et al., 1986; 1988; Centelles et al., 1987; 1988) 
that there is an ectoenzyme form which is often located near to the ecto-5- 
nucleotidase. Thus extracellularly adenosine can also be deaminated via adenosine 
deaminase to its pharmacologically inactive metabolite inosine. In visceral smooth 
muscle of the guinea-pig taenia caeci and urinary bladder the rate of metabolism of 
adenosine is very slow with approximately 70% remaining after 60 minutes, 
indicating a low capacity to metabolise adenosine (Welford et al., 1986; 1987). This 
is similar to that of pig aortic smooth muscle (Gordon et al., 1989). In contrast, 
adenosine is rapidly metabolised by the rat duodenum to inosine, with no adenosine 
being detected after 5 minutes (Nicholls et al., 1992b). Two compounds which have 
been used as potent inhibitors of adenosine deaminase are eiythro-9-(2-hydroxy-3- 
nonyl)adenine (EHNA) and deoxycoformycin (Henderson et al., 1977; Agarwal, 
1982).
1.3. SOURCES AND FATE OF ADENOSINE 5'-TRIPHOSPHATE
ATP is a ubiquitous compound present within the cytoplasm of essentially all cells
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where it has a number of physiological roles, and can be synthesized by glycolysis 
and by mitochondrial oxidative phosphorylation as well as via the purine salvage 
pathway. However, ATP is stored within secretory vesicles within nerves from which 
it is released as a transmitter or cotransmitter by exocytosis when the vesicle 
contents are secreted. Once released extracellularly ATP can then exert its 
physiological effects by acting at P2 -purinoceptors (see section 1.4.2.). Quinacrine, a 
fluorescent dye which binds to ATP, has been used to confirm the presence of ATP 
in nerves such as those supplying the rabbit stomach and ileum (Crowe & Bumstock, 
1981), whereas the incorporation of radiolabelled tracers such as [^Hjadenosine into 
nerve endings has also been used to show the storage of ATP in tissues such as the 
guinea-pig taenia caeci (Su et al., 1971). There is also a very sensitive and specific 
luminescence method for the detection of ATP, the luciferin-luciferase firefly assay, 
which is able to detect the presence of ATP before any significant degree of 
degradation occurs (Israël et a l, 1976; White et al., 1981). There is evidence that 
ATP is stored with acetylcholine within cholinergic synaptic vesicles (Dowdall et al., 
1974), with noradrenaline in sympathetic vesicles (Von Kügelgen & Starke, 1991; 
Kennedy, 1993), with both noradrenaline and adrenaline in adrenal chromaffin 
granules (Winkler et al., 1987), and with 5-HT and ADP in platelets (Da Prada et ah, 
1978).
It was originally observed in 1950 by Binet and Bumstein, that circulating ATP is 
rapidly degraded on a single passage through the pulmonary capillary bed, and the 
rapidity of this degradation led to the suggestion that ectoenzymes exist on the 
external surface of cells which degrade adenine nucleotides (Pearson, 1985). As the 
overall negative charge of adenine nucleotides prevents their entry into cells 
(Dubyak, 1991), extracellularly released ATP is unlikely to be metabolised 
intracellularly, although there have been a few reports that adenine nucleotides can
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cross cell plasma membranes such as in rat soleus muscles and hemidiaphragms 
(Chaudry & Baue, 1980). The extracellular location of ectoenzymes has been 
confirmed with diazotized sulphanilic acid which attacks and inactivates exposed 
proteins (De Pierre & Kamovsky, 1974).
1.3.1. Ectonucleotidases
Once released ATP is rapidly and sequentially dephosphoiylated to ADP, AMP and 
adenosine by ecto-ATPase, ecto-ADPase and ecto-5'-nucleotidase respectively, and 
although this is a major route of extracellular ATP degradation, there is also 
evidence for the presence of ATP-diphosphohydrolase as an ectoenzyme in some 
tissues which equipotently hydrolyses both ATP and ADP (Battastini et al., 1991; 
Yagi et al., 1991; Meghji, 1993; Picher et al., 1993; Plesner, 1995). In the mouse 
liver and dog kidney for example the activity of this enzyme has been shown to be 
more dominant than that of ecto-ATPase (Knowles et al., 1983). The general term 
"ectonucleotidase” has been used to encompass all of the ectoenzymes which 
degrade extracellular nucleotides.
The activity of ectonucleotidases is highly dependent on the divalent cations Ca^+ 
and/or Mg^+, and different forms of ectonucleotidases show different sensitivity 
towards these cations. Other cations are able to activate ectonucleotidases albeit with 
a lower potency (Pearson, 1985; Ziganshin et al., 1994a; 1995). The requirement for 
Ca2+ and/or Mg^+ is not surprising as the normally negatively charged nucleotides 
have been shown to form complexes with divalent cations in physiological salt 
solutions. For example, approximately 70% of ATP is seen to complex with Mg^+ 
and approximately 20% with Ca^+, with the remaining 10% complexed to several 
other cations including H+, K+ and Na'"', and a small percentage of approximately 3%
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existing as the fully unionized form (ATP"^ ") (Fine et al., 1989; Lustig et al., 1992).
There are a number of other ectoenzymes which have been documented, but which 
do not appear to play primary roles in the degradation of extracellular nucleotides in 
most tissues, and these include ATP-pyrophosphatase and nonspecific phosphatases 
(Pearson, 1985; Ziganshin et al., 1994a), as well as ecto-protein kinases which 
utilizes ATP as a substrate for the phosphorylation of specific membrane proteins 
(Ehrlich etal., 1986).
Ectonucleotidases are widespread and have been shown to be present on most cells 
including arterial endothelial and smooth muscle cells, synaptosomes, cardiac 
myocytes, hepatocytes, various blood cells, and visceral smooth muscle cells 
(Pearson, 1985; Meghji, 1993; Ziganshin et a l, 1994a). In pig aortic endothelial cells 
separate ecto-ATPase and ecto-ADPase have been demonstrated by their ability to 
selectively dephosphorylate the non-terminally substituted phosphorothioate 
analogues of ATP (adenosine 5-0-(2-thiotriphosphate); ATP-|3-S) and ADP 
(adenosine 5 -0-( 1 -thiodiphosphate); ADP-a-S) respectively. In addition, ATPpS and 
ADPaS exist as and Sp diastereoisomers and ecto-ATPase and ecto-ADPase 
show stereospecificity and discriminate between the two forms. In contrast, the 
terminally substituted phosphorothioate analogues of ATP (adenosine 5-0-(3- 
thiotriphosphate); ATP-y-S) and ADP (adenosine 5-0-(2-thiodiphosphate); 
ADP-P-S) are resistant to degradation. Similarly, while AMP is degraded by ecto-5'- 
nucleotidase, resistance to degradation is seen for the terminally substituted analogue 
adenosine 5-0-monophosphorothioate (AMPS). Stereoselectivity of ecto-ATPase, 
ecto-ADPase and ecto-5'-nucleotidase is shown for the naturally occurring 
D-enantiomers of ATP, ADP and AMP respectively, although to different extents. 
L-ATP and L-ADP are dephosphorylated at one fifth and one fifteenth the rate of
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their D-enantiomers, whereas L-AMP is not dephosphorylated (Cusack et al., 1983; 
Pearson & Cusack, 1985; Pearson, 1986).
There are differences as well as similarities between ectonucleotidases located on 
different types of cells. Using similar experiments with nucleotide phosphorothioate 
diastereoisomers as above, the ecto-ATPase and ecto-ADPase in pig aortic smooth 
muscle cells were observed to be similar to their counterparts in pig aortic 
endothelial cells. In contrast, the ecto-5-nucleotidase of aortic smooth muscle cells 
showed distinct differences from the endothelial enzyme. Although both ecto-5- 
nucleotidases are inhibited by ADP, the smooth muscle enzyme degraded AMPS to 
adenosine, and had a 10-fold lower affinity for AMP than the endothelial enzyme 
(Pearson et al., 1985). Even though it has been shown that smooth muscle and 
endothelial cells have a similar capacity to dephosphorylate ATP via ecto-ATPase, in 
smooth muscle cells the production of adenosine is rapid, whereas in endothelial 
cells it is much slower requiring most of the ADP to have been converted to AMP, 
before adenosine is formed (Gordon et al., 1986; 1989). It has been suggested that 
the reason for this difference in kinetics is due to the preferential delivery of 
intermediates between ectonucleotidases at the surface of smooth muscle cells 
(Gordon et al., 1989; Slakey et al., 1990; Meghji et al., 1995). In addition, smooth 
muscle cells lack the high affinity adenosine transport system found on endothelial 
cells via which extracellular adenosine can be removed from the near vicinity of its 
receptors (Pearson et al., 1978).
Ectonucleotidases are also located on visceral smooth muscle cells, for which their 
structure activity requirements have been determined within the guinea-pig taenia 
caeci and urinary bladder (Welford et al., 1986; 1987). In both guinea-pig taenia 
caeci and urinary bladder ATP, ADP and AMP are degraded to adenosine and
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substitutions on the purine ring do not affect their rate of dephosphorylation. For 
example, 2-methylthioadenosine 5-triphosphate (2-MeSATP) is dephosphorylated at 
a similar rate to ATP. Stereoselectivity is shown for the D - over the L-enantiomer, in 
a manner similar to that observed in aortic endothelial cells (Pearson et al., 1980; 
1985). The purine nucleoside triphosphates ATP and guanosine 5 -triphosphate 
(GTP), and the pyrimidine nucleoside triphosphates uridine 5'-triphosphate (UTP) 
and cytosine 5 -triphosphate (CTP) are all degraded at a similar rate. There is also 
stereoselectivity shown between the diastereomeric forms of the non-terminally 
substituted phosphorothioates, whereas the terminally substituted analogues 
(ATP-y-S and ADP-(3-S) are resistant to degradation. Methylene isosteres of ATP and 
ADP (such as adenosine 5 -(a,(3-methylene)triphosphonate; AMPCPP, adenylyl 5- 
(P,y-methylene) diphosphonate; AMPPCP and adenosine 5'-(a,P-methylene) 
diphosphonate; AMPCP), are resistant to dephosphorylation at the point the 
methylene group replaces an oxygen (Welford et al., 1986; 1987). A distinctive 
difference between the two visceral smooth muscle tissues is the ability of the 
guinea-pig urinaiy bladder (Welford et al., 1987) but not the guinea-pig taenia caeci 
(Welford et al., 1986) to degrade adenosine 5'-0-( 1 -thiotriphosphate) (ATP-a-S) and 
AMPS to adenosine. This indicates a similarity of the ecto-5-nucleotidases on 
guinea-pig urinary bladder to that on pig aortic smooth muscle cells which is able to 
metabolise AMPS (Pearson et al., 1985), and a similarity of the ecto-5'-nucleotidases 
on guinea-pig taenia caeci to that on pig aortic endothelial cells which is not able to 
metabolise AMPS (Cusack et al., 1983).
The action of ATP and its analogues at P2 -purinoceptors can be complicated by the 
presence of ectonucleotidases on smooth muscle which sequentially dephosphorylate 
them to their corresponding nucleosides which may then act at Pj-purinoceptors 
(Bailey & Hourani, 1990; 1992; Slakey et al., 1990). Déphosphorylation of ATP and
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some of its analogues has been shown to result in reduced potency in some tissues 
such as the guinea-pig urinary bladder which contains P2X"purinoceptors, and in 
which ATP and adenosine elicit opposing responses (Welford et al., 1987), but not in 
others such as the guinea-pig taenia caeci which contains P2Y-purinoceptors, and in 
which ATP and adenosine elicit the same response (Welford et al., 1986). Thus the 
development of selective ectonucleotidase inhibitors would greatly aid receptor 
classification.
There are a number of compounds which have been shown to be able to inhibit 
ectonucleotidases although most of them lack selectivity. AMPCP and thymidine 5- 
triphosphate (TTP) have been shown to be potent inhibitors of 5 -nucleotidase in 
smooth muscle from the rat small intestine (Burger & Lowenstein, 1970), and in 
vascular endothelial cells ecto-ADPase has been shown to be inhibited by 
nucleotides such as AMPPCP and ATP-y-S (Pearson, 1986), however, these 
compounds are also P2 -purinoceptor agonists and this can complicate their use. 
Another compound which has activity at P2 -purinoceptors is diadenosine 5 ',5 "-Pi,P5- 
pentaphosphate (Ap^A), but which has been shown to be an inhibitor of ecto-ATP- 
diphosphohydrolase in bovine aortic endothelial and smooth muscle cells (Yagi et 
al., 1991). Suramin has been shown in the guinea-pig urinary bladder to be a 
compound which can inhibit ecto-ATPase (Hourani & Chown, 1989), however its 
use in this respect is limited by the fact it is also a P2-purinoceptor antagonist (see 
section 1.4.2.7.). Recently an analogue of ATP, 6 -N,N-diethyl-P,y-dibromomethylene 
D-ATP (FPL 67156), has been reported to be a selective inhibitor of ecto-ATPase in 
the rabbit ear artery. It was observed to potentiate the pharmacological responses of 
nucleotides susceptible to degradation (e.g. ATP), but not those which are resistant 
(e.g. AMPCPP) (Crack et al., 1995). However, FPL 67156 is not yet commercially 
available.
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1.4. PÜRINOCEPTORS
The physiological actions of extracellular adenosine and adenine nucleotides are 
mediated via a class of receptors called purinoceptors. In 1978, Bumstock proposed 
a subdivision into ?]- and ?2-purinoceptors based on several criteria. It was proposed 
that at ?!-purinoceptors there was an agonist potency order of adenosine>AMP> 
ADP>ATP, methylxanthines such as caffeine (1,3-dimethylxanthine) and 
theophylline (1,3,7-trimethylxanthine) were antagonists, and occupation of the 
receptor leads to changes in intracellular cAMP levels. In contrast, it was proposed 
that at P2-purinoceptors there was an agonist potency order of 
ATP>ADP>AMP>adenosine, methylxanthines were not antagonists, and occupation 
of the receptor leads to prostaglandin synthesis (Bumstock, 1978). Although this 
division into P%- and P2-purinoceptors has been retained, each of these two major 
classes have since been divided into a number of subtypes.
1.4.1. Pi-Purinoceptors
P%-Purinoceptors are also called adenosine receptors due to their preference for 
adenosine over ATP. Based on the ability to inhibit or activate adenylate cyclase, P -^ 
purinoceptors were initially divided into Ri and Ra subtypes respectively by Van 
Calker et al. (1979). These same receptors were named A% and A2 by Londos et al. 
(1980), and the A 1/A2 nomenclature has become the preferred nomenclature. 
However, it is now known that the Aj subtype in addition to modulating adenylate 
cyclase activity can activate other effectors such as phospholipase A2 (PLA2 ), 
phospholipase C (PTC), guanylate cyclase, potassium channels and calcium channels 
(Olsson & Pearson, 1990; Fredholm, 1995a, b). The A2 subtype is further subdivided 
into A2A A2B receptors based on high and low affinity for adenosine and its
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analogues and to a series of methylxanthine antagonists (Daly et al., 1983; Bruns et 
al., 1986; 1987). P%-purinoceptor subtypes are functionally classified based on 
agonist and antagonist potency orders (see Table 1).
Adenosine analogues substituted in the N^-position such as N^-cyclopentyladenosine 
(CPA) are selective for the A% subtype, whereas analogues substituted in the C-2 
position with large substituents such as 2-/>-((carboxyethyl) phenethylamino)-5'-N- 
carboxamidoadenosine (CGS21680) are selective for the A2A subtype. In contrast, 
there are no selective agonists for the A2B subtype as it has a low affinity for agonists 
compared to Aj and A2A subtypes. However, the C-5 substituted analogue 5-N- 
ethylcarboxamidoadenosine (NECA) is more potent than the C-2 substituted 
analogue 2-chloroadenosine (2-CADO), which in turn is more potent than CPA at 
the A2A A2B subtypes (Collis & Hourani, 1993; Daly & Jacobson, 1995). (See 
Figure 1 for the structural formulae of some P%-purinoceptor agonists).
Classification of P % -purinoceptors has been further aided by the presence of selective 
and non-selective antagonists. Three xanthine antagonists which have been used to 
distinguish between Pj-purinoceptor subtypes are 1,3-dipropyl-8-cyclopentyl- 
xanthine (DPCPX), N-[2-(dimethyl-amino)ethyl]-N-methyl-4(2,3,6,7-tetrahydro-2,6- 
dioxo-l,3-dipropyl-lH-purin-8-yl)benzenesulfonamide (PDl 15199) and 8 -phenyl- 
theophylline (8 -PT) (Collis & Hourani, 1993). DPCPX is a highly selective 
antagonist for the Aj subtype, whereas 8 -PT is not selective. Another non-selective 
Pj-purinoceptor antagonist is 8 -/?-(sulphophenyl)theophylline (8 -SPT) which is more 
soluble and has been used to discriminate between Pj- and P2 -purinoceptors (Collis 
et al., 1987). A selective antagonist for the A2A over the A2B subtype is PDl 15199 
as is the triazolo-quinazoline, 9-chloro-2(2-furyl)-5,6-dihydro[l,2,4]-triazolo[l,5-c]- 
quinazolin-5-imine (CGS15943) (Jacobson et al., 1992; Daly & Jacobson, 1995).
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Figure 1. P^-purinoceptor agonists.
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Structural formulae of adenosine and some of its analogues which act as Pi- 
purinoceptor agonists.
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(See Figure 2 for the structural formulae of some Pj-purinoceptor antagonists).
Due to the rank orders of potencies for adenosine analogues not always 
corresponding completely with either Aj and A2 subtype classification, an A3 
subtype was proposed by Ribeiro and Sebastiao, (1986). This A3 subtype has been 
claimed for a receptor located in atrial tissue and at prejunctional sites on nerves, 
which is not coupled to adenylate cyclase but to calcium channels and for which the 
agonist potency order is L-N^-phenylisopropyladenosine (L-PIA)=N^-cyclohexyl- 
adenosine (CHA)=NECA>2-CAD0. However this A3 subtypes has not gained wide 
acceptance, and where both A^  and A2 subtypes exist in a tissue which mediate the 
same functional response and C-5 substituted analogues may be equipotent, and 
could account for an observed agonist potency order not of a classical Aj or A2 
subtype. For example, in the rat duodenum and rat vas deferens which both contain 
Al and A2 receptors, an agonist potency order of NECA>CPA>AMPPCP= 
adenosine>CGS 21680 and CPA=NECA>adenosine has been observed respectively 
(Nicholls et al., 1992a; Hourani et a l, 1993a).
Recently an adenosine receptor has been cloned and expressed which can inhibit 
adenylate cyclase, but which has an agonist potency order not characteristic of either 
the Al and A2 subtypes. This receptor which has been cloned from the rat (Meyerhof 
et al., 1991; Zhou et al., 1992), sheep (Linden et al., 1993) and human (Salvatore et 
al., 1993) has been termed an A3 receptor, but is different to that proposed by 
Ribeiro and Sebastiao, (1986). However, whilst antagonists have been identified for 
the sheep and human A3 receptor, no potent antagonists either xanthine or non­
xanthine have been identified for the rat A3 receptor. The Ai, A2A -^ 2B subtypes 
have also all been cloned (Linden et al., 1991) confirming the existence of the 
separate ?i-purinoceptor subtypes. In addition, this has also confirmed that Pi-
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Figure 2. Pj-purinoceptor antagonists.
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Structural formulae of some Pj-purinoceptor antagonists.
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purinoceptors (Aj, A2A, ^ 2B A^  subtypes) form a class of G-protein coupled 
receptors (Abbracchio et al., 1993; Fredholm et al., 1994; Fredholm, 1995a, b; Olah 
& Stiles, 1995).
I.4.I.I. Action Of Adenosine 5’-Triphosphate At Pi-Purinoceptors
As well as a direct action on P2 -purinoceptors, ATP can have an indirect action on 
Pj-purinoceptors via its déphosphorylation ultimately to adenosine. However, there 
is also evidence in some tissues that ATP can have a direct action on Pj- 
purinoceptors. In tissues such as guinea-pig atrium (Collis & Pettinger, 1982; Moody 
et al., 1984) and guinea-pig ileum (Moody et al., 1984; Wiklund et al., 1985) the 
effects of ATP and AMPPCP are antagonised by theophylline or 8 -SPT. As 
AMPPCP is resistant to dephosphorylation by ectonucleotidases, this has been taken 
to indicate a direct action at P % -purinoceptors and not via their degradation to 
adenosine. In addition, in the presence of adenosine deaminase which would convert 
any adenosine formed to inosine, there was no reduction in the responses to ATP or 
AMPPCP. Based on similar observations in the rat caudal artery Shinozuka et al., 
(1988) proposed that since these receptors respond to adenine nucleosides and 
nucleotides, they represent another class of purinoceptors which they tentatively 
termed P3 . However, this proposal has not gained wide acceptance, and it has since 
been suggested in a number of tissues such as the rat colon muscularis mucosae 
(Bailey & Hourani, 1990), guinea-pig taenia caeci and the rat duodenum (Hourani et 
al., 1991), that AMPPCP can act directly on Pj-purinoceptors, as its effects are 
antagonised by 8 -SPT, whereas the responses to other P2-purinoceptor agonists such 
as ATP, AMPCPP and 2-MeSATP are not. As AMPPCP, unlike ATP, is highly 
resistant to degradation in the rat colon muscularis mucosae (Bailey & Hourani, 
1990), the guinea-pig taenia caeci (Welford et al., 1986) and the rat duodenum
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(Hourani et al., 1991) its action at Pj-purinoceptors would appear to be direct and 
not via its degradation to adenosine.
1.4.2. P2 “Purinoceptors
The receptors via which extracellular ATP exerts its physiological effects have been 
termed P2 -purinoceptors. The classification of P2 -purinoceptors to date has relied 
heavily upon structure-activity relationships to a series of agonists, and using this 
means of characterisation several subtypes have been convincingly identified (see 
Table 2). ATP can be modified in the purine, ribose and triphosphate chain to form a 
number of analogues which can discriminate between the major P2  subtypes. 
However, particularly with the recent data from the expression of cloned receptors, it 
has become clear that care must be taken when interpreting data from 
pharmacological studies in whole tissues, as the agonist potency order from these 
studies does not always correspond with that at the cloned receptor, due primarily to 
the presence of ectonucleotidases in whole tissues which dephosphorylate ATP and 
some of its analogues. In addition, there is a lack of truly selective antagonists for P2 
subtypes and often a mixed population of receptors reside in some tissues.
The initial subdivision of P2 -purinoceptors into P2X and P2Y subtypes was made by 
Bumstock & Keimedy (1985). They proposed that the P2X subtype had an agonist 
potency order of AMPCPP=AMPPCP>ATP=2-MeSATP and mediated contraction 
of smooth muscle preparations, whereas the P2Y subtype mediated relaxation and 
had an agonist potency order of 2-MeSATP»ATP>AMPCPP=AMPPCP. Two 
further P2 subtypes were proposed by Gordon (1986), for the receptors on mast cells 
and macrophages which he termed P2Z and those on platelets which he termed P2X, 
which was based on activation of these receptors by ATP^" and ADP respectively.
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Recently an additional ? 2  subtype has been proposed for a receptor at which the 
pyrimidine nucleotide UTP shows equipotency to ATP, and at which other P2 
subtype selective agonists show little or no activity. This subtype has been termed a 
P2U or "nucleotide" receptor (O’Connor et al., 1991; Dubyak, 1991). These five 
subtypes are widely acknowledged and are thus reviewed in detail in the following 
sections, although with the recent cloning of some of these receptors (see section
1.7.) the classification of P2 -purinoceptors is starting to undergo a major revision 
(see section 1.8.). The structural formulae of some P2-purinoceptor agonists are 
shown in Figure 3.
I.4.2.I. P2x-Purinoceptor
As previously mentioned, structure-activity relationships to a series of agonists have 
been the major basis for the identification and classification of P2 subtypes. The 
observed agonist potency order for classification of the classical P2X subtype in 
isolated smooth muscle preparations such as the guinea-pig urinaiy bladder and vas 
deferens is AMPCPP=AMPPCP>ATP=2-MeSATP (Bumstock & Kennedy, 1985), 
although the potency at this subtype for a number of other ATP analogues has also 
been determined.
ATP analogues which have substitutions in the C-2 and C- 8  positions of the adenine 
base, such as 2-chloroadenosine 5’-triphosphate (2-ClATP), 2-MeSATP and 
8 -bromoadenosine 5’-triphosphate (8 -BrATP) are no more potent than ATP, whereas 
analogues substituted in the N^-position such as N^-phenyladenosine 5’-triphosphate 
(N^-phenylATP) are inactive (Bumstock et al., 1983; 1985; 1994; Welford et al., 
1987). No stereoselectivity is shown for either of the enantiomers of ATP, 2-ClATP 
or 2-MeSATP by the urinary bladder (Bumstock et al., 1983), whereas in the vas
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Figure 3. P2 -purinoceptor agonists.
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deferens stereoselectivity is shown as the L-enantiomer is less potent than the 
D-enantiomer (Bumstock et al., 1985; 1994).
In both the urinaiy bladder and vas deferens methylene phosphonate analogues such 
as AMPCPP and AMPPCP in which a methylene link is substituted for an oxygen in 
the triphosphate chain are more potent than ATP. Stereoselectivity is shown for the 
unnatural L- over the D-enantiomer, and L-AMPPCP is a very potent and specific 
agonist for the P2X subtype (Cusack & Hourani, 1984; Hourani et al., 1985; 1986; 
Tatham et al., 1988).
Phosphorothioate analogues in which a phosphate oxygen atom is replaced by a 
sulphur atom show varying degrees of potency, as ATP-y-S and ATP-^-S are more 
potent than ATP, whereas ATP-a-S is of similar potency (Bumstock et al., 1984a; 
1985; Stone, 1985). In addition, in the urinary bladder, ADP-|3-S, ADP-a-S and 
AMPS all have a similar potency to ATP (Bumstock et al., 1984a).
Modifications in the length of the triphosphate chain affect potency, as ADP is less 
potent than ATP, and AMP is inactive (Lukacsko & Krell, 1982). Replacement of the 
adenine base with uridine to form the pyrimidine nucleotide UTP also affects 
potency as UTP is less potent than ATP (Bailey & Hourani, 1994; 1995).
There is now evidence from data obtained with cloned receptors, that the above 
potency orders obtained from studies with whole tissues does not reflect the tme 
potency at the receptor, and that there is more than one type of the P2X subtype. At 
the P2X receptor cloned from rat vas deferens (Valera et al., 1994) and human 
urinary bladder (Evans et al., 1995), ATP and 2-MeSATP are approximately 
equipotent while AMPCPP is slightly less potent and ADP markedly less potent.
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whereas at the ?2x  receptor cloned from rat pheochromocytoma PC 12 cells, ATP, 
2-MeSATP and ATP-y-S are approximately equipotent while AMPCPP, AMPPCP, 
ADP and UTP are inactive (Brake et al., 1994). In addition, at the P2X receptor 
cloned from rat dorsal root ganglia which shows marked desensitisation in response 
to ATP, the potency order to low concentrations of agonists is 2-MeSATP»ATP> 
AMPCPP>ATP-y-S>ADP»UTP=AMPPCP (Chen et a l, 1995). This difference in 
potency of agonists at the cloned receptors and whole tissue preparations, has been 
attributed to the presence of ectonucleotidases in whole tissue preparations which 
rapidly dephosphorylate ATP and 2-MeSATP, resulting in a reduction in their 
observed potency, while AMPCPP and ATP-y-S which are resistant to 
dephosphorylation will not be so greatly affected (Kennedy & Leff, 1995). 
Furthermore, in normal physiological salt solution the agonist potency order in the 
rat isolated vagus nerve was observed to be AMPCPP>ATP-y-S>P,y-imidoadenosine 
5-triphosphate (AMPPNP)=AMPPCP>2-MeSATP>ATP, which was taken to 
indicate the presence of a P2x-purinoceptor (Trezise et al., 1993). In contrast, the 
agonist potency order in Ca '^ /^Mg2+ free physiological salt solution was observed to 
be ATP=2-MeSATP=ATP-y-S>>AMPCPP^AMPPNP=AMPPCP, for which it was 
postulated that in the whole nerve preparation removal of Ca^+ and Mg^+ prevents 
the rapid dephosphorylation of the more susceptible nucleotides ATP and 
2-MeSATP by Ca^+ZMg^ -^dependent ectonucleotidases resulting in their increased 
potency (Trezise et a l, 1994). This agonist potency order in Ca2+/Mg^+ free 
physiological salt solution being similar to that observed for the cloned P2X- 
purinoceptor from rat pheochromocytoma PC 12 cells. In addition, it has been 
observed in the guinea-pig urinary bladder that analogues resistant to 
dephosphorylation are more potent than those which are readily degraded (Welford 
et a l, 1987). Although this has great significance in terms of P2 -purinoceptor 
classification, until selective ecto-ATPase inhibitors become commercially available,
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the observed potency orders in pharmacological studies have been a useful basis for 
distinguishing between the major P2  subtypes.
Another basis for the original classification of the P2 X subtype was that they mediate 
contraction of smooth muscle preparations such as the rat and guinea-pig urinary 
bladder and vas deferens, and of blood vessels such as the rat femoral artery and 
rabbit central ear artery (Bumstock & Kennedy, 1985). In addition, P2X- 
purinoceptors can be differentiated from the other P2 -purinoceptor subtypes based on 
their signal transduction mechanism as they are intrinsic ion channels permeable to 
Na+, K+ and Ca^+, and this now forms the major basis for the classification of the 
P2X subtype (Fredholm, 1995b).
ATP-gated ion channels (P2x-purinoceptors) are present on tissues such as nerve and 
smooth muscle cells where they are involved in fast excitatory transmission (Bean, 
1992; Dubyak & El-Moatassim, 1993). Activation of ATP-gated ion charmels by 
ATP leads to an opening of the ion channel which results in an increase in 
intracellular Ca^+. This increase in intracellular Ca^  ^can occur directly via an influx 
of Ca^+ through the open ion charmel, and indirectly via an influx of Na"^  which 
rapidly depolarises the cell’s plasma membrane leading to activation and thus 
opening of secondary voltage dependent Ca^  ^ charmels through which there is an 
influx of Ca2+ (Bean & Friel, 1990; Benham, 1990; Dubyak, 1991; Dubyak & 
El-Moatassim, 1993; Harden et al., 1995). However, the overall increase in 
intracellular Ca^  ^ ultimately leads to the ATP-induced functional response of the 
cell. As mentioned above, complimentary DNAs (cDNAs) that encode ATP-gated 
ion charmels in the rat vas deferens, human urinary bladder, rat PC 12 cells and rat 
dorsal root ganglia have now been cloned (see section 1.7.), and have confirmed that 
P2X"Purinoceptors form a heterogeneous group of ATP-gated ion charmels, although
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which consist of two and not four transmembrane domains as other classes of 
receptor operated channels.
1.4.2.2. P2Y-Furinoceptor
The P2Y subtype was originally classified by an agonist potency order of 
2-MeSATP»ATP>AMPCPP=AMPPCP and mediating relaxation of smooth muscle 
preparations such as the guinea-pig taenia caeci and the rabbit portal vein, and of 
blood vessels such as the pig aorta and rat femoral artery (via an endothelium- 
dependent mechanism, including the generation of prostacyclin and nitric oxide) 
(Bumstock & Kennedy, 1985). However, characterisation of receptors via their 
response is theoretically unreliable, and receptors with a stmcture-activity 
relationship characteristic of the P2Y subtype but which mediate contraction have 
been reported to exist in tissues such as the rat colon muscularis mucosae (Bailey & 
Hourani, 1990) and the rat neonatal duodenum (Nicholls et a l, 1990). Several 
G-protein coupled receptors have now been cloned from chick brain (Webb et a l,
1993), turkey brain (Filtz et a l, 1994), rat and mouse insulinoma cells (Tokuyama et 
al., 1995) and bovine aortic endothelial cells (Henderson et a l, 1995) which have 
stmcture-activity relationships characteristic of the P2Y subtype (see section 1.7.).
Although 2-MeSATP is a potent agonist at P2y-purinoceptors, it has been suggested 
based on differences in the order of potencies of various other ATP analogues 
between tissues that multiple P2Y subtypes exist. One subtype has been proposed to 
be present on guinea-pig taenia caeci and turkey erythrocytes for which 
2-deoxyadenosine 5'-triphosphate and N^-methyladenosine 5'-triphosphate are 
selective agonists, whilst another subtype has been proposed present on endothelial 
cells such as the rabbit aorta at which 8 -(6 -aminohexylamino)adenosine 5-
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triphosphate and adenosine -oxide 5'-triphosphate are selective agonists. In 
contrast, the compounds mentioned above which are selective for the proposed ?2Y 
subtype in rabbit aortic endothelial cells, turkey erythrocytes and guinea-pig taenia 
caeci are inactive in vascular smooth muscle such as rabbit hepatic and mesenteric 
arteries, and this has led to the suggestion of a further subtype (Fisher et a l, 1993; 
Abbracchio & Bumstock, 1994; Bumstock et a l, 1994). However, the guinea-pig 
taenia caeci has been a useful tissue for defining stmcture-activity relationships at 
the ?2Y subtype in visceral smooth muscle, as it has allowed a direct comparison 
with the ?2x  subtype in the urinary bladder and vas deferens of the same species.
At the taenia caeci ?2Y subtype ATP analogues substituted in the C-2 position of the 
adenine base such as 2-ClATP and 2-MeSATP are much more potent than ATP 
(Bumstock et a l, 1983), whereas those substituted in the C- 8  position such as 
8 -BrATP are of similar potency (Satchell & Maguire, 1982) and N^-substituted 
analogues such as N^-phenylATP are inactive (Cusack & Hourani, 1990). Although 
only slight stereoselectivity is seen for the D - over the L-enantiomer of ATP (Cusack 
& Planker, 1979), C-2 substitution enhances this stereoselectivity with the 
D-enantiomers of 2-ClATP and 2-MeSATP being more potent than their 
L-enantiomers (Bumstock et a l, 1983).
ATP and its methylenephosphonate analogues produce different maximum responses 
in the guinea-pig taenia caeci with adenosine 5 -(a-methylene)triphosphonate (homo- 
ATP; AMCPPP) being more potent, AMPCPP approximately equipotent and 
AMPPCP less potent than ATP (Satchell & Maguire, 1975; Cusack & Hourani, 
1990), and stereoselectivity is observed with the enantiomer L-AMPPCP being 
inactive (Hourani et al., 1985).
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Of the phosphorothioate analogues, ATP-y-S and ATP-p-S are approximately as 
potent as ATP, whereas ATP-a-S is more potent than ATP (Bumstock et al., 1984a). 
A phosphorofluorate analogue of ADP, adenosine 5-(2-fluorodiphosphate) 
(ADP-P-F), has been proposed to be selective for the P2Y subtype. In the taenia caeci 
it is less potent than ATP in mediating relaxation, but is inactive in the urinary 
bladder and vas deferens which contain the P2X subtype (Hourani et al., 1988). 
However, at low concentrations ADP-P-F has been shown to have activity at Pj- 
purinoceptors in the rabbit jugular vein (Wood et al., 1992), which may be an 
indirect action, as although resistant, it does undergo slow dephosphorylation to 
adenosine in some tissues (Hourani et al., 1988). In contrast to the P2X subtype, at 
the P2Y subtype in the taenia caeci no correlation is found between the potency of an 
analogue and its rate of degradation (Welford et al., 1986).
The length of the phosphate chain affects agonist potency at the P2Y subtype as ADP 
is equipotent, but AMP much less potent than ATP in relaxing the guinea-pig taenia 
caeci (Satchell & Maguire, 1975). Replacement of the adenine base with uridine also 
affects potency as UTP and uridine 5 -diphosphate (UDP) are much less potent than 
ATP (Brown & Bumstock, 1981; Bumstock et a l, 1994).
Another characteristic of P2Y-purinoceptors is that they are G-protein coupled 
receptors, although this is also tme of the P2U and P2T purinoceptor subtypes and has 
recently led to a proposal for the reclassification of P2 purinoceptors (see section
1.8.). The primary effector mechanism to which P2Y-purinoceptors are coupled is 
PTC, activation of which results in cleavage of phosphatidyl inositol bisphosphate 
(PIP2) with the formation of diacylglycerol (DAG) and inositol trisphosphate, 
leading to a subsequent rise in intracellular Ca^+. This increase in intracellular 
cytosolic Ca^  ^occurs from its mobilisation from intracellular stores, which can lead
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to an influx of Ca^+ into the cell via the activation of Ca^^-sensitive ion channels. 
However, a number of other secondary signal transduction mechanisms can also be 
activated as a result of PLC activation and these include PLA2 , phospholipases C and 
D which selectively hydrolyse phosphatidylcholine, and protein kinase C (PKC) (via 
DAG). In the case of visceral smooth muscle cells, the increase in intracellular Ca^+ 
is associated with the opening of Ca^  ^ dependent ion channels which cause 
hyperpolarisation and thus relaxation of the smooth muscle (Ferrero & Frischknecht, 
1983; White, 1988; Dubyak, 1991; Dubyak & El-Moatassim, 1993; Boarder et a l,  
1995; Harden et al., 1995). In addition, rat C6-2B glioma cells (Boyer et a l,  1993; 
1994; Lin & Chuang, 1994) contain a P2Y-purinoceptor which does not activate PLC 
but inhibits adenylyl cyclase through a pertussis toxin-sensitive G-protein. As 
G-protein linked receptors generally couple selectively to a given G-protein and 
second-messenger signalling pathway, this supports the existence of multiple P2Y 
subtypes.
1.4.2.3, P2u-Purmoceptor
In a number of tissues the receptor at which ATP acts is coupled to the activation of 
PLC, but does not have an agonist potency order characteristic of a classical P2Y- 
purinoceptor. At this receptor both P2Y selective agonists such as 2-MeSATP and 
P2X selective agonists such as AMPCPP show little or no activity, whereas the 
pyrimidine nucleotide UTP is a potent agonist. As this receptor is activated by ATP 
it falls into the classification of a P2 -purinoceptor, and the terms P2U (or 
"nucleotide") receptor have been proposed for this receptor coupled to PLC 
activation at which ATP and UTP are approximately equipotent in eliciting the same 
response, and which can be characterised by an agonist potency order of 
UTP=ATP=ATP-y-S»2-MeSATP=AMPCPP (Dubyak, 1991; O'Connor gr a/., 1991;
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Fredholm et al., 1994). In some tissues an overall agonist potency order of 
2-MeSATP>ATP=UTP has been seen, where 2-MeSATP is a potent agonist but has 
a lower maximal response than ATP. As 2-MeSATP does not have the inhibitory 
effects which are expected of a partial agonist, these tissues have until recently often 
been classed as containing a P2Y“like receptor. It is now recognised that these tissues 
contain a mixed population of P2U and P2 Y subtypes which mediate the same 
functional response leading to an observed agonist potency order not characteristic 
of either single subtype (O’Connor et al., 1991).
P2U receptors have been proposed to occur in a number of cell types which include, 
human neutrophils (Merrit & Moores, 1991; Walker et al., 1991; Yu et al., 1991), rat 
renal mesangial cells (Pfeilschifter, 1990), sheep pituitary cells (Davidson et al.,
1990), human fibroblasts (Fine et al., 1989), bovine aortic smooth muscle cells 
(Demolle et al., 1988), bovine aortic endothelial cells (Motte et al., 1993b; 
Wilkinson et al., 1993; Purkiss et al., 1994), bovine aortic collateral artery rings 
(Wilkinson et al., 1994a) and human airway epithelial cells (Brown et al., 1991). 
Recently cDNAs that encode G-proteins with the characteristics of the P2U subtype 
have been cloned from mouse neuroblastoma cells (Lustig et al., 1993), human 
airway epithelial cells (Parr et al., 1994), rat alveolar type 11 cells (Rice et al., 1995) 
and human osteoclastoma cells (Bowler et al., 1995) confirming the existence of this 
subtype (see section 1.7.). In addition, subtypes of the P2U receptor have been 
proposed to exist on the basis of their sensitivity to the P2 antagonist suramin (see 
section 1.4.2.7.).
Although not as extensively investigated as for the other P2 subtypes, the structure- 
activity relationship at the P2U subtype is clearly different. ATP analogues 
substituted in the C-2 position such as 2-MeSATP and methylenephosphonate
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analogues such as AMPCPP and AMPPCP show little or no activity at the P2U 
subtype, whereas UTP is approximately equipotent to ATP (O'Connor et al., 1991; 
Dubyak & El-Moatassim, 1993). The phosphorothioate analogue ATP-y-S is 
approximately as potent as ATP, whereas ATP-|3-S is almost inactive (Demolle et 
a l, 1988; Brown et a l, 1991). In fact where investigated ATP-y-S is a potent agonist 
at the P2XJ subtype. Modifications in the length of the triphosphate chain affect 
agonist potency as ADP and UDP are much less potent than ATP, whereas AMP, 
uridine 5'-monophosphate (UMP), adenosine and uridine are inactive (Fine et a l, 
1989; Seifert et a l, 1989a, b; Brown et a l, 1991). In addition, several diadenosine 
polyphosphates (compounds which are active at the putative P21)- and P4 - 
purinoceptors; see section 1 .4.2.6.), have also been shown to be active at the P21J- 
purinoceptor cloned from human colonic epithelial cells and expressed in 132 INI 
human astrocytoma cells. Diadenosine 5',5"-P ,^P4 -tetraphosphate (Ap^A) was shown 
to be slightly less potent, diadenosine 5',5"-P%,P3 -triphosphate (ApgA) less potent and 
Ap^A much less potent than ATP (Lazarowski et a l, 1995).
P2U purinoceptors are G-protein coupled receptors, which in a similar way to P2Y“ 
purinoceptors, can activate a number of secondary signal transduction mechanisms 
via the activation of PLC (see section 1.4.2.2.; Dubyak, 1991; Dubyak & 
El-Moatassim, 1993; Boarder et a l, 1995; Harden et a l, 1995). However differences 
in the signal transduction mechanisms between P2Y and P2U subtypes have been 
reported. For example, in bovine aortic endothelial cells activation of PLC by ATP 
and UTP (acting at a P2U"purinoceptor) is largely pertussis toxin sensitive, whereas 
activation of PLC by 2-MeSATP (acting at a P2Y-purinoceptor) is pertussis toxin 
insensitive (Motte et a l, 1993b; Purkiss et a l, 1994). In addition, in bovine aortic 
endothelial cells the PLC mediated response by P2U receptors is not affected by PKC 
inhibition or activation whereas the P2Y mediated response is (Purkiss et a l,  1994).
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1.4.2.4. P2X“Pui'inoceptor
The P2x-purinoceptor is present on platelets and has a unique structure-activity 
relationship in that ATP is not an agonist but is a competitive antagonist, and it is 
ADP which is the principle agonist (Gordon, 1986). Analogues substituted in the C-2 
position such as 2-methylthioadenosine 5'-diphosphate (2-MeSADP) and 
2-chloroadenosine 5'-diphosphate (2-ClADP) are more potent than ADP, and 
absolute stereoselectivity is shown for the D-enantiomer of ADP as the L-enantiomer 
is inactive (Cusack et a l, 1979; Cusack & Hourani, 1982b). In contrast, 
methylenephosphonate analogues such as AMPCP and adenosine S'-(a-methylene) 
diphosphonate (homo-ADP; AMCPP) are inactive (Cusack & Pettey, 1988), and 
phosphorothioate analogues such as ADP-a-S and ADP-P-S are partial agonists 
(Cusack & Hourani, 1981a, b).
The activation of platelets by ADP is associated with mobilisation of Ca^  ^ from 
intracellular stores as well as with an influx of extracellular Ca^+, and also with 
inhibition of stimulated adenylyl cyclase. The signal transduction mechanism is 
unclear, and it has been suggested that there may be two P2T purinoceptors which 
recognise ADP, one a G-protein coupled receptor and the other an ion channel 
coupled receptor (Hourani & Hall, 1994). However, no P2 X purinoceptor(s) has yet 
been cloned.
1.4.2.5. P22;-Purinoceptor
In physiological salt solutions an equilibrium is formed with the majority of ATP 
being complexed to Mg^+ or Ca^+, with the free tetrabasic anion ATP^" forming only 
a minor component of the total ATP (Cockcroft & Gomperts, 1979). The receptor on
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mast cells, macrophages and lymphocytes at which ATP^" is the agonist have been 
termed P2z-pnrinoceptors (Gordon, 1986). Occupation of the P2z~purinoceptor by 
ATP4- renders the cell reversibly permeable by inducing the formation of 
nonselective pores in the plasma membrane, a result of which is an influx of Ca^+ 
(Dubyak & El-Moatassim, 1993).
Analogues of ATP4- substituted in the C-2 position are no more potent than ATP^-, 
and an absolute stereoselectivity is shown for the naturally occurring D-enantiomer 
(Tatham et al., 1988). In contrast, phosphorothioate analogues are more potent than 
ATP4-, whereas methylenephosphonate analogues are inactive (Tatham et al., 1988). 
An analogue which is a potent agonist at the P2z-purinoceptor is 3'-0-(4- 
benzoyl)benzoyladenosine 5 -triphosphate (BzATP^-) (Erb et al., 1990; Wiley et al., 
1994). The other nucleotide triphosphates as well as their free tetrabasic anionic 
forms are all inactive at the P2Z subtype (Cockcroft & Gomperts, 1980).
1.4.2.5.1, Action Of The Fully Ionized Form Of Nucleotides At P2"Pii*'inoceptors
It is recognised that at the P2z-purinoceptor the fully ionized form of ATP (ATP^-) is 
the principle agonist (Gordon, 1986). However, it has also been observed in 
pharmacological studies with a number of tissues that increasing the concentration of 
Mg2+ or Ca^+ in the buffer shifts the concentration-response curves of ATP to the 
right. As ATP4- is a minor component of the total ATP, this has been attributed to a 
shift in the concentration of ATP^" to MgATP^- or CaATP2". As the P2  
purinoceptors in these tissues are not of the P2Z subtype, this has been taken to 
indicate that ATP^" is the active agonist species at other P2 subtypes. This has been 
observed at the P2X subtype in the guinea-pig vas deferens (Fedan et a l, 1990) and 
PC 12 cells (Kim & Rabin, 1994), the P21J subtype in sheep pituitary cells (Davidson
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et a l, 1990), human fibroblasts (Fine et al., 1989), human neutrophils (Walker et al.,
1991) and bovine pulmonary artery endothelial cells (Lustig et al., 1992), and at both 
P2Y and P2U subtypes in bovine aortic endothelial cells (Motte et al., 1993a). This 
has also been observed with UTP at the P2U subtype in bovine pulmonary artery 
endothelial cells (Lustig et al., 1992) and in bovine aortic endothelial cells (Motte et 
al., 1993a) indicating that UTP4" and not UTP is the active agonist species, and for 
ADP and ATP at the P2T subtype in human blood platelets indicating that ADP^“ is 
the active agonist species and ATP^" is the active antagonist species (Hall et al.,
1994). Although due to the requirement of ectonucleotidases for Ca^ '^ /Mg^ '^  ions 
(see section 1.3.1.) a change in the concentration of these cations will affect 
ectonucleotidase activity and thus the rate at which ATP and its degradable 
analogues are dephosphorylated, it is unlikely that this does solely account for the 
observed rightward shifts in the concentration-response curves of ATP, UTP and 
ADP in the presence of increasing concentrations of divalent cations as mentioned 
above. For example, when the results of these studies were plotted in terms of 
calculated uncomplexed nucleotide concentrations, a close correlation was observed 
between nucleotide concentration-response curves in the absence and presence of the 
divalent cation concentrations. This therefore suggests that it is the uncomplexed 
form of the nucleotide which is the active agonist species at P2-purinoceptors, and by 
complexing with divalent cations via the negatively charged phosphate chain, may 
then bind to ectonucleotidases with high affinity and undergo degradation.
I.4.2.6. P2D- and P4- Purinoceptors
Diadenosine polyphosphates are a class of compounds consisting of two adenosine's 
linked to three to six phosphates. It has been shown that diadenosine polyphosphates 
are present in platelets (Lüthje & Ogilvie, 1983; Schliiter et al., 1994), secretory
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granules of chromaffin cells (Rodriguez del Castillo et al., 1988; Sillero et al., 1994), 
Torpedo synaptic vesicles and rat brain synaptosomes (Pintor & Miras-Portugal,
1993). In rat brain synaptosomes, binding studies with p^S]ADP-|3-S and [^HjAp^A 
both revealed high and low affinity binding sites. As the potency order of 
displacement of both p5S]ADP-p-S and [^HjAp^A from their binding sites by 
diadenosine polyphosphates and ATP analogues does not correspond with any of the 
recognised P2 subtypes, this has led to the proposal for an additional P2 subtype 
which has been tentatively termed a P2D-purinoceptor (Pintor et al., 1993). In 
addition to the putative P2D-purinoceptor, diadenosine polyphosphates have been 
reported to trigger Ca2+ entry via an additional mechanism in rat brain synaptosomes 
which is not sensitive to ATP. This has led to the proposal that this receptor is not a 
member of the P2-purinoceptor family but represents another subdivision of 
purinoceptors which are selective for dinucleotides, and has thus been tentatively 
termed a P4 receptor (Pintor & Miras-Portugal, 1995). However, diadenosine 
polyphosphates have been shown to act at P2x-purinoceptors in guinea-pig vas 
deferens (MacKenzie et al., 1988) and human urinaiy bladder (Hoyle et al., 1989), 
P2Y-ptu"inoceptors in bovine adrenal chromaffin cells (Pintor et a l, 1991) and at a 
P2u-purinoceptor (cloned from human colonic epithelial cells) expressed in 132 INI 
human astrocytoma cells (Lazarowski et al., 1995), and the proposed P2D- and P4- 
purinoceptors have not yet gained wide acceptance.
I.4.2.7. P2-Purinoceptor Antagonists
A number of compounds have been proposed to be P2 -purinoceptor antagonists, and 
although they lack selectivity have nevertheless been of use in the study of this class 
of receptors. The structural formulae of some P2 -purinoceptor antagonists are shown 
in Figure 4.
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Figure 4. P2-purinoceptor antagonists.
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Reactive blue 2 is an anthraquinone-sulphonic acid derivative which has been shown 
to antagonise P2Y-purinoceptor mediated responses to ATP in tissues such as the rat 
duodenum (Manzini et al., 1986), rabbit mesenteric artery (Bumstock & Warland, 
1987), dog coronary artery (Houston et a l,  1987) and rabbit portal vein (Reilly et a l, 
1987). The degree of selectivity of this compound for the P2Y subtype is however 
questionable, as P2x-purinoceptor mediated responses to ATP are not antagonised in 
the rabbit mesenteric artery (Bumstock & Warland, 1987) and the rat urinary bladder 
(Choo, 1981), whereas those in the rabbit portal vein (Reilly et al., 1987) and guinea- 
pig urinaiy bladder (Choo, 1981) are antagonised, as are the P2x-purinoceptors 
which have been cloned from rat pheochromocytoma PCI2 cells (Brake et a l,
1994). Furthermore, reactive blue 2 has been shown to antagonise P2z-purinoceptor 
mediated responses to ATP"^ " in rat parotid acinar cells (Soltoff et a l, 1989). 
However, reactive blue 2 has been used to discriminate between P2 -purinoceptors 
and pyrimidinoceptors (see section 1.5.1.)
An analogue of ATP which has been used as a P2x-purinoceptor antagonist is 3 -0 -  
{3[N-(4-azido-2-nitro-phenyl)amino]propionyl}adenosine 5-triphosphate (ANAPP3). 
This compound is a P2 agonist which initially activates the receptor, but is able to 
form a covalent bond with the receptor on exposure to U.V. light and thus act as an 
irreversible and thus non-competitive antagonist (Fedan et al., 1985). In tissues 
containing P2X"purinoceptors such as the guinea-pig vas deferens (Hogaboom et a l, 
1980; Fedan et a l, 1982a, c) and the guinea-pig urinary bladder (Westfall et a l,
1983) ANAPP3 has been shown to antagonise the responses to ATP. Antagonism of 
the responses to ATP are also observed in the guinea-pig taenia caeci, albeit to a 
lesser extent, indicating a weak action of ANAPP3 at P2Y-purinoceptors (Westfall et 
a l, 1982). However, in the guinea-pig taenia caeci responses to adenosine are also 
weakly antagonised suggesting an interaction at Pj-purinoceptors (Westfall et a l.
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1982), and nonphotolysed ANAPP3 has been shown to act as a P% agonist via its 
metabolism to adenosine in the guinea-pig ileum longitudinal muscle (Frew & 
Lundy, 1986). The use of ANAPP3 as a P2-antagonist is thus limited due to its lack 
of selectivity in some tissues and from its action as a non-competitive antagonist not 
enabling the calculation of pA2 values.
The trypanocidal drug .sy7w-bis(/??-aminobenzoyl-w-amino-/7-methylbenzoyl-l- 
naphthylamino-4,6,8-trisulphonate) carbamide, (suramin), has been widely used as a 
P2 -purinoceptor antagonist. In tissues such as the mouse vas deferens (Dimn & 
Blakely, 1988), guinea-pig urinary bladder (Hoyle et a l, 1990) and rabbit ear artery 
(Leff et a l, 1990) suramin antagonises the responses to AMPCPP acting at P2X- 
purinoceptors, whereas in tissues such as the guinea-pig taenia caeci (Den Hertog et 
al., 1989; Hoyle et al., 1990) suramin antagonises the response to ATP acting at P2Y- 
purinoceptors. As the apparent pA2 values are similar in the guinea-pig urinary 
bladder and taenia caeci (4.7 and 5.0 respectively), suramin does not appear to 
discriminate between the P2X or P2Y subtypes (Hoyle et al., 1990). Suramin is also a 
P2T-purinoceptor antagonist, as it inhibits the responses to ADP in human platelets 
with an apparent pA2  of 4.6 (Hourani et al., 1992). In some studies suramin has been 
observed to cause a steepening of concentration-response curves or a depression of 
the maximum response indicating non-competitive antagonism (Durm & Blakely, 
1988; Hoyle et al., 1990). However in the rabbit ear artery, suramin has been shown 
to be a slowly equilibrating antagonist with low concentrations of suramin (30pM) 
requiring long (3 hour) incubation periods, but high concentrations (ImM) requiring 
only short incubation periods (15 minutes) for competitive antagonism to be 
achieved (Leff et al., 1990). In the mouse vas deferens suramin shifts the 
concentration-response curves for AMPCPP, ATP-y-S, UTP and lower 
concentrations of ATP to the right, but the effects of higher concentrations of ATP
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are largely resistant to suramin, from which it has been suggested that ATP activates 
a suramin-insensitive site in addition to a suramin-sensitive P2x-purinoceptor (Von 
Kiigelgen et al., 1990). The presence of a suramin-insensitive contractile receptor in 
addition to a suramin-sensitive P2x-purinoceptor has also been suggested in the 
guinea-pig vas deferens, as suramin antagonises responses to AMPCPP, ATP-y-S, 
and UTP, but not responses to ATP which are potenciated at high concentrations 
(Bailey & Hourani, 1994; 1995).
Based on sensitivity to suramin there appear to be subtypes of P2(j-purinoceptors, as 
in rat PC 12 cells suramin is a competitive antagonist at P2xj-purinoceptors (Murrin & 
Boarder, 1991), whereas in bovine aortic endothelial cells (Wilkinson et al., 1993) 
and bovine aortic collateral arteries (Wilkinson et al., 1994a) which contain a mixed 
population of P2Y and P2U subtypes, suramin is a competitive antagonist of the P2Y 
selective agonists, but has little effect on the responses to UTP. This is further 
supported by the observations that suramin shifts the concentration-response curves 
for ATP, UTP and ATP-y-S in the rat aorta, but not in canine tracheal epithelial cells, 
which both contain P2xj-purinoceptors (Dainty et al., 1994).
Suramin as well as being a P2-purinoceptor antagonist, has a number of other 
pharmacological actions (Wills & Wormall, 1950; Voogd et al., 1993), including the 
ability to inhibit ectonucleotidases (Hourani & Chown, 1989; Crack et al., 1994) 
which rapidly dephosphoiylate ATP and some of its analogues (see section 1.3.1.). A 
’self cancelling’ effect of P2-purinoceptor antagonism and inhibition of 
ectonucleotidases by suramin has been suggested to explain the differential effects of 
suramin on ATP analogues in the rabbit ear artery (Crack et al., 1994), in which 
suramin causes a large shift to the right in the concentration-response curve for 
AMPCPP (an ATP analogue resistant to degradation by ectonucleotidases; Welford
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et al., 1986; 1987) (Leff et al., 1990), whereas the concentration-response curve to 
ATP is only slightly shifted to the right (Crack et al., 1994). It has thus been 
proposed that the inhibition of ectonucleotidases by suramin leads to enhanced 
potency of ATP which would oppose any shift in its observed concentration-response 
curve, whereas the shift in the concentration-response curve for AMPCPP is due 
primarily to receptor antagonism.
An analogue of ATP which has been shown to be a competitive antagonist at P2X“ 
purinoceptors in the rabbit ear artery is p,y-methylenedibromo-2-methylthio-L-ATP 
(FPL 66301) (Leff et al., 1993). However, like suramin, FPL 66301 is also an 
ectonucleotidase inhibitor, and causes a greater shift to the right of the 
concentration-response curve for AMPCPP than for ATP (Leff et al., 1993; Crack et 
a/., 1994).
A compound of recent interest is pyridoxalphosphate-6-azophenyl-2,4-disulphonic 
acid (PPADS), which in tissues such as the rabbit vas deferens (Lambrecht et al., 
1992), rabbit urinary bladder (Ziganshin et a l, 1993), guinea-pig vas deferens 
(McLaren et al., 1994) and rabbit central ear and saphenous arteries (Ziganshin et 
al., 1994b), has been shown to antagonise responses to AMPCPP indicating an 
action at P2X"Purinoceptors. PPADS has also be shown to be an antagonist at the 
P2X"Purinoceptor cloned from rat vas deferens (Valera et a l, 1994) and human 
urinary bladder (Evans et a l, 1995). However, whilst in the above studies PPADS at 
concentrations of <30pM was observed to be a P2x-purinoceptor antagonist, the 
concentration of PPADS appears to discriminate between different P2y- 
purinoceptors. At concentrations of <30pM PPADS has been shown to be a 
competitive antagonist at the P2Y-purinoceptor coupled to PLC on turkey 
erythrocytes, but not at concentrations of up to lOOpM at the P2Y"purinoceptor
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which inhibits adenylyl cyclase on G6  rat glioma cells (Boyer et aL, 1994). In 
contrast, in the guinea-pig taenia caeci and rat duodenum PPADS at higher 
concentrations of 100 and 30pM respectively was found to antagonise P2y-mediated 
responses to 2-MeSATP (Ziyal et al., 1994). Use of low concentration of PPADS 
appears to allow discrimination between P2 subtypes, as in the rat mesenteric arterial 
bed PPADS (lOpM) is observed to antagonise P2X“PUJ'inoceptor mediated 
vasoconstriction, but only slightly antagonise P2Y-pwinoceptor mediated 
vasodilation, whereas responses to separate P2%j-purinoceptors mediating 
vasodilation and vasoconstriction are not antagonised (Windscheif et a l, 1994). 
However, at a concentration of >10pM, PPADS has been shown to inhibit 
ectonucleotidase activity in the taenia caeci, which can complicate its use as an 
antagonist (Windscheif et a l, 1995).
ATP and analogues of ATP and AMP (Macfarlane & Mills, 1975; Cusack & 
Hourani, 1982a, b) and suramin (Hourani et a l, 1992), are antagonists at the P2 T- 
purinoceptor, but are non-selective for P2T compared to other P2 subtypes. An ATP 
analogue which has been shown to be a potent and selective P2x-purinoceptor 
antagonist is 2-propylthio-D-P,y-diflouro-methylene ATP (FPL 66096), which shows 
no agonist or antagonist activity at P2X or P2Y purinoceptors at a concentration of 
3|xM (1400 fold higher than its Kg against ADP-induced platelet aggregation) 
(Humphries et a l, 1994).
In the absence of truly selective P2 -purinoceptor antagonists desensitisation has been 
used to try and discriminate between P2  subtypes. ATP was initially used as the 
desensitising agent (Ambache & Zar, 1970), but it can induce prostaglandin 
synthesis and is rapidly dephosphorylated by ectonucleotidases which can influence 
its action as a desensitising agent. However, the methylenephosphonate analogues of
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ATP are resistant to dephosphorylation (Welford et al., 1986; 1987) and do not 
induce prostaglandin synthesis (Brown & Bumstock, 1981), making them more 
suitable for this purpose. L-AMPPCP has been shown to be a more potent contractile 
agonist than AMPCPP or AMPPCP (Cusack & Hourani, 1984), and also readily 
induces desensitisation of the P2X“Purinoceptors in the urinary bladder (Hourani,
1984). An advantage of using L-AMPPCP as a desensitising agonist is that in 
addition to being resistant to degradation by ectonucleotidases, its potential 
breakdown product L-adenosine is inactive (Cusack & Hourani, 1984). Repeated 
administration of AMPCPP has been used to selectively desensitize P2X" 
purinoceptors in a number of visceral and vascular smooth muscle preparations such 
as guinea-pig urinary bladder (Kasakov & Bumstock, 1983), guinea-pig vas deferens 
(Meldrum & Bumstock, 1983), rat pulmonary vessels (Liu et al., 1989b) and rat 
portal vein (Reilly & Bumstock, 1987). However, although desensitisation readily 
occurs at the P2X subtype cloned from rat vas deferens (Valera et al., 1994) and rat 
dorsal root ganglia (Chen et al., 1995), at the P2X subtype cloned from rat PC12 
(neuronal) cells desensitisation occurs slowly (Brake et al., 1994).
In contrast to P2x-purinoceptors, P2Y“purinoceptors such as those in the guinea-pig 
taenia caeci and rabbit portal vein, generally do not readily undergo marked 
desensitisation although in some tissues such as rabbit and cat colon desensitisation 
of P2Y-purinoceptors has been reported (Crema et al., 1982; Hedlund et ah, 1983; 
Bumstock & Kennedy, 1985). The P2Y"Purinoceptor on turkey erythrocytes has also 
been shown to undergo desensitisation following preincubation with ADP-p-S 
(Martin & Harden, 1989). P2xj-purinoceptors also do not readily undergo marked 
desensitisation, although in bovine aortic endothelial cells desensitisation of the P2U- 
purinoceptor in response to UTP has been observed. P2Y-purinoceptors are also 
present in this tissue which undergo desensitisation in response to 2-MeSATP, but
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interestingly whereas desensitisation of the P2Y receptor does not affect the P21J 
receptor, desensitisation of the P2U receptor causes heterologous desensitisation of 
the P2Y receptor by a PKC dependent mechanism (Wilkinson et al., 1994b).
1.5. URIDINE 5’-TRIPHOSPHATE
Although most research has centred on the actions of adenine nucleotides, there is 
increasing interest in the effects of other nucleoside triphosphates, in particular the 
pyrimidine nucleotide UTP. Uracil nucleotides can be synthesised via de novo 
synthesis and salvage pathways in the body to meet metabolic needs (Traut, 1994), 
but there is little known about their storage and regulation of release. It is known 
they are stored in platelet granules where they are released upon platelet activation, 
and in adrenal medullary chromaffin granules (Goetz et al., 1971), and are also 
present in appreciable amounts in the liver, brain, kidney, various blood cells and to 
a lesser extent in skeletal muscle (Keppler et al., 1970; Traut, 1994). UTP is active 
in eliciting responses in many tissues, and can bring about relaxation and contraction 
of smooth muscle via acting at receptors, although differences in the specificity of 
uracil nucleotides between different tissues suggests there are multiple receptors at 
which they act. Furthermore, the presence of receptors at which uracil nucleotides 
can act does support the idea that they are important extracellular signalling 
compounds.
1.5.1. Activation Of Purinoceptors And Pyrimidinoceptors By Uridine 5’- 
Triphosphate
UTP is a potent agonist at the P2u-purinoceptor as previously mentioned (see section 
1.4.2.3.). However the actions of UTP cannot be solely attributed to the P2U subtype.
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as in some tissues where UTP is approximately equipotent with ATP in eliciting the 
same functional response, UTP has been shown to act at purinoceptors not of the P2U 
subtype. For example, in the mouse vas deferens at which the agonist potency order 
in eliciting contraction is AMPCPP>ATP-y-S>ATP>UTP, prolonged exposure to 
AMPCPP reduces the contractile responses to ATP, UTP and ATP-y-S, indicating an 
action at the P2X subtype. Furthermore, cross-desensitisation is seen between ATP 
and UTP and suramin antagonises the response to all four of the nucleotides (Von 
Kiigelgen gr a/., 1989b; 1990).
UTP has been shown to act at prejunctional P%-purinoceptors in the mouse and rat 
vas deferens, as the Pj-purinoceptor antagonist 8 -SPT blocks its ability to reduce 
presynaptic transmitter release of noradrenaline. As its potential breakdown product 
uridine is inactive in this tissue these effects are likely to be direct (Von Kiigelgen et 
al., 1989b). Similarly in the rat vas deferens, 8 -SPT has been shown to antagonise 
inhibition of presynaptic noradrenaline release by UTP. However, in the rat vas 
deferens it was suggested that UTP is acting at the putative Pg-purinoceptor as 
proposed by Shinozuka et al. (1988) (see section 1.4.1.1.). This was based on the 
observations that 8 -SPT also antagonised inhibition of presynaptic noradrenaline 
release by ATP, AMPCPP, adenosine and 2-CADO, and as adenosine deaminase 
reduced responses to adenosine but not ATP this was likely a direct action of all the 
nucleosides and nucleotides at a prejunctional receptor (Forsyth et al., 1991).
Pyrimidinoceptors, analogous to purinoceptors but responding to uracil nucleotides 
and at which adenine nucleotides are inactive, have been proposed to exist partly on 
the basis of differences in the responses of some tissues to ATP and UTP (Seifert & 
Schultz, 1989). For example, in perfused rat liver differences such as haemodynamic 
changes, oxygen consumption, net K+ and Ca^+ movements across the hepatocyte
64
plasma membrane and stimulation of glycogenolysis has led to the proposal that the 
action of ATP was primarily due to its action at a P2Y-purinoceptor, whereas the 
action of UTP involved a separate receptor (Haussinger et al., 1987). Differences in 
the response of superoxide formation by ATP and UTP have been observed in human 
neutrophils and differentiated HL60 cells, and it has thus been suggested that ATP 
and UTP act on purino- and pyrimidino- ceptors respectively (Seifert et al., 1989a). 
Although there are some differences between the responses to UTP and ATP in some 
tissues, the evidence for pyrimidinoceptors has not always been conclusive, and in 
isolated hepatocytes it has been concluded that no differences are observed between 
ATP and UTP and they are in fact acting at the same P2  receptors (Keppens et al., 
1992; Keppens, 1993). In addition, some of the effects elicited by ATP and UTP in 
human neutrophils have since been attributed to P2U receptors, such as superoxide 
fonnation by ATP and UTP (Seifert et al., 1989b), and increases in intracellular 
Ca2+(Walker g/a/., 1991).
In a number of blood vessels desensitisation has been used to discriminate between 
the contractile responses to ATP and UTP, providing some support for the existence 
of pyrimidinoceptors. For example, in the smooth muscle of the rat tail and femoral 
arteries and dog saphenous vein, ATP but not UTP induced contractions are 
desensitized by AMPCPP. Furthennore, ATP and UTP desensitized responses to 
themselves but not to each other, which has been taken to indicate that ATP and 
UTP elicit contraction via a P2X“purinoceptor and a pyrimidinoceptor respectively 
(Saïag et al., 1987; 1990). In the rabbit basilar artery ATP-y-S, ATP and UTP are 
observed to elicit marked contractions, unlike AMPCPP, AMPPCP and 2-MeSATP 
which are almost inactive, and could therefore suggests the presence of a 
contraction-mediating P2xj-purinoceptor. However, subsequent responses to ATP are 
reduced following prolonged exposure to ATP-y-S, whilst subsequent responses to
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UTP are slightly enhanced. Furthermore, ATP was found to elicit marked additional 
vasoconstriction after precontraction with UTP, whereas UTP elicited only a small 
additional vasoconstriction after precontraction with itself. It has thus been suggested 
that the UTP induced contractions are mediated via a pyrimidinoceptor, whereas the 
ATP induced contractions are mediated via a P2 receptor. In addition, reactive blue 2 
did not reduce the responses to ATP or UTP, indicating it was unable to antagonise 
the P2"purinoceptor or pyrimidinoceptor in this tissue (Von Kiigelgen & Starke, 
1990).
Neurones of the rat superior cervical ganglion, undergo depolarisation/ 
hyperpolarisation in response to purines and pyrimidines. The potency order in 
eliciting depolarisation of these neurones is UTP>AMPCPP»2-MeSATP, whereas 
the potency order in eliciting hyperpolarisation is adenosine=AMPPCP>ATP, 
although ATP induced hyperpolarisations are reversed into depolarisations and the 
adenosine induced hyperpolarisations abolished in the presence of the Pj- 
purinoceptor antagonist 8 -PT (Connolly et al., 1993). It has also been observed that 
AMPCPP desensitized subsequent depolarisations to AMPCPP and ATP (in the 
presence of the Pj-purinoceptor antagonist DPCPX) but not those to UTP, whereas 
UTP desensitized subsequent depolarisations to UTP but not those to AMPCPP. It 
has therefore been suggested that depolarisations to AMPCPP and UTP are mediated 
via a P2x-purinoceptor and pyrimidinoceptor respectively (Connolly, 1994). This is 
further supported with the demonstrations that suramin reduces depolarisations to 
AMPCPP whilst potentiating those to UTP (Connolly et al., 1993), reactive blue 2 
antagonises responses to ATP and AMPCPP, but not those to UTP (Connolly & 
Harrison, 1994) and that PPADS antagonises responses to AMPCPP, but not those to 
UTP (Connolly, 1995). The proposed P2 antagonists, suramin, reactive blue 2 and 
PPADS are thus able to discriminate between this neuronal P2X"Purinoceptor and
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pyrimidinoceptor.
A receptor at which UDP is a more potent agonist than UTP, and at which purine 
nucleotides are inactive has been reported in rat C6-2B glioma cells. This receptor is 
coupled to PLC by a pertussis toxin sensitive G-protein, and is susceptible to 
desensitisation by UDP and UTP (Lazarowski & Harden, 1994). In addition to this 
uridine nucleotide receptor (or pyrimidinoceptor), a P2y-purinoceptor which inhibits 
adenylyl cyclase has also been reported in rat C6-2B glioma cells (Boyer et al., 1993;
1994). In contrast, other workers have shown that in rat C6-2B glioma cells there is 
P2(j-purinoceptor linked to PLC by a pertussis toxin-insensitive G-protein, as well as 
a P2Y“purinoceptor linked to adenylyl cyclase by a pertussis toxin-sensitive 
G-protein (Lin & Chuang, 1994). This difference in receptor populations has since 
been attributed to the subclone of C6-2B glioma cells used, but illustrates that 
conflicting data is often reported in the literature (Lazarowski & Harden, 1994).
1.6. BINDING STUDIES
To date characterisation of the P2-purinoceptor family has been hampered by a lack 
of suitable radioligands, and with a lack of selective competitive P2-purinoceptor 
antagonists, a number of radiolabelled P2~purinoceptor agonists have been used in 
binding studies. However, there are a number of problems which can result from the 
use of P2 agonists in binding studies, and these include their degradation by 
ectonucleotidases, binding of some agonists to more than one P2  subtype and non­
specific binding to other ATP binding proteins.
P^S]ADP-P-S (Cooper et al., 1989) and a photoaffinity analogue of ATP, BzATP 
(Boyer et al., 1990), have been used in binding studies in turkey erythrocyte
67
membranes. Both S]ADP-p-S and [a^^P]BzATP were found to bind to a single 
population of high affinity sites, which were displaced with a series of agonists 
indicative of the P2Y subtype (Cooper et al., 1989; Boyer et al., 1990). After binding 
of p 5S] ADP-P-S and photoaffinity labelling by [a^^P]BzATP of this P2Y subtype, 
solubilisation of the membrane revealed a labelled protein species of apparent 
molecular mass >300-kDa. Incubation of this labelled protein species with guanosine 
5-0-(3-thiotriphosphate) (GTP-y-S) resulted in loss of labelling by p^S]ADP-P-S 
and a shift in the apparent size of the covalently [a^^P]BzATP labelled species to an 
apparent molecular weight of 53-kDa. It was concluded that the P2Y“Purinoceptor 
and its associated G-protein form a macromolecular complex of molecular weight 
>300-kDa, from which the G-protein complex is lost with gaunine nucleotide 
incubation, leaving the ligand binding subunit of the P2Y“purinoceptor of apparent 
molecular mass of 53-kDa (Boyer et ah, 1990; Jeffs et al., 1991). The molecular 
weight of the P2Y-purinoceptors cloned from chick whole brain and bovine aortic 
endothelial cells have been calculated to be 41-kDa and 42-kDa respectively (Webb 
et al., 1993; Henderson et al., 1995), and the higher molecular weight of the P2Y 
receptor solubilized from turkey erythrocyte membranes (53-kDa) may therefore 
reflect glycosylation.
P^S]ADP-P-S has also been used in binding studies in bovine aortic and bovine 
adrenal medulla endothelial cells. In bovine aortic endothelial cells p^S]ADP-P-S 
has been shown to bind to two sites, one of low affinity and the other of high affinity. 
Bovine aortic endothelial cells have been shown to contain both P2Y- and P2U- 
purinoceptors, with ADP-P-S acting only at the p2Y"Purinoceptor, but the order of 
potency of a series of nucleotides in inhibiting p^S] ADP-P-S binding was ADP-p-S> 
ATP-y-S»ATP>AMPPCP>2-MeSATP>UTP which is not characteristic of the 
presence of a P2Y-parinoceptor. However, in the presence of AMPPCP,
68
S] ADP-p-S binding was observed to be at a single site, although displacement of 
P^S]ADP-p-S was still inhibited by nucleotides with a potency order not 
characteristic of a P2Y-purinoceptor (ATP-y-S=ADP-P-S»2-MeSATP>UTP). In 
bovine adrenal medulla endothelial cells which have been shown to contain P2%j- 
purinoceptors at which ADP-p-S is not an agonist, p^S]ADP-P-S was also shown to 
bind to one site (Wilkinson & Boarder, 1995). This indicates that although 
P^S] ADP-P-S may be of use as a radioligand for the P2Y-purinoceptor, it is only so 
in the absence of non-specific binding.
A radioligand which has been used to investigate the P2X"purinoceptor is 
[^H]AMPCPP, but like p^S]ADP-p-S has been shown to bind to sites other than P2- 
purinoceptors, and it has been shown that divalent cations have a marked effect on 
the binding of AMPCPP. In the absence of divalent cations AMPCPP has 
been shown to label both high and low affinity binding sites in the rat vas deferens, 
but whereas in the presence of CaCl2 the affinity of the radioligand for its high 
affinity sites is increased, enabling these sites to be selectively labelled, in the 
presence of MgCl2 the B^^x the low affinity binding sites is increased, enabling 
these sites to be selectively labelled (Michel & Humphrey, 1994). The rat vas 
deferens membrane has been shown to contain high affinity and low affinity binding 
sites for pH] AMPCPP, with the rank order of displacement by a series of agonists at 
the high affinity binding site being characteristic of the P2x-purinoceptor (Bo et al., 
1992). High affinity binding sites for [^H]AMPCPP have also been identified in a 
wide range of tissues which include the urinary bladder (Bo & Bumstock, 1990), 
spleen, heart, cerebral cortex and liver (Michel & Humphrey, 1993) and blood 
vessels (Bo & Bumstock, 1993). Photoaffinity labelling of pH]AMPCPP to the P2X- 
purinoceptor on rat vas deferens membrane has been shown on solubilisation of the 
membrane to reveal a polypeptide of apparent molecular weight of 62-kDa, which is
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proposed to be the ligand binding subunit of the P2x-purinoceptor (Bo et a l, 1992). 
The apparent molecular mass of the P2X receptors cloned from rat vas deferens and 
rat dorsal root ganglia have been calculated to be 45-kDa (Valera et a l, 1994; Chen 
et al., 1995), and the higher molecular weight of the P2X receptor solubilized from 
rat vas deferens (62-kDa) may therefore reflect glycosylation.
As well as p^S]ADP-|3-S and pH]AMPCPP a number of other radioligands have 
been used in binding studies, and similar problems in terms of binding to sites other 
than P2-purinoceptors as well as differing potency orders of nucleotides between 
binding and functional studies have been seen. p^S]ATP-a-S (Keppens & De Wulf, 
1986; 1991; Keppens et al., 1989; 1990) and p^S]ADP-p-S (Keppens et al., 1993; 
Van Rhee et al., 1993) have been used to bind to P2-purinoceptors in liver 
parenchymal cells and intact hepatocyte plasma membranes. The data from these 
studies, along with those from functional studies, has been taken to suggest that liver 
contains a mixed population of receptors of differing affinity for these ligands, which 
appear to include P2Y and P2U subtypes (Keppens, 1993). In addition, [^H]Ap^A and 
P^S]ADP-p-S have been used in binding studies in rat brain synaptic terminals, for 
which it was found that the rank order of displacement by a series of adenine 
nucleotides and dinucleotides was not characteristic of binding to any of the 
recognised P2 subtypes (Pintor et al., 1993). This was taken by Pintor and colleagues 
to suggest the presence of a new P2-purinoceptor which they tentatively termed as a 
P2D-purinoceptor.
1.7. CLONED P2 -PURINOCEPTORS
Only recently has molecular information concerning P2 -purinoceptors started to 
become available with the cloning of some of the cDNAs of this family of receptors.
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and their subsequent expression in isolated cells. Several cDNAs encoding receptors 
with structural features characteristic of G-protein coupled receptors at which 
adenine and/or uracil nucleotides are active have now been cloned. They have seven 
hydrophobic domains, a consensus N-linked glycosylation sequence near the amino 
tenuinus, potential phosphorylation sites in intracellular and carboxy tenninal 
domains, and contain a number of residues which are highly conserved among other 
G-protein coupled receptors. Upon expression in isolated cells, these receptors have 
been shown to have structure-activity relationships characteristic of either the P2Y- 
or P2u-purinoceptor subtypes.
A cDNA encoding a P2-purinoceptor of the P2Y subtype was originally cloned from 
chick whole brains. The agonist potency order at this receptor was 2-MeSATP>ATP 
>ADP»AMPCPP=AMPPCP=UTP, and for which suramin and reactive blue 2 were 
antagonists. The messenger RNA (mRNA) for this receptor was detected in chick 
brain, spinal chord, gastrointestinal tract, spleen and leg muscle, but not in the heart, 
liver, stomach, lung or kidney (Webb et a l, 1993). A wide distribution of this mRNA 
was subsequently shown in the cerebellum and telencephalon and in specific nuclei 
of the mesencephalon and diencephalon of one day post hatched chick brain, 
suggesting a neuronal localisation of this P2Y-purinoceptor (Webb et a l, 1994). A 
cDNA has also been isolated from turkey whole brains, which shows >98% 
homology to the cDNA from chick whole brains, and encodes a receptor which when 
expressed in isolated cells has a structure-activity relationship characteristic of a 
P2Y"purinoceptor. The distribution of the turkey mRNA differed slightly from that of 
the chick, as it was widely distributed in brain, lung, blood and to a lesser extent in 
the stomach, gut and skeletal muscle (Filtz et al., 1994). P2Y-purinoceptors have also 
been cloned from bovine aortic endothelial cells (Henderson et al., 1995) and rat and 
mouse insulinoma cells (Tokuyama et al., 1995), which all show approximately 8 6 %
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homology with the P2Y-purinoceptor cloned from chick whole brain. As all of these 
cloned P2Y-purinoceptors show a high homology to each other, they have been at 
present tentatively grouped as a single P2Y subtype (P2yi)-
A cDNA encoding a G-protein coupled P2 -purinoceptor not of the P2Y-subtype was 
originally cloned from mouse neuroblastoma-glioma hybrid (NG108-15) cells. This 
receptor has the characteristics of a P2u-purinoceptor as ATP and UTP are 
approximately equipotent in eliciting a response, and at which ATP-y-S is also a 
potent agonist, whilst 2-MeSATP, AMPCPP, AMPPCP, ADP and adenosine show 
little or no activity. The mRNA of this receptor is also widely distributed, being 
present in the spleen, testes, kidney, liver, lung, heart, brain and neuroblastoma cells 
(Lustig et aL, 1993). However, this receptor, although in the same family of 
G-protein coupled receptors as the P2Y-subtypes described above, shares only about 
40% homology with them (Barnard et al., 1994). Other cDNAs encoding receptors of 
the P2U subtype have also been cloned, and show widespread but slightly different 
distribution to the P21J subtype cloned from the mouse. A P2U receptor has been 
cloned from rat alveolar type II cells (Rice et al., 1995) which show >97% homology 
with the mouse P2U, and from human airway epithelial (CF/T43) and colonic 
epithelial (HT29) cells (Parr et al., 1994) which shows 89% homology with the 
mouse P2U- In addition, these P2u-purinoceptors also only show approximately 
35-40% homology to the cloned P2Y"pnrinoceptors (Parr et al., 1994; Rice et al.,
1995). As all of these cloned P2u-purinoceptors are G-protein coupled and show a 
high homology to each other, but not to the cloned P2Y-purinoceptors, they have 
been at present tentatively grouped as a second P2Y subtype (P2 Y2 )-
A further P2 -purinoceptor has been cloned from chick whole brain but for which no 
primary data has yet been published. This G-protein coupled receptor when
72
expressed in isolated cells has been reported to have a strong preference for ADP, 
but as ATP is of similar potency as an agonist it is not identical to the P2T- 
purinoceptor of human platelets. This receptor shows only 39% homology to the 
P2Y-purinoceptor cloned from chick whole brain, and its mRNA has been reported to 
be present within some peripheral tissues as well as the brain (Barnard et al., 1995; 
Harden et al., 1995). This receptor has been tentatively assigned as a third P2Y 
subtype (P2Y3>-
The cDNAs encoding P2-purinoceptors with the structural features characteristic of 
ligand-gated ion channels (e.g. two hydrophobic transmembrane domains and a pore 
forming motif) have been cloned from the rat vas deferens (Valera et al., 1994), rat 
pheochromocytoma PC 12 cells (Brake et al., 1994) and rat dorsal root ganglia (Chen 
et al., 1995). These cloned receptors are thus P2x-pwinoceptors, but as only about 
40-45% homology is shown between these receptors they appear to represent 
different subtypes of the P2x-purinoceptor family (Chen et a l, 1995; Surprenant et 
a l, 1995). In addition, pharmacological differences are seen between these P2X 
subtypes when they are expressed in isolated cells, such as differences in agonist- 
potency orders (see section 1 .4.2.1.) and sensitivity to desensitisation (see section 
1.4.2.7.), further supporting that there is more than one type of the P2X subtype, 
although at each type suramin is an antagonist (Brake et a l, 1994; Valera et a l, 
1994; Chen et a l, 1995). Although the primary data has yet been published, a P2X“ 
purinoceptor has also been cloned from human urinaiy bladder smooth muscle which 
is the human homologue of the P2x-purinoceptor cloned from the rat vas deferens 
(Evans et a l, 1995). It has been proposed that the cloned receptor from the rat vas 
deferens represents the P2x-purinoceptor found on tissues such as visceral and 
vascular smooth muscle, whereas the cloned receptor from the rat PC 12 cells 
represents the P2x-purinoceptor found in a number of neuronal tissues (Surprenant et
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al., 1995), which agrees with the tissue distribution of the mRNA for these cloned 
receptors (Brake et al., 1994; Valera et al., 1994). In addition, the tissue distribution 
of the mRNA for the cloned receptor from rat dorsal root ganglia indicates it 
represents a P2X"purinoceptor found in sensory neurones (Chen et al., 1995). It has 
also been shown that the P2x-purinoceptor cloned rat dorsal root ganglia does not 
only form a functional ion channel when expressed on its own, but can also form a 
heteromultimer when coexpressed with the P2x-purinoceptor cloned from rat PCI2 
cells, but not with the P2X“purinoceptors cloned from rat vas deferens or human 
urinary bladder, and therefore has characteristics of both receptors (AMPCPP 
sensitive, non-desensitising) (Lewis et al., 1995). The P2x-purinoceptors cloned from 
rat vas deferens, PC 12 cells and dorsal root ganglia have been assigned as P2X1, 
P2X2 P2X3 subtypes, with the P2x-purinoceptor cloned from human urinary 
bladder appearing to be of the P2X1 subtypes.
Not only have P2X“> ^2Y" P2U"P i^i^oceptors been cloned, but so has a receptor 
with a preference for pyrimidine over purine nucleotides. This receptor, which has 
been isolated from a human genomic DNA library, is a G-protein coupled receptor 
with a molecular weight of 36.5-kDa, but which has no N-glycosylation consensus 
sequence. UTP and UDP have both been shown to be potent and full agonists at this 
receptor, whereas ATP has been shown to be less potent and a partial agonist, ADP 
to be only slightly active and 2-MeSATP to be inactive. However this 
pyrimidinoceptor, which only shows 35% homology to the cloned chick P2Y- 
purinoceptor and 51% homology to the cloned human colonic and airway epithelial 
P2U"purinoceptor, appears to be a member of the same family of G-protein coupled 
receptors (Communi et al., 1995a).
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1.8. REVISION OF P2 -PÜRINOCEPTOR NOMENCLATURE
With the recent cloning of members of the P2-purinoceptor family structural 
information has started to become available, and although incomplete, a revision of 
the existing nomenclature is presently underway to meet the criteria of the lUPHAR 
Committee on Receptor Nomenclature and Drug Classification. It has been proposed 
that the receptors will fall into two main classes, those that are intrinsic ion channels 
(P2X family) and those that are G-protein coupled receptors (P2Y family), and a 
further class consisting of receptors that do not fall into either of the other two 
categories such as the receptor on mast cells and macrophages which are non- 
selective pores (P2Z family), at least for the time being. Whether a complete revision 
of the nomenclature will eventually arise with receptor designation occurring from 
the start of the alphabet, such as P^a, P2b> etc., or a numerical system such as P2 1, 
P2 2 Gtc. has yet to be established, although it has been suggested that any new 
receptor subtypes should be designated as P2 Xi 2,3 .. 2 3^ ... etc. to prevent
confusion with the present usage of subscripts, and to facilitate the use of lower case 
such as in p2yl, p2y2,...etc. to refer to the cloned receptors (Abbracchio & 
Bumstock, 1994; Fredholm et al., 1994; Fredholm, 1995b). However, with this 
classification the presently recognised P2Y, P2U ^ 2 1  subtypes fall into the same 
category of the P2Y-purinoceptor family.
In light of the uncertainty concerning the future nomenclature of the P2 -purinoceptor 
family I have used the current and widely recognised nomenclature in the writing of 
this thesis, although it will be interesting to see how the proposed pyrimidinoceptors 
and dinucleotide receptors (P2D and P4 ), will fall into the newly revised P2 - 
purinoceptor nomenclature.
75
1.9. PHARMACOLOGICAL ACTIONS OF ADENOSINE 5'-
TRIPHOSPHATE, URIDINE 5-TRIPHOSPHATE AND RELATED
ANALOGUES IN SMOOTH MUSCLE
In a wide variety of cells and tissues the pharmacological actions of ATP and UTP, 
as well as some of their analogues, are mediated via P2X-, P2Y“ P2%j- 
purinoceptors (summarised within Tables 3 and 4). This includes visceral smooth 
muscle (e.g. gastrointestinal tract, vas deferens and urinary bladder), and vascular 
smooth muscle and endothelial cells, which are reviewed in detail in the following 
sections. However, in most tissues there are mixed populations of P%- and P2- 
purinoceptors, and as ectonucleotidases which rapidly dephosphorylate ATP and 
some of its analogues to adenosine are present on the surface of these cells, a brief 
discussion of the action of P % -purinoceptors in these tissues has also been made.
1.9.1. Gastrointestinal tract
The gastrointestinal tract comprises a number of tissues including the stomach, 
duodenum, ileum, taenia caeci, colon and anococcygeus, each of which are reviewed 
in turn.
1.9.1.1. Stomach
It has been shown that the rat gastric fundus longitudinal muscle relaxes to purines 
with an agonist potency order of 2-MeSATP»AMPCPP>ATP»adenosine, and that 
relaxations induced by ATP and 2-MeSATP but not AMPCPP or adenosine are 
followed by contractions (Lefebvre & Bumstock, 1990; Matham & Hollingsworth, 
1992). As contractions have been shown to be reduced in the presence of
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Table 3. Pharmacological actions of ATP mediated via P2 X- and P2 Y"purinoceptors
in visceral and vascular tissues.
Tissue Receptor Response Reference
Rat duodenum P2Y Relaxation Hourani et a l, 1991
Guinea-pig ileum ?2Y Relaxation Kennedy & Humphrey, 1994
Rat colon
longitudinal muscle
^2Y Relaxation Bailey & Hourani, 1990
Rat colon
muscularis mucosae
?2Y Contraction Bailey & Hourani, 1992
Guinea-pig taenia 
caeci
^2Y Relaxation Satchell & Maguire, 1975 
Bumstock & Kennedy, 1985
Guinea-pig urinaiy 
bladder
?2X Contraction Hourani et a l, 1985 
Bumstock & Kennedy, 1985
Rat vas deferens f*2X Contraction Fedan et al., 1982b 
Bumstock & Kennedy, 1985
Rat pulmonaiy 
arteiy
?2X
^2Y
Contraction^
Relaxation^
Liu et al., 1989b
Human pulmonary 
arteiy
?2X
^2Y
Contraction^
Relaxation^
Liu et al., 1989a
Rat mesenteric 
arteiy
?2X
^2Y
Contraction^
Relaxation^
Ralevic & Bumstock, 1988
Rabbit ear artery ?2X Contraction Leff et al., 1990; 1993 
Crack et al., 1994
Bovine aortic 
endothelial cells
?2Y Increase in inositol 
phosphate
Motte et al., 1993b 
Wilkinson ûf/., 1993
Bovine aortic ^2Y Relaxation^ Wilkinson era/., 1994a
collateral artery rings
Table showing some pharmacological actions of ATP mediated via P2X- and P2Y- 
purinoceptors in visceral and vascular tissues, where  ^ and  ^ refer to location of 
receptor on vascular smooth muscle and endothelial cells respectively.
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Table 4. Pharmacological actions of UTP in various tissues.
Tissue 
Rat colon
muscularis mucosae
Rat tail and femoral 
artery and dog 
saphenous vein
Rat superior cervical 
ganglion
Rat PC 12 cells
Receptor Response
P2Y Contraction
Pyrimid Contraction
Pyrimid Membrane
depolarisation
Human fibroblasts
Rat renal mesangial 
cells
Human airway 
epithelial cells
Human nasal 
epithelial cells
Bovine aortic 
endothelial cells
Bovine aortic 
smooth muscle cells
Rat C6-2B glioma 
cells
2U
Sheep pituitary cells P2U
2U
2U
2U
2U
2U
2U
Increase in inositol 
phosphate
Increase in inositol 
phosphate
Increase in inositol 
phosphate
Increase in inositol 
phosphate
Increase in inositol 
phosphate
Increase in ion 
transport
Increase in inositol 
phosphate
Release of 
prostacyclin
Pyrimid Increase in inositol 
P21J phosphate
Reference
Bailey & Hourani, 1992 
Saiag g/ a/., 1987; 1990
Connolly, 1994 
Murrin & Boarder, 1992 
Davidson a/., 1990 
Fine et al., 1989 
Pfeilschifter, 1990 
Browne/'a/., 1991 
Masoned a/., 1991
Motte et al., 1993b 
Wilkinson et al., 1993
Demolle et al., 1988
Lazarowski & Harden, 1994 
Lin & Chuang, 1994
Table showing some pharmacological actions of UTP in various tissues. 
Pyrimidinoceptor abbreviated to 'Pyrimid’ for brevity.
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indomethacin this has been taken to indicate that they are 'rebound contractions' 
which are secondary to relaxation (Lefebvre & Bumstock, 1990), and 'rebound 
contractions' have been observed in other gastrointestinal tissues where they have 
been suggested to play a role in peristalsis, and have been shown to result from 
prostaglandin synthesis following activation of relaxant P2 -purinoceptors (Bumstock 
et al., 1975; Brown & Bumstock, 1981). However, whereas in the presence of 
indomethacin desensitisation with AMPCPP was shown to completely abolish 
relaxations induced by ATP, contractions induced by ATP were increased, which 
suggests that contractions are not completely secondary to relaxation and therefore 
not purely 'rebound contractions' (Matham & Hollingsworth, 1992). It has thus been 
proposed that in the rat gastric fundus longitudinal muscle there are separate 
receptors which mediate relaxation and contraction. As 2-MeSATP is more potent 
than ATP, and AMPCPP is inactive in inducing contraction (in presence or absence 
of indomethacin), contraction has been suggested to be mediated via a P2 Y- 
purinoceptor. In contrast, as AMPCPP is more potent than ATP in inducing 
relaxation, and complete desensitisation is seen to AMPCPP, it has been proposed 
that relaxation is mediated via a P2x-purinoceptor. However, in the presence of 
AMPCPP only slight desensitisation was seen to 2-MeSATP, unlike ATP, and it has 
therefore been suggested that relaxations to 2-MeSATP are mediated by a further 
mechanism as well as the P2X“Purinoceptor at which AMPCPP and ATP act 
(Matham & Hollingsworth, 1992). In addition, 8 -SPT has been shown to antagonise 
responses to adenosine but not to ATP, indicating the presence of a relaxation- 
mediating Pj-purinoceptor in this tissue (Matham & Hollingsworth, 1992).
I.9.I.2. Duodenum
The rat duodenum in response to ATP undergoes a transient relaxation followed by a
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rebound contraction. As this rebound contraction is abolished by indomethacin it 
appears to be mediated via prostaglandin synthesis, which can result from ?2Y- 
purinoceptor activation (Manzini et al., 1985). In addition, the agonist potency order 
in mediating relaxation of the rat duodenum has been shown to be 2-MeSATP 
>ATP>AMPCPP>AMPPCP, which is characteristic of a P2Y"puriiioceptor (Nicholls 
et al., 1990; Hourani et a l, 1991). At concentrations of lO-lOOpM both suramin 
(Ziyal et al., 1994) and PPADS (Windscheif et a l, 1995) have been shown to shift 
the relaxation concentration-response curve for 2-MeSATP to the right, a response 
which is characteristic of action at a P2Y-purinoceptor.
The rat duodenum also relaxes in response to adenosine, but as these relaxations are 
antagonised by methylxanthines such as theophylline, 8 -PT and 8 -SPT they are 
mediated by P%-purinoceptors (Gaion et al., 1988; Hourani et al., 1991). However, 
unlike relaxations induced by ATP, 2-MeSATP and AMPCPP, those induced by 
AMPPCP are antagonised by 8 -SPT. As AMPPCP is resistant to degradation by 
ectonucleotidases imlike ATP, AMPPCP induced relaxations appear to be due to a 
direct action at Pj-purinoceptors (Hourani et al., 1991). It has been shown that there 
are a mixed population of Pj-purinoceptors in the rat duodenum, as the potency 
order of a series of Pj agonists is NECA>CPA>AMPPCP=adenosine>CGS21680 
which is not characteristic of any one Pj subtype. As DPCPX at a concentration of 
InM antagonises relaxations induced by CPA and AMPPCP, and at a concentration 
of IpM those induced by NECA and adenosine, it has been suggested that the Pj- 
purinoceptors in the rat duodenum are a mixture of Aj and A2 subtypes. This also 
strongly supports a direct action of AMPPCP at the A% subtype, and not an indirect 
action via its degradation to adenosine, as the concentration of DPCPX required to 
antagonise relaxations to adenosine indicates its action at the A2 subtype, unlike 
AMPPCP. In addition, the low potency of CGS21680 indicates that the A2 receptor
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is of the A2B subtype (Nicholls et al., 1992a). It has since been demonstrated that the 
rat duodenum muscularis mucosae contains a contraction-mediating A2B receptor, 
and that the rat duodenum longitudinal muscle contains both A% and A2B receptors 
which mediate the same functional response of relaxation (Nicholls et a l, 1995).
The rat duodenum has been shown to degrade ATP rapidly and sequentially to ADP, 
AMP, adenosine and inosine, with around 10% of ATP remaining after 20 minutes. 
However, whilst inosine is the end product of ATP degradation in the presence of the 
duodemun, in buffer in which the duodenum had been incubated for 45 minutes and 
then removed AMP is the end product of degradation. This indicates that the 
enzymes responsible are not purely membrane bound ectoenzymes but also soluble 
enzymes which had leaked into the medium. However, degradation of AMP to 
adenosine appears to be due solely to an ecto-5'-nucleotidase (Nicholls et a l, 1992b).
I.9.I.3. Ileum
In the guinea-pig whole ileum and the guinea-pig ileum longitudinal muscle an 
action of ATP and adenosine is to inhibit nerve stimulated release of acetylcholine 
suggesting a prejunctional site of action, and as the P^  antagonists theophylline and 
8 -SPT antagonise this response it appears to be mediated via a P%-purinoceptor 
(Moody & Bumstock, 1982; Wiklund et al., 1985). Agonist potency order and 
antagonism by DPCPX suggest this Pj-receptor is of the Aj subtype (Coates et al., 
1994). This inhibitory action of ATP has been suggested to be partly mediated via its 
degradation to AMP and adenosine, as in the presence of 5'-AMP deaminase and 
adenosine deaminase responses to ATP are reduced, whereas they are potenciated in 
the presence of the adenosine uptake inhibitor dipyridamole (Moody & Bumstock, 
1982; Moody et al., 1984). A direct action of ATP has also been suggested, as the
81
inhibitory action of ATP is enhanced in the presence of compounds such as inosine 
5'-diphosphate (IDP) and inosine 5-triphosphate (ITP) (Wiklund & Gustafsson, 
1986), two compounds which have been shown to reduce the breakdown of ADP and 
ATP respectively in pig aortic smooth muscle and endothelial cells (Pearson et al., 
1980).
ATP and several of its analogues have also been shown to contract the guinea-pig 
whole ileum (Moody & Bumstock, 1982) and the guinea-pig ileum longitudinal 
muscle (Wiklund et al., 1985; Wiklund & Gustafsson, 1988a, b; Kennedy & 
Humphrey, 1994) whereas AMP and adenosine do not, indicating the presence of a 
P2-purinoceptor. It was shown by Wiklund and Gustafsson (1988b) that the agonist 
potency order for mediating contraction of the guinea-pig ileum longitudinal muscle 
was 2-MeSATP>ATP=ADP, and that contractions induced by ATP were not 
antagonised by the putative P2Y'Purinoceptor antagonist reactive blue 2 , nor 
desensitized by AMPCPP. These authors therefore concluded, that as the 
observations did not fit the classical P2x~ and P2Y“purinoceptor subtypes as proposed 
by Bumstock & Kennedy (1985), then the P2-purinoceptor in the guinea-pig ileiun 
represented a novel subtype which they tentatively designated a P2 s-purinoceptor. 
However, reactive blue 2 only shows some selectivity for the P2Y-purinoceptor 
within a narrow concentration range of below lOOpM (Kennedy, 1990), and cannot 
be considered selective for the P2Y subtype particularly when used at higher 
concentrations such as ImM as used by Wiklund and Gustafsson (1988b). Also, 
whilst desensitisation by AMPCPP has been used as evidence of the P2 X subtype, 
recent data from the cloning of P2x~purinoceptors has shown that although 
desensitisation readily occurs at the P2X subtype cloned from rat vas deferens 
(Valera et al., 1994) and rat dorsal root ganglia (Chen et al., 1995), at the P2X 
subtype cloned from rat PC 12 cells desensitisation only occurs slowly and not to
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AMPCPP which is inactive at this P2X subtype (Brake et a l, 1994). The suggestion 
of a P2 s-purinoceptor has therefore not gained wide acceptance. AMPCPP also 
contracts the guinea-pig ileum longitudinal muscle, but unlike contractions to ATP, 
those to AMPCPP are desensitized in response to AMPCPP, which suggests the 
presence of a separate contraction-mediating receptor in addition to the contraction- 
mediating receptor tentatively termed as a P2 S‘purinoceptor (Wiklund & Gustafsson, 
1988b). It has since been shown in the guinea-pig ileum longitudinal muscle that 
contractions induced by both AMPCPP and 2-MeSATP are antagonised by suramin, 
and those to AMPCPP but not to 2-MeSATP or ATP are also antagonised by 
atropine and tetrodotoxin (Kennedy & Humphrey, 1994). Furthermore, contractions 
induced by 2-MeSATP and ATP are not reduced by indomethacin indicating they are 
not mediated via prostaglandins (Wiklund & Gustafsson, 1988a). It has thus been 
suggested that there is a prejunctional P2X“purinoceptor at which AMPCPP acts, and 
that there is also a postjunctional P2 -purinoceptor located on the longitudinal muscle 
(designated as a P2 s-purinoceptor by Wiklund and Gustafsson (1988b)), which based 
on a greater potency of 2-MeSATP relative to ATP has characteristics of the P2Y 
subtype (Kennedy & Humphrey, 1994). In the longitudinal muscle UTP was found 
not to elicit contraction and therefore indicates purinoceptors of the P2U subtype are 
not present (Kennedy & Humphrey, 1994).
I.9.I.4. Colon
The smooth muscle of the rat colon has been demonstrated to contain a mixed 
population of Pj- and P2 -purinoceptors which mediate both contraction and 
relaxation of this tissue. The location of these receptors are however differentially 
located on the separate muscle layers of the colon.
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It has been shown that the rat colon longitudinal muscle relaxes to purines with an 
agonist potency order of NECA>CPA=AMPCPP>adenosine=AMPPCP=ATP, and 
that the P% antagonist DPCPX at a concentration of 3pM antagonises responses 
induced by all of these agonists except AMPCPP. The potency order of adenosine 
and its analogues and the concentration of DPCPX required to cause antagonism, 
therefore indicates the presence of a Pi-purinoceptor of the A2 subtype. As 
adenosine deaminase abolishes relaxations induced by adenosine and reduces those 
induced by ATP and AMPPCP, it appears that ATP and AMPPCP are acting 
indirectly at this A2  receptor via their dephosphorylation to adenosine. This has been 
supported by the observation that both ATP and AMPPCP are degraded ultimately to 
adenosine by the rat colon longitudinal muscle (Bailey & Hourani, 1992). In 
contrast, relaxations induced by AMPCPP, which is degraded to AMPCP by the 
longitudinal muscle, are antagonised by suramin whereas relaxations induced by the 
other agonists are not. As the potent P2X selective agonist L-AMPPCP is inactive, it 
has been proposed that there is also a relaxation-mediating P2Y-purinoceptor at 
which AMPCPP is acting (Bailey & Hourani, 1992). However, 2-MeSATP was 
observed to be a weak agonist in the rat colon longitudinal muscle, but this is likely 
to be due to its rapid degradation by the longitudinal muscle, and as 
2-methylthioadenosine is less active than adenosine in the taenia caeci (Satchell & 
Maguire, 1975), this has been taken to explain the lack of activity of 2-MeSATP in 
the rat colon longitudinal muscle (Bailey & Hourani, 1992).
In contrast to the longitudinal muscle, the rat colon muscularis mucosae has been 
shown to contract in response to purines. The agonist potency order for adenosine 
and its analogues in inducing contraction is observed to be CPA>NECA>adenosine, 
and DPCPX at a concentration of InM is an antagonist of these agonist induced 
contractions, which indicates contractions are mediated via an A% purinoceptor
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(Bailey et al., 1992). It has also been shown that AMPPCP contracts the rat colon 
muscularis mucosae with a potency order of AMPPCP>adenosine, and that 
contractions to AMPPCP are inhibited by DPCPX (InM) (Bailey et al., 1992). As 
AMPCPP is not significantly degraded by the muscularis mucosae (Bailey & 
Hourani, 1990), it has been suggested that this is a direct action of AMPPCP at the 
Aj subtype (Bailey et al., 1992). In addition, while suramin had no effect on 
contractions induced by adenosine or AMPPCP, those induced by AMPCPP were 
abolished suggesting the presence of a P2 -purinoceptor which also mediates 
contraction. Contractions to ATP were unaffected by DPCPX, partially inhibited by 
suramin and almost abolished by a combination of DPCPX and suramin, indicating 
both P2 and A^  components of its action (Bailey et al., 1992). As the order of 
potency of nucleotides in inducing contraction of the muscularis mucosae has been 
shown to be 2-MeSATP>ATP>AMPCPP, it has been proposed that they are acting at 
a contraction-mediating P2Y-purinoceptor (Bailey & Hourani, 1990). However, a 
lower maximal response is seen for 2-MeSATP relative to ATP (Bailey & Hourani, 
1990), similar to that seen in tissues which contain a mixed population of P2U and 
P2Y receptors (O'Connor et al., 1991). As the response to UTP has not been 
investigated in the rat colon muscularis mucosae, the presence of an additional 
contraction-mediating P2U receptor cannot be ruled out.
I.9.I.5. Taenia Caeci
To a large extent it was observations in the guinea-pig taenia caeci which led to the 
proposal of the P2Y-parinoceptor subtype (Bumstock & Kennedy, 1985). It has been 
shown that 2-MeSATP is more potent than ATP, and that ADP is equipotent with 
ATP in inducing relaxation of the taenia caeci (Satchell & Maguire, 1975), whereas 
L-AMPPCP is inactive (Hourani et ah, 1985). Although ATP and its
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methylenephosphonate analogues produce different maximum responses in the 
guinea-pig taenia caeci, with AMPCPP being approximately equipotent and 
AMPPCP less potent than ATP (Satchell & Maguire, 1975). ATP induced 
relaxations are followed by a rebound contraction which can be blocked by 
indomethacin, whereas AMPCPP and AMPPCP which also induce relaxation, do not 
induce prostaglandin synthesis as no rebound contractions are seen (Brown & 
Bumstock, 1981). In addition, suramin has been shown to antagonise relaxations 
induced by ATP (Den Hertog et al., 1989; Hoyle et al., 1990).
There is no evidence for the presence of P2%j-purinoceptors in the taenia caeci as 
UTP and UDP are much less potent than ATP in inducing relaxation (Brown & 
Bumstock, 1981; Bumstock et ah, 1994; Piper & Hollingsworth, 1995). However, it 
has been proposed that in addition to a relaxation-mediating P2Y-ptmnoceptor in the 
taenia caeci, there is an additional relaxation-mediating P2 -purinoceptor which does 
not fit into any of the presently recognised subtypes (Windscheif et al., 1994; 
Dudeck et al., 1995; Windscheif et al., 1995). The compound 4,4'-diisothio- 
cyanatostilbene-2,2'-disulphonate (DIDS), which has been shown to block responses 
mediated via the P2Z subtype in rat parotid acinar cells (Soltoff et al., 1993) and the 
P2X subtype in rat vas deferens (Biiltmann & Starke, 1994), was found to block 
responses to AMPCPP, but not to ATP, 2-MeSATP, ADP-P-S or adenosine in the 
taenia caeci (Dudeck et al., 1995). However, as mentioned above, the lack of 
potency of L-AMPPCP has been taken to suggest that there is not a P2X“Purinoceptor 
in the taenia caeci (Hourani et al., 1985). DIDS has been reported to retard the 
breakdown of 2-MeSATP and ATP in the taenia caeci, but inhibition by DIDS of 
2-MeSATP and ATP degradation is unlikely to explain its differential antagonism of 
AMPCPP, 2-MeSATP and ATP induced relaxations, as relaxations to the P2Y 
selective agonist ADP-p-S (a nucleotide which like AMPCPP is resistant to
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degradation by ectonucleotidases) were not antagonised by DIDS. This suggests that 
in addition to a relaxation-mediating P2Y-purinoceptor which is insensitive to DIDS 
(for which the agonist potency order in the presence of DIDS is 
2-MeSATP»ATP»AMPCPP), there is an additional relaxation-mediating DIDS- 
sensitive P2-purinoceptor at which AMPCPP can act (Dudeck et al., 1995). It has 
also been observed that responses to ATP and 2-MeSATP require a higher 
concentration of PPADS to antagonise them to the same degree as did AMPCPP, and 
biphasic Schild plots were observed. This has also led to the proposal that in addition 
to a relaxation-mediating P2Y-purinoceptor which is resistant to PPADS, there is an 
additional P2-purinoceptor which is sensitive to PPADS (Windscheif et al., 1994; 
Windscheif et al., 1995). However, PPADS (>10pM) was observed to cause 
approximately a 2 0 % inhibition of ectonucleotidase activity, although which was not 
dependent on the concentration of PPADS over lOpM (Windscheif et al., 1995). 
Further evidence that there is an additional relaxation-mediating receptor in the 
taenia caeci comes from the finding that AMPCPP activates apamin-sensitive 
channels by both a direct action and via the mobilisation of intracellular Ca^+, 
whereas ATP only activates these channels by mobilising intracellular Ca^  ^ (Den 
Hertog et al., 1985).
ATP and 2-MeSATP have been shown to be rapidly degraded by ectonucleotidases 
on the guinea-pig taenia caeci to their corresponding nucleosides, whilst AMPPCP 
and AMPCPP are both resistant to degradation. As 2-MeSATP is more potent and 
the methylene phosphonates less potent than ATP in inducing relaxation, this 
suggests that there is no correlation between the relative potency of an analogue at 
the P2Y subtype and its rate of degradation (Welford et al., 1986).
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In the taenia caeci the agonist potency order of adenosine analogues in eliciting 
relaxation is NECA>2-CADO>L-PIA>CHA>D-PIA>adenosine, and for which 8 -SPT 
is an antagonist, indicating adenosine acts at an A2 receptor to induce the same 
functional response as ATP (Bumstock et al., 1984b). In contrast, relaxations to 
ATP, 2-MeSATP and AMPCPP are not antagonised by 8 -SPT, indicating that they 
are not mediated either directly or indirectly via P|-purinoceptors in the taenia caeci. 
However, relaxations to AMPPCP are slightly inhibited by 8 -SPT indicating in part 
that relaxations are mediated via Pj-purinoceptors (Hourani et al., 1991).
I.9.I.6. Anococcygeus
ATP has been shown to induce contraction of the rat anococcygeus muscle 
(Gillespie, 1972; Bumstock et al., 1978; Carpenter & Joshi, 1980; Stone, 1983). 
Bumstock and coworkers found that contractions induced by ATP were converted to 
relaxations in the presence of indomethacin and have therefore suggested that 
prostaglandin biosynthesis is involved (Bumstock et al., 1978), although other 
workers have reported that indomethacin did not abolish contractions and are 
therefore not due to prostaglandins (Carpenter & Joshi, 1980). It has been 
subsequently suggested that this discrepancy is as a result of contractions to ATP 
becoming smaller as muscle tone progressively declines in some but not all 
preparations in the presence of indomethacin (Stone, 1983). An agonist potency 
order of L-AMPPCP>AMPPCP>ATP in inducing contraction has been shown in the 
rat anococcygeus (Hourani et al., 1986), and it has been reported that desensitisation 
of this contractile response on repeated administration of ATP or AMPPCP is 
observed from which the presence of a contraction mediating P2X"purinoceptor has 
been proposed (Kulkami & Sharma, 1994). This is in contrast to the rabbit 
anococcygeus muscle in which ATP is observed to induce relaxation rather than
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contraction (Creed et al., 1977; Bumstock et al., 1978; Sneddon et al., 1982b), 
although occasional dose-related contractions have been reported (Creed et ah, 
1977). It has been shown that ATP induced relaxations of the rabbit anococcygeus 
are reduced in the presence of 8 -SPT indicating that part of its action is due to its 
breakdown to adenosine. In addition, suramin does not antagonise relaxations 
induced by ATP suggesting that if part of its action is mediated via a P2 -purinoceptor 
then this receptor is suramin-insensitive (Graham & Sneddon, 1993).
Contractions in response to field stimulation of adrenergic nerves in the rat 
anococcygeus muscle are inhibited by adenosine, resulting in an observed relaxation. 
The agonist potency order for this inhibition, and antagonism by DPCPX has led to 
the proposal that this inhibition is mediated via a prejunctional Pj-purinoceptor of 
the Aj subtype (Stone, 1983; Coates et al., 1994). ATP also inhibits contractions 
induced by adrenergic nerve stimulation, and like adenosine these inhibitory effects 
are blocked by theophylline, suggesting an action of ATP at Pj-purinoceptors. This 
action of ATP appears to be indirect via its degradation to adenosine, as adenosine 
deaminase has been shown to reduce inhibitory responses to ATP and adenosine to a 
similar extent (Stone, 1983).
1.9.2. Urinary Bladder
The original classification of the P2X"Pwinoceptor subtype (Bumstock & Kennedy,
1985), was partly based on the observations in the guinea-pig and rat urinary bladder, 
that contractions were observed with an agonist potency order of AMPCPP= 
AMPPCP>ATP=2-MeSATP (Brown et al., 1979; Bumstock et al., 1983; Kasakov & 
Bumstock, 1983) and that marked desensitisation rapidly occurred following the 
administration of AMPCPP or AMPPCP (Lukacsko & Krell, 1982; Hourani, 1984).
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Binding studies in the rat urinary bladder using pH]AMPCPP have since been 
carried out, and a potency order of AMPCPP>AMPPCP>suramin>ATP>ADP> 
2-MeSATP»adenosine was observed in displacing [^H]AMPCPP from its binding 
site. Based on the observed agonist potency order this has been taken to indicate 
binding to P2X"Purinoceptors (Bo & Bumstock, 1990). It has also been shown that 
there is a higher density of [^H]AMPCPP binding in the rat than the rabbit or guinea- 
pig urinary bladder, reflecting a difference between species (Bo & Bumstock, 1992). 
However, with the cloning of the cDNA encoding the P2X“Purinoceptor from the 
human urinary bladder smooth muscle and its subsequent expression in isolated 
cells, it has now become apparent that while the above agonist potency order is seen 
in pharmacological studies with whole tissues, it does not reflect the tme potency at 
this P2X receptor in the human urinary bladder smooth muscle, which has been 
shown to be 2-MeSATP>ATP>AMPCPP»ADP (Evans et al., 1995). As previously 
mentioned, the presence of ectonucleotidases on whole cells but not on isolated cells 
in which the cloned receptor has been expressed has been proposed to account for 
this difference in observed potency orders (Kennedy & Leff, 1995).
ATP, and its analogues which have substitutions on the purine ring such as 
2-MeSATP, have been shown to be rapidly and sequentially dephosphorylated to 
their corresponding nucleosides by ectonucleotidases on the guinea-pig urinary 
bladder, whereas methylene phosphonate analogues such as AMPCPP and AMPPCP 
are resistant, which indicates that susceptibility to degradation does limit the potency 
of ATP and its degradable analogues (Welford et al., 1987). With the development 
of more sensitive high perfonnance liquid chromatography (h.p.l.c.) separation 
methods, it has since been shown that ATP is actually degraded beyond its 
nucleoside adenosine to inosine, indicating the presence of adenosine deaminase on 
the guinea-pig urinary bladder (Bailey & Hourani, 1994).
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Two compounds which have been shown to antagonise the contractile effects of 
AMPCPP in the urinary bladder are PPADS (Ziganshin et a l, 1993) and suramin 
(Hoyle et al., 1990) which has led to the suggestion that they are antagonists at the 
P2X subtype. However, in addition to being a P2 antagonist, suramin has been shown 
to be an inhibitor of ectonucleotidases in the guinea-pig urinaiy bladder, as ATP is 
seen to be degraded more slowly in the presence of suramin (Hourani & Chown, 
1988; Bailey & Hourani, 1994), and this can complicate its use as an antagonist. As 
previously mentioned, PPADS has also been shown to be an inhibitor of 
ectonucleotidases in the taenia caeci (Windscheif et al., 1995).
UTP has been shown to be a very weak agonist in contracting the guinea-pig urinary 
bladder and these contractions are abolished by suramin, which argues against the 
presence of P2u-purinoceptors in this tissue, and suggests that UTP is acting at P2X- 
purinoceptors (Bailey & Hourani, 1994). In addition, at the P2X receptor cloned from 
the human urinary bladder smooth muscle UTP is almost inactive (Evans et al., 
1995). However, it has also been proposed there are other P2  subt>q)es in the urinary 
bladder. It has been observed in the rat urinary bladder that contractions induced by 
ATP and AMPCPP are fast and transient, while those to ADP-p-S and UTP are 
slower and sustained, with biphasic contractile responses being seen in the presence 
of ATP plus UTP. In addition, following desensitisation with AMPCPP subsequent 
responses to ADP-p-S were only partially reduced while those to UTP were 
unaffected. It has therefore been proposed that in addition to a P2x-purinoceptor, 
there is an additional contraction-mediating receptor at which ADP-P-S and UTP are 
acting (Bolego et al., 1995a). Suzuki and Kokubun have also proposed the presence 
of an additional contraction-mediating P2 receptor in the rat urinary bladder at which 
ADP-P-S but not AMPCPP is active, as both ADP-p-S and AMPCP were found to 
induce contractions following desensitisation of the P2X subtype with AMPCPP
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(Suzuki & Kokubun, 1994). In contrast, following desensitisation of the P2X- 
purinoceptor in the dog urinary bladder with AMPCPP, contractions were not 
induced by AMPCP, which was taken as evidence for a single contraction-mediating 
P2X“Purinoceptor (Suzuki & Kokubun, 1994). However, a contraction-mediating 
receptor at which ADP-p-S but not AMPCPP is active has been proposed in the 
human urinary bladder (Palea et al., 1994). In the mouse urinaiy bladder in addition 
to contractions, relaxations have been shown, and the agonist potency order for 
eliciting relaxations was 2-MeSATP>ATP>AMPPCP. As 8 -SPT did not antagonise 
responses to ATP, it was proposed that in addition to a contracting-mediating P2X- 
purinoceptor, there is a relaxation-mediating P2Y-purinoceptor (Boland et al., 1993). 
Similarly, a relaxation-mediating P2Y-purinoceptor has also been proposed in the rat 
urinary bladder (Bolego et al., 1995b).
Adenosine and AMP have been shown to relax the urinaiy bladder and to be 
antagonised by theophylline, suggesting the presence of relaxation-mediating Pj- 
purinoceptors (Bumstock et al., 1972; Brown et al., 1979; Lukacsko & Krell, 1982). 
The agonist potency order in inducing relaxation has been shown to be N E C A »  
adenosine>CPA=CGS21680, and as DPCPX at a concentration of IpM is required to 
antagonise relaxations induced by adenosine and NECA, it has been proposed that 
they are acting via a P^-purinoceptor of the A2B subtype (Nicholls et al., 1992a). As 
contractions induced by ATP and AMPPCP are not affected by theophylline (Brown 
et al., 1979) or DPCPX (Nicholls et al., 1992a) it appears that they are not acting at 
the PI-purinoceptor in the urinaiy bladder whether directly or indirectly.
1.9.3. Vas Deferens
The vas deferens is another tissue which has been instrumental in the original
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classification of the ?2x  subtype, and for which the agonist potency order in 
inducing contraction is AMPCPP=AMPPCP>ATP=2-MeSATP (Fedan et ah, 1982b; 
1986; Bumstock et al., 1985; Bumstock & Kennedy, 1985). However, as previously 
mentioned, while the above agonist potency order is seen in pharmacological studies 
with whole tissues it does not reflect the tme potency at the cloned P2X" 
purinoceptors, and an agonist potency order of 2-MeSATP>ATP>AMPCPP»ADP 
has been shown at the cloned P2x-purinoceptor from rat vas deferens (Valera et al., 
1994).
It has been shown in the mouse, rat and guinea-pig vas deferens that electrical 
stimulation of sympathetic nerves results in biphasic contractions. As contractions 
for the first phase are blocked by ANAPP3 (Fedan et al., 1982c; Sneddon et al., 
1982a), suramin (Von Kügelgen et al., 1989a; Mallard et al., 1992; Sneddon, 1992) 
and by desensitisation with AMPCPP (Meldmm & Bumstock., 1983), it is thought 
that they are mediated by ATP acting at P2x-purinoceptors. In contrast, the second 
contractile phase is blocked by a-adrenoceptor antagonists such as prazosin, 
indicating that it is mediated by noradrenaline acting at ai-adrenoceptors (Sneddon 
et al., 1982a; Von Kügelgen et al., 1989a). It has been shown in the guinea-pig vas 
deferens that reducing extracellular divalent cation concentrations potentiates 
contractions induced by ATP, and it has therefore been suggested that ATP^" is the 
active form of ATP in this tissue (Morishita & Fumkawa, 1989; Fedan et al., 1990).
In the guinea-pig vas deferens contractions induced by ATP are biphasic, although 
the second tonic phase is only seen at high concentrations of ATP and has been 
proposed to be due to the transfer of phosphate to the tissue following cleavage of 
the phosphate chain by an ecto-kinase (Fedan & Lamport, 1990; Lamport-Vrana et 
al., 1991). In contrast, the initial phase has been shown to be antagonised by
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ANAPPg (Fedan et al., 1982c) and suramin (Dunn & Blakeley, 1988; Hoyle et al., 
1990) suggesting the involvement of a P2X-purinoceptor. It has also been reported 
that whilst low concentrations of suramin have little effect, high concentrations of 
suramin (>100pM) potentiate ATP (100-500pM) induced contractions. Although 
this might be explained in terms of suramin inhibiting ectonucleotidase activity, it 
was also observed that while desensitisation of the P2x-purinoceptor with AMPCPP 
abolished contractions induced by ATP, contractions induced in the presence of 
suramin were unaffected by prior desensitisation. It has therefore been proposed that 
in addition to the P2X"purinoceptor, there is a suramin-insensitive contractile 
receptor at which ATP can also act (Bailey & Hourani, 1994). It has also been 
suggested that ATP elicits contractions via more than one site of action in the mouse 
vas deferens, as suramin was found to antagonise AMPCPP over a range of 
concentrations, but ATP only at low concentrations (Von Kügelgen et al., 1990). 
However, a point not considered by the authors is differential antagonism by suramin 
of contractions induced by AMPCPP and ATP in relation to inhibition of 
ectonucleotidase activity.
A biphasic response of a slight contraction followed by a marked relaxation has been 
observed in the mouse vas deferens and the agonist potency order in eliciting 
relaxation was 2-MeSATP>ATP>AMPPCP, and reactive blue 2 but not 8 -PT has 
been found to be an antagonist of the relaxations induced by ATP. It has therefore 
been proposed that in addition to a contraction-mediating P2x-purinoceptor there is 
also a relaxation-mediating P2y-purinoceptor in the mouse vas deferens. (Boland et 
al., 1992). The presence of a relaxation-mediating P2Y-purinoceptor in addition to a 
contraction-mediating P2x~purinoceptor has also been proposed to exist in the mouse 
vas deferens based on observed differences of suramin and reactive blue 2  to shift 
the contraction concentration-response curve to AMPCPP (Blakeley et al., 1991).
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Although UTP has been shown to be inactive at the cloned P2x-purinoceptor from 
rat vas deferens (Valera et al., 1994), it has been observed to be a less potent 
contractile agonist than ATP in the guinea-pig (Bailey & Hourani, 1994) and mouse 
(Von Kügelgen et al., 1990) vas deferens. However, it has been suggested that it is 
acting like ATP at P2x-purinoceptors, as suramin has been found to completely 
antagonise contractions induced by UTP, and in the mouse vas deferens AMPCPP 
desensitized responses to both ATP and UTP, which were also observed to induce 
cross-desensitisation to each other (Von Kügelgen et al., 1990; Bailey & Hourani, 
1994). UTP has also been proposed to have a direct agonist action at prejunctional 
Pj-purinoceptors in the mouse (Von Kügelgen et al., 1989b) and rat vas deferens 
(Forsyth et al., 1991), as 8 -SPT has been shown to antagonise its action in inhibiting 
noradrenaline release.
Agonist potency orders and the use of antagonists have demonstrated the presence of 
Pj-purinoceptors in the rat vas deferens. In addition to an inhibitory prejunctional Aj 
receptor, it has been shown that there is also an inhibitory postjunctional A2  and an 
excitatory postjunctional A| receptor (Hourani et a l, 1993a; Hourani & Jones, 
1994).
In the DDTi MF-2 cell line derived from smooth muscle cells of the Syrian hamster 
vas deferens, it has been shown that an outward K+ current is induced with the 
potency order of ATP>UTP>TTP>CTP=GTP, which is blocked by suramin, and at 
which adenosine, ADP, AMPCPP and 2-MeSATP are inactive. It has thus been 
proposed that this is as a result of P2xj-purinoceptor activation (Van der Zee et al., 
1992). In addition, ATP (Hoiting et a l, 1990a, b) and UTP (Sipma et al., 1995) have 
been shown to induce inositol phosphate accumulation which is indicative of a 
G-protein coupled response. A separate G-protein coupled receptor of the A% subtype
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at which adenosine and CPA, but not ATP act has also been shown to be present in 
DDT2 MF-2 cells (Gerwins & Fredholm, 1992).
1.9.4. Blood Vessels
ATP modulates vascular tone of blood vessels by acting at P2-purinoceptors which 
are located both on endothelial cells and smooth muscle cells. In general, 
vasoconstriction is mediated via P2x~purinoceptors located on the vascular smooth 
muscle, whilst vasodilation is mediated via P2Y"purinoceptors located on the 
endothelial cells, although exceptions have been noted (Bumstock & Kennedy, 1985; 
1986; Pearson & Gordon, 1989; Ralevic & Bumstock, 1991b).
I.9.4.I. Vascular Endothelial Cells
ATP produces vasodilation of blood vessels via P2Y"Purinoceptors which have been 
shown to be located on the endothelial cells, as removal of the endothelium from a 
number of blood vessels including the canine femoral artery (De Mey & Vanhoutte, 
1981), rat femoral artery (Kennedy et al., 1985), dog coronary artery (Houston et al., 
1987), rat pulmonary vessels (Liu et al., 1989b) and rat mesenteric arterial bed 
(Ralevic & Bumstock, 1988) has been shown abolish relaxations induced by ATP. 
Stimulation of the P2Y-purinoceptors on endothelial cells by ATP results in release 
of endothelium derived relaxing factor (EDRF) (Pearson & Gordon, 1989; 
Boeynaems & Pearson, 1990), now identified as nitric oxide (NO) (Palmer et al., 
1987; 1988), which relaxes the subjacent smooth muscle. ATP also induces the 
release of prostaglandins including prostacyclin (PGI2 ) from endothelial cells 
(Pearson & Gordon, 1989; Boeynaems & Pearson, 1990), which contributes to 
endothelium-dependent vasodilation in some blood vessels. There are however
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differences between the formation of the two effector molecules, PGI2 and NO, in 
response to ATP acting at P2Y-purinoceptors. Whilst PGI2  release is rapid and 
transient, NO release is rapid and sustained. Furthermore, release of PGI2 is subject 
to P2Y agonist-specific desensitisation whereas NO release is not (Boeynaems & 
Pearson, 1990).
Vasodilation-mediating P2u-purinoceptors have also been shown to be located on 
vascular endothelial cells. The concept that both P2Y- and P2u-purinoceptors are 
expressed on endothelial cells was originally proposed by O'Connor et al. (1991), 
although the relative contribution of P2Y- and P2u-purinoceptors to the action of 
ATP has been shown to vary between different vascular tissues. In endothelial cells 
derived from the microvasculature of bovine adrenal medulla (Allsup & Boarder, 
1990; Wilkinson et al., 1993), rabbit microvessels from cardiac muscle (Mannix et 
a l, 1993) and rat brain (Frelin et al., 1993), hydrolysis of inositol phosphate in 
response to ATP has been proposed to be mediated via P2Xj-purinoceptors. In 
contrast, the cell line AG4762 derived from bovine aortic endothelial cells have been 
shown to contain only P2Y-purinoceptors (Allsup & Boarder, 1990), whereas both 
P2Y- and P2xj-purinoceptors coexist on bovine aortic endothelial cells (Motte et al., 
1993b; Purkiss et al., 1994; Wilkinson et al., 1993; 1994b; Communi et al., 1995b) 
and bovine aortic collateral artery rings (Wilkinson et al., 1994a).
It has been shown in the canine basilar artery that whilst vasoconstriction elicited by 
AMPCPP and AMPPCP occurs in the presence and absence of endothelium, 
vasoconstriction elicited by 2-MeSATP is nearly abolished by removal of the 
endothelium. Furthermore, both reactive blue 2 and aspirin were found to attenuate 
vasoconstriction induced by 2-MeSATP but not AMPCPP. It has thus been proposed 
that as well as a vasoconstriction-mediating P2x-purinoceptor on the smooth muscle.
97
there is an additional endothelium-dependent vasoconstriction-mediating P2- 
purinoceptor for which thromboxane A2 has been suggested to be the mediator 
(Shirahase etal., 1991).
Adenosine also elicits vasodilation of blood vessels via acting at Pj-purinoceptors, 
and although the vasodilatory activity of adenosine has been thought to be a direct 
effect on vascular smooth muscle (Olsson & Pearson, 1990), in tissues such as the 
pig aorta (Gordon & Martin, 1983) and rat mesenteric artery (Vuorinen et al., 1992) 
the relaxant effects of adenosine have been shown to be at least partly endothelium- 
dependent. In addition, although endothelial cells possess ectonucleotidases which 
degrade ATP to adenosine, the predominant effect of ATP in isolated tissues does 
not appear to be an indirect action via its degradation to adenosine, as selective 
inhibition of adenosine receptors with P%-purinoceptor antagonists rarely blocks the 
effect of ATP (De Mey & Vanhoutte, 1981; Bumstock & Kennedy, 1986; Gordon,
1986).
I.9.4.2. Vascular Smooth Muscle
P2X“purinoceptors have been shown to mediate vasoconstriction in a number of 
blood vessels, including the rabbit ear artery (Leff et al., 1990; O'Connor et al., 
1990), rat portal vein (Reilly & Bumstock., 1987), rat and human pulmonary vessels 
(Liu et al., 1989a, b), rabbit and rat mesenteric artery (Bumstock & Warland, 1987; 
Ralevic & Bumstock, 1988; Windscheif et al., 1994), dog coronary artery (Houston 
et al., 1987), rat femoral artery (Kennedy et al., 1985) and rat coronary vasculature 
(Hopwood & Bumstock, 1987). In addition to a higher potency of AMPCPP than 
ATP in eliciting vasoconstriction, desensitisation to AMPCPP (Houston et al., 1987; 
Ralevic & Bumstock, 1988; Leff et al., 1990; O'Connor et al., 1990), as well as
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antagonism by suramin (Leff et al., 1990) and PPADS (Windscheif et ah, 1994; 
Ziganshin et aï., 1994b) have also been demonstrated. The location of these P2X' 
purinoceptors is on the vascular smooth muscle as removal of the endothelium has 
been shown not to abolish vasoconstriction in response to nucleotides, but often to 
enhance them (Kennedy et al., 1985; Ralevic & Bumstock, 1988; Liu et al., 1989a, 
b; Ralevic & Bumstock, 1991a; Shirahase et al., 1991).
In the smooth muscle of the rat tail and femoral arteries and dog saphenous vein it 
has been proposed that ATP and UTP elicit vasoconstriction via a P2X“purinoceptor 
and a pyrimidinoceptor respectively. This was based partly on the observations that 
ATP but not UTP induced contractions are desensitized by AMPCPP, and that ATP 
and UTP desensitized responses to themselves but not to each other (Saïag et al., 
1987; 1990). It has also been proposed in the rabbit basilar artery that UTP induced 
contractions are mediated via a pyrimidinoceptor, whereas ATP induced contractions 
are mediated via a P2 receptor distinct from the P2x-purinoceptor. This was based on 
the observations that while ATP-y-S, ATP and UTP were shown to elicit marked 
contractions, unlike AMPCPP, AMPPCP and 2-MeSATP which were almost 
inactive, subsequent responses to ATP were reduced following prolonged exposure 
to ATP-y-S, whilst subsequent responses to UTP were veiy slightly enhanced. In 
addition, ATP was found to elicit marked additional vasoconstriction after 
precontraction with UTP, whereas UTP elicited only a small additional 
vasoconstriction after precontraction with itself (Von Kügelgen & Starke, 1990).
Vasoconstriction-mediating receptors at which UTP is equipotent with ATP, and 
therefore resemble P2xj-purinoceptors, have been demonstrated in a number of blood 
vessels including the rat mesenteric arterial bed (Ralevic & Bumstock, 1991a; 
Windscheif et al., 1994), rabbit aorta (Pavenstadt et al., 1991; Chinellato et al..
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1992), bovine aortic smooth muscle cells (Demolle et al., 1988) and rat pulmonary 
artery (Rubino & Bumstock, 1995).
Although P2Y-purinoceptors are usually located on endothelial cells, it has been 
shown in some blood vessels such as the rabbit portal vein (Kennedy & Bumstock, 
1985), rabbit mesenteric arteiy (Mathieson & Bumstock, 1985), rabbit hepatic artery 
(Brizzolara & Bumstock, 1991) and human pulmonary arteries (Liu et al., 1989a), 
that P2Y-purinoceptors mediating vasodilation are located on the smooth muscle. 
This has been based on the observations that removal of the endothelium does not 
affect relaxations induced by ATP, and that these are not mediated indirectly via its 
degradation to adenosine, as while adenosine also elicits endothelium-independent 
relaxations, P%-antagonists such as 8 -PT antagonise responses to adenosine but not to 
ATP.
1.10. Aim Of The Thesis
The aim of this thesis was to classify the P2-purinoceptors mediating responses to 
nucleotides in some visceral smooth muscles of the rat: The rat colon muscularis 
mucosae contracts to ATP via a P2-purinoceptor at which the potency order of 
analogues is 2-MeSATP>ATP>AMPCPP, and which has been characterised as a 
P2Y"purinoceptor (Bailey & Hourani, 1990). However, the maximal response to 
2-MeSATP is less than that to ATP, and preliminary studies indicated that UTP was 
also active here, so it seemed likely that this would be a suitable tissue in which to 
investigate the possible existence of pyrimidinoceptors or P2%j-purinoceptors. The rat 
whole duodenum contains P% (Aj and A2 subtypes) (Nicholls et al., 1992a) and P2Y- 
purinoceptors (Nicholls et al., 1990), which mediate relaxation to adenosine and 
ATP respectively. However, preliminary studies with UTP revealed that this
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nucleotide causes contraction rather than relaxation of this tissue, and UTP was 
therefore chosen to investigate the receptor involved. In the rat colon the response to 
adenosine and to nucleotides on the longitudinal muscle (Bailey & Hourani, 1992) 
and the muscularis mucosae (Bailey & Hourani, 1990; Bailey et a l,  1992) are 
different, and it seemed likely that in the duodenum that different receptors might 
also be located on the different muscle layers. The longitudinal muscle and the 
muscularis mucosae of the rat duodenum were thus investigated to determine which 
P2 receptors were present on each muscle layer. With a lack of pharmacological 
tools with which to investigate P2-purinoceptors, a range of nucleotides, antagonism 
by suramin and desensitisation was employed to classify the receptors in the rat 
colon and duodenum. In addition, the rat duodenum has been shown to 
dephosphorylate ATP rapidly via ectonucleotidases and adenosine deaminase 
(Franco et a l, 1986; 1988; Nicholls et a l,  1992b). The rate of degradation of some 
of these nucleotides in the rat duodenum muscularis mucosae was thus also 
investigated.
101
CHAPTER 2: METHODS
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2.1. ANIMALS
Wistar Albino rats were obtained from the University of Surrey Breeding Unit. 
Litters of neonatal rats were cross fostered at birth and culled to 8  rats per mother. 
Day of birth was designated as day 1 and neonatal rats were weaned around day 20.
Adult male Wistar Albino rats (200-250g) were killed by cervical dislocation, 
whereas neonatal male 2 day old (7g) and 5 day old (12g) rats were killed by 
decapitation. The abdomen was opened up and the colon or duodenum removed.
2.1.1. Rat Colon Muscularis Mucosae
The distal colon, cut as far towards the rectum as possible and 40mm (adults) or 
20mm (neonates) from this point, was removed and placed in warm (32°C) Tyrode 
buffer. The tissues were cleared of any connective tissue, and washed thoroughly to 
remove any faecal matter by passing Tyrode buffer through the lumen using à plastic 
pasteur pipette (1ml). A glass pipette, external diameter 5mm (adults), or a needle, 
external diameter <lmm (neonates) was placed inside the colon. The outer 
longitudinal muscle was removed by gentle rubbing with moist cotton wool and 
discarded. The remaining thick walled tube of mucosal tissue, containing the 
muscularis mucosae, was then cut down to lengths of 2 0 mm (adults) or 1 0 mm 
(neonates), the more distal of the two ends being used.
The dissection technique was slightly modified for experiments using suramin. The 
40mm length of adult distal colon was cut into two halves of 20mm lengths, and 
each half suspended into separate organ baths. This was to allow paired experiments 
in the absence and presence of suramin to be performed on tissues from the same
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animal. In these experiments, which of the two ends were preincubated with suramin 
and which were preincubated with water was alternated in tissues from different 
animals.
Adult and neonatal rat colon muscularis mucosae differed in appearance, the 
neonatal tissue being very thin and almost transparent in appearance and extremely 
fragile unlike adult tissue. Adult and neonatal tissues were thus suspended in the 
organ baths using slightly different techniques. For adults, cotton threads (Silko, 60 
gauge) were threaded through the muscle wall at each end of the segment of 
muscularis mucosae so that the lumen was open, whereas due to the fragility of the 
neonatal tissue cotton thread was tied round each end of the segment of muscularis 
mucosae so that the lumen was sealed.
2.1.2. Rat Duodenum
The duodenum was dissected out by cutting at the base of the pyloris and at 15- 
20mm from this point, was removed and placed in warm 35-36°C Krebs buffer. The 
tissues were cleared of any connective tissue and washed thoroughly with Krebs 
solution using a pasteur pipette (1mm) to remove any faecal matter. Cotton thread 
(Silko, 60 gauge) was tied round each end of the segment of the whole duodenum so 
that the lumen was sealed.
To obtain the rat duodenum longitudinal muscle and the muscularis mucosae, the 
whole duodenum was dissected as above, then a glass pipette (external diameter 
5mm) placed inside the tissue. A scalpel was gently run down the length of the 
duodenum cutting only the outer longitudinal muscle layer, leaving the inner 
muscularis mucosae intact. The longitudinal muscle was then removed as a sheet
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from the muscularis mucosae by gentle rubbing with moist cotton wool. For each of 
the muscle layers cotton thread (Silko, 60 gauge) was tied round each end of the 
segment of tissue, so that in the case of the muscularis mucosae the lumen was 
sealed.
2.1.3. Muscle Layers Of The Colon And The Duodenum
The colon and the duodenum consist of both inner and outer muscle layers. The 
outer muscle layer consists of longitudinal smooth muscle and is therefore referred 
to as the longitudinal muscle throughout this thesis. The muscle layers below the 
outer longitudinal muscle are referred to as the circular muscle and the muscularis 
mucosae. The muscularis mucosae is also a longitudinal smooth muscle layer. For 
the work on this thesis, as cotton thread was attached to each end of the segment of 
colon/duodenum after the outer longitudinal muscle was removed, when mounted in 
the organ baths contractile and relaxant responses were recorded longitudinally along 
the length of the tissue, and it was therefore the muscularis mucosae (inner 
longitudinal muscle) and not the circular muscle which was investigated.
2.2. PHARMACOLOGICAL STUDIES ON THE RAT COLON 
MUSCULARIS MUCOSAE
The rat colon muscularis mucosae were mounted in 4ml organ baths containing 
Tyrode solution, aerated with 95% O2  / 5% CO2  and maintained at 32°C. The 
Tyrode solution had the following composition (mM): NaCl 136.9, KCl 2.8, CaCfy 
1.8, MgCfy 2.1, NaHCOg 11.9, NaH2P0 4  0.3 and glucose 5.6. A resting tension of Ig 
(adults) or 0 .2 g (neonates) were applied to the tissues and isometric responses 
recorded with a Grass FT03 transducer and displayed on a Grass 79C polygraph.
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Tissues were allowed to equilibrate for 90 minutes, with regular washes at 20 
minutes intervals, before the addition of drugs.
2.2.1. Desensitisation Studies
Concentration-response curves to ATP, UTP or adenosine were determined with or 
without desensitisation with ATP, UTP, adenosine, 2-MeSATP or AMPCPP. For the 
control concentration-response curves increasing doses of agonist were given non- 
cumulatively, with a contact time of approximately 1 minute, a washout period of 30 
seconds and a recovery period of 10 minutes for ATP and adenosine and 15 minutes 
for UTP. These recovery periods were shown in preliminary experiments to allow 
repeated administration of the agonists (lOpM) to be given without a decrease in the 
observed responses. Concentration-response curves to ATP and UTP were 
determined on the same piece of tissue by applying doses of each agonist alternately, 
and concentration-response curves to adenosine were determined on separate tissues. 
Concentration-response curves for each agonist were obtained using tissues from 4 
animals. Desensitisation was achieved in separate experiments by applying the 
agonists at a concentration of 200pM with a contact time of 5 minutes (4 minutes in 
the case of 2-MeSATP) during which time the contraction reached a peak and 
declined, followed by a 30 seconds washout to allow the tissue to relax completely 
before challenging with ATP, UTP or adenosine. The desensitising agonist was 
applied before each dose of the test agonist, and a recovery period of 15 minutes was 
allowed between doses. All contractions were expressed as a percentage of the 
maximum contractile response induced by carbachol (50pM) applied at the end of 
the experiments, and results were expressed graphically as the mean and s.e. mean of 
the responses obtained. Because the concentration-response curves did not achieve a 
maximum response, ECgg values were calculated for the agonists, representing the
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concentration of the agonist which induced 30% of the maximum response to 
carbachol (50p,M), to allow comparison of potencies. EC30  values were generated 
from the mean pECgg values. For each individual log concentration-response curve a 
pECgo value (the negative log of the concentration required to give 30% of the 
maximal response to carbachol (50pM)) was calculated by regression analysis of the 
linear portions of the curve, and the mean and s.e. mean of these values used for 
statistical comparison. The pECgo values were compared in the presence and 
absence of desensitisation using analysis of variance followed by Dunnetfs two- 
tailed test.
2.2.2. Studies With Suramin
Contraction concentration-response curves to ATP and UTP were also determined in 
the presence of suramin (lOOpM) or water (40pl) (paired controls) preincubated for 
1 hour, and readded after each washout of test agonist. Doses of agonist were given 
non-cumulatively, with a contact time of approximately 1 minute, a washout period 
of 30 seconds and a recovery period of 15 minutes. Only one agonist was applied to 
any single piece of tissue, and concentration-response curves were obtained using 
tissues from 4 animals. All contractions were expressed as a percentage of the mean 
contraction induced by the mean of three doses of carbachol (50pM) applied before 
preincubation with suramin or water, and results were expressed graphically as the 
mean and s.e. mean of the responses obtained.
For statistical analysis of concentration-response curves in the presence and absence 
of suramin the pECgg values were compared using Student's t-test and a value of 
p<0.05 considered to be significant. For UTP, the pECgq value in the presence of 
suramin was extrapolated by linear regression analysis of each of its individual log
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concentration-response curves, as contractile responses fell just below this value.
2.2.3. Neonatal Rat Colon Muscularis Mucosae
Concentration-response curves to ATP and UTP were determined non-cumulatively 
on separate pieces of tissue, using tissues from 4 animals for each. A contact time of 
1 minute was used followed by a washout period of 30 seconds and a dose-cycle of 
15 minutes. Contractions were expressed as a percentage of the contraction induced 
by carbachol (50pM) applied at the end of the of the experiments, and results were 
expressed graphically as the mean and s.e. mean of the responses obtained. The 
pECgo values were calculated as for the adults, to allow a comparison.
2.3 PHARMACOLOGICAL STUDIES ON THE RAT DUODENUM
The whole duodenum, duodenum muscularis mucosae or duodenum longitudinal 
muscle were mounted in 4ml organ baths containing Krebs solution, aerated with 
95% O2 / 5% CO2 and maintained at 35-36°C. The Krebs solution had the following 
composition (mM); NaCl 118, KCl 4.8, CaCfy 2.5, MgCfy 1.2, NaHCOg 2.5, 
KH2PO4  1.2 and glucose 11. A resting tension of Ig were applied to the tissues and 
isometric responses recorded with a Grass FT03 transducer and displayed on a Grass 
79C polygraph. Tissues were allowed to equilibrate for 45 minutes, with regular 
washes at 15 minute intervals, before the addition of drugs.
2.3.1. Rat Whole Duodenum
A number of pharmacological studies were carried out on the rat whole duodenum.
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2.3.I.I. Concentration-Response Curves
Concentration-response curves to only one agonist (ATP, UTP, ATP-y-S, 
2-MeSATP, AMPCPP, ADP, UDP and GTP) were carried out on any single tissue. 
Relaxations were first measured, followed by contractile responses on the same 
piece of tissue. Relaxations were quantified by precontracting the duodenum with 
carbachol (0.1 pM) with a contact time of 1.5 minutes and challenging with agonist 
(contact time 1 minute). The concentration of the precontracting dose of carbachol, 
0.1 pM, was chosen as it was the concentration previously used by Nicholls et al. 
(1990) to precontract the rat duodenum. Contractions to carbachol (approximately 
1.4g tension) were measured from the centre of spontaneous baseline activity to the 
highest point of carbachol contraction. Relaxations were measured as the reduction 
in the height of the rhythmic contractions, relative to the time immediately before 
addition of the relaxant agonist and expressed as per cent reversal of carbachol 
contraction (per cent relaxation = (BC/AB) x 100 in Figure 20a). Contractions were 
observed by adding agonist (contact time 1 minute) without precontracting the tissue 
and contractions were expressed as percentage of the contraction caused by 
carbachol (0.1 pM) (determined as the mean value of all the doses of carbachol 
(0.1 pM) used in determining relaxations). Where agonists induced contractions with 
marked spontaneous activity, contractions were measured as the centre point of this 
activity (DE in Figure 20b). Atropine (0.1 pM) was administered following the 
relaxation concentration-response curve and prior to determination of the contraction 
concentration-response curve, incubated for 15 minutes and then readded after each 
washout. Atropine was used to suppress spontaneous activity in the tissue, and thus 
allow a more accurate measurement of contractions to agonists. Atropine did not 
affect the response to any of the nucleotides. A 10 minute dose-cycle was used and a 
30-60 second washout following each dose of test agonist. Concentration-response
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curves were obtained non-cumulatively using tissues from 4 animals, and results 
were expressed graphically as the mean and s.e. mean of the responses obtained. 
Because the concentration-response curves did not achieve a maximum response, 
EC50 values were calculated for the agonists, representing the concentration of the 
agonist which induced 50% of the response to carbachol (0.1 pM), to allow 
comparison of potencies. EC50 values were generated from the mean pECgo values. 
For each individual log concentration-response curve a pECgo value (the negative log 
of the concentration required to give 50% of the maximal response to carbachol 
(0.1 pM)) was calculated by regression analysis of the linear portions of the curve, 
and the mean and s.e. mean of these values used for statistical comparison.
2.3.1.2. Studies With Suramin
Relaxation and contraction concentration-response curves to ATP, UTP and ATP-y-S 
were also determined in the presence of suramin (lOOpM or ImM) preincubated for 
1 hour, and readded after each washout of test agonist, in separate experiments. Only 
one agonist was applied to any single piece of tissue, and concentration-response 
curves to each agonist were obtained using tissues from 4 animals. Suramin was 
observed to affect basal tone of the tissue in some preparations when precontracted 
with carbachol (0.1 pM), making the spontaneous contractions more variable, and 
thus making quantification of relaxant responses difficult on some of these 
preparations. When this was observed the experiment was repeated rather than use 
these data.
Results were expressed graphically as the mean and s.e. mean of the responses 
obtained. For statistical analysis of concentration-response curves in the presence 
and absence of suramin the pEC^o values were compared using Student’s t-test and a
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value of p<0.05 considered to be significant.
2.3.1.3. Studies With Indomethacin
A relaxation and contraction concentration-response curve to UTP was also 
determined in the presence of indomethacin (25pM) preincubated for 45 minutes, 
and readded after each washout of test agonist. Inhibition of cyclo-oxygenase by 
indomethacin was confirmed by the ability of indomethacin (25pM) to inhibit 
contractions induced by arachidonic acid (lOOpM). Results were expressed 
graphically as the mean and s.e. mean of the responses obtained. For statistical 
analysis of concentration-response curves in the presence and absence of 
indomethacin the pEC^o values were compared using Student’s t-test and a value of 
p<0.05 considered to be significant.
2.3.1.4. Desensitisation Studies
ATP-y-S and UTP were used in an attempt to desensitize the receptors at which they 
act to cause contraction. A lOOpM concentration of the agonist was administered 
repeatedly over 90 minutes with a contact time of 5-10 minutes and 1-2 minutes 
between washing and readdition of the agonist. The agonists were tested on separate 
tissues, and the percentage contraction for each dose of agonist was determined as a 
percentage relative to the initial dose of the agonist given. Results were expressed 
graphically as the mean and s.e. mean of the responses obtained. For statistical 
analysis of the results, tension in grams to each dose of agonist were compared 
against the initial dose given using analysis of variance followed by Dunnetfs two- 
tailed test and a value of p<0.05 considered to be significant.
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2.3.I.5. Purification Of Adenosine 5'-0-(3-Thiotriphosphate)
High performance liquid chromatographic analysis of ATP-y-S as obtained from the 
supplier showed an 11% impurity of ADP to be present. Relaxation and contraction 
concentration-response curves were therefore obtained for ATP-y-S both in the 
presence of the ADP impurity and also for ATP-y-S enzymically treated to degrade 
the ADP impurity to inosine. Different pieces of tissue were used for the experiments 
with enzymically and non-enzymically treated ATP-y-S. The enzyme mixture was 
also given on its own to ensure it did not cause relaxation or contraction of the tissue. 
For lOOpM of ATP-y-S containing the ADP impurity, 10 units of alkaline 
phosphatase and 10 units of adenosine deaminase in tris buffer (15mM, pH8.0) were 
added for 5 minutes at room temperature and then kept on ice until use. Solutions of 
ATP-y-S were made also at concentrations of 10"^M, lO'^M, 10“^ M and 10"^M, and 
to these the enzymes were added at the appropriate concentrations being diluted in 
the same ratio. Each dilution of ATP-y-S had the enzymes added immediately prior 
to use for two consecutive concentrations. Aliquots were taken of the enzymically 
treated ATP-y-S during the experiment and stored at -20°C, then analysed by h.p.l.c. 
at a later date. H.p.l.c. analysis was carried out using a Waters h.p.l.c. with a 
Techsphere 5pm ODS Cjg column eluted with O.IM KH2PO4  / 8 mM 
tetrabutylammonium hydrogen sulphate (pH6.0) (solvent A) and a 60:40 mixture of 
solvent A and acetonitrile (pH6.73) (solvent B), using a non-linear gradient (0-2.5 
min 0% B, 2.5-5 min 0-20% B, 5-10 min 20-40% B, 10-13 min 40-100% B, 13-18 
min 100% B), at a flow rate of 1.3ml/min. The purines were detected by U.V. 
absorbence at 259nm and quantified from the height of their absorbence peaks, 
which was linearly related to the concentration. Where ATP-y-S is mentioned on the 
whole rat duodenum in the text, this refers to the enzymatically treated nucleotide 
unless otherwise stated, and the true concentrations were calculated by subtracting
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the concentration of ADP initially present.
2.3.2. Rat Duodenum Longitudinal Muscle
A number of pharmacological studies were carried out on the rat duodenum 
longitudinal muscle.
2.3.2.1. Carbachol Concentration-Response Curves
A concentration-response curves to carbachol was constructed so that a suitable dose 
for precontracting the tissue and for standardising results could be chosen (see Figure 
5a). Contraction concentration-response curves to carbachol were carried out using 
tissues from 4 animals. Carbachol was administered in increasing doses, given non- 
cumulatively, with a contact time of approximately 1 minute, a washout period of 30 
seconds and a recovery period of 10-15 minutes before the addition of the next dose. 
All contractions were expressed as a percentage of a maximum contractile response 
induced by carbachol (lOpM), and results were expressed graphically as the mean 
and s.e. mean of the responses obtained. 0.3pM carbachol gave a contraction that 
was approximately 40% of the maximum response and it produced steady rhythmic 
contractions. It was therefore chosen as the precontracting dose.
2.3.2.2. Nucleotide Concentration-Response Curves
Concentration-response curves to only one agonist were carried out on any single 
tissue, and relaxation and contraction concentration-response curves were 
determined on different pieces of tissue. Relaxations to 2-MeSATP, ATP, ATP-y-S, 
AMPCPP, UTP and UDP were determined by precontracting the tissue with
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Figure 5. Concentration-response curve for carbachol on the rat duodenum 
longitudinal muscle and muscularis mucosae.
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Concentration-response curve for carbachol on the rat duodenum (a) longitudinal 
muscle and (b) muscularis mucosae. Responses are expressed as percentage of 
maximum contraction with carbachol. Each point is the mean of four determinations, 
and the vertical bars show s.e. mean.
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carbachol (0.3jxM) with a contact time of 1.5 minutes and challenging with agonist 
(contact time 1 minute). Relaxations were measured as for the whole duodenum (see
2.3.1.1.), and expressed as per cent reversal of carbachol (0.3pM) induced 
contraction. Contractions to ATP-y-S, AMPCP, AMPCPP, ATP, UTP, ADP, UDP 
and 2-MeSATP were investigated by adding agonist (contact time 1 minute) without 
precontracting the tissue and expressed as per cent of contraction caused by a 
concentration of carbachol which gave a maximal response (lOpM), determined as 
the mean value of 3 doses of carbachol given before addition of any other drugs. A 
10-15 minute dose-cycle was used and a 30-60 second washout following each dose 
of test agonist. Concentration-response curves were obtained non-cumulatively using 
4-8 animals, and results expressed graphically as the mean and s.e. mean of the 
responses obtained. Because the relaxation concentration-response curves did not 
achieve a maximum response, EC50 values were calculated for the agonists, 
representing the concentration of the agonist which induced 50% of the response to 
carbachol (0.3pM), to allow comparison of potencies. EC50 values were generated 
from the mean pEC^o values. For each individual log concentration-response curve a 
PEC50 value (the negative log of the concentration required to give 50% of the 
maximal response to carbachol (0.3pM)) was calculated by regression analysis of the 
linear portions of the curve, and the mean and s.e. mean of these values used for 
statistical comparison.
23 .23 , Studies With Suramin
On the longitudinal muscle relaxation concentration-response curves to ATP were 
also determined in the presence of suramin (ImM) preincubated for 1 hour, and 
readded after each washout of test agonists. Contractions to ATP-y-S, AMPCP, 
AMPCPP, ATP, UTP, ADP, UDP and 2-MeSATP were also determined in the
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presence of suramin (ImM) preincubated for 1 hour, and readded after each washout 
of test agonists. Concentration-response curves to each agonist were obtained using 
tissues from 4 animals. Results were expressed graphically as the mean and s.e. 
mean of the responses obtained. For statistical analysis of results the pEC^g values 
for ATP induced relaxations were compared using Student's t-test and a value of 
p<0.05 considered to be significant.
2.3.3. Rat Duodenum Muscularis Mucosae
A number of pharmacological studies were carried out on the rat duodenum 
muscularis mucosae.
2.3.3.1. Carbachol Conccntration-Rcsponsc Curves
A concentration-response curves to carbachol was constructed so that a suitable dose 
for precontracting the tissue could be chosen (see Figure 5b). Contraction 
concentration-response curves to carbachol were carried out using tissues from 4 
animals. Carbachol was administered in increasing doses, given non-cumulatively, 
with a contact time of approximately 1 minute, a washout period of 30 seconds and a 
recovery period of 10-15 minutes before the addition of the next dose. All 
contractions were expressed as a percentage of a maximum contractile response 
induced by carbachol (lOOpM), and results were expressed graphically as the mean 
and s.e. mean of the responses obtained. lOpM carbachol gave a contraction that was 
approximately 90% of the maximum response and it produced steady rhythmic 
contractions and was therefore chosen as the precontracting dose to investigate 
relaxation.
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2.3.3.2. Nucleotide Concentration-Response Curves
Relaxant and contractile responses of the muscularis mucosae to ATP-y-S, AMPCP, 
AMPCPP, ATP, UTP, ADP, UDP and 2-MeSATP were obtained using a similar 
protocol as that used for the longitudinal muscle (see section 2.3.2.2.). However, for 
investigating the presence of relaxant responses lOpM carbachol was used to 
precontract the muscularis mucosae, and for contractile responses a concentration of 
lOOjxM carbachol gave a maximal response. Contractions were expressed as a 
percentage of a maximum contractile response induced by carbachol (lOOpM). 
Because the contraction concentration-response curves did not achieve a maximum 
response, EC50  values were calculated for the agonists, representing the 
concentration of the agonist which induced 50% of the maximum response to 
carbachol (lOOpM), to allow comparison of potencies. EC50 values were generated 
from the mean pEC^g values. For each individual log concentration-response curve a 
pEC^g value (the negative log of the concentration required to give 50% of the 
maximal response to carbachol (lOOpM)) was calculated by regression analysis of 
the linear portions of the curve, and the mean and s.e. mean of these values used for 
statistical comparison.
2.3.3.3. Studies With Suramin
On the muscularis mucosae contraction concentration-response curves to ATP, UTP, 
ATP-y-S and AMPCPP were also determined in the presence of suramin (ImM) 
preincubated for 1 hour, and readded after each washout of test agonists. 
Concentration-response curves to each agonist were obtained using tissues from 4 
animals. For AMPCPP, the pEC$g value in the presence of suramin was extrapolated 
by linear regression analysis of each of its individual log concentration-response
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curves, as contractile responses fell just below this value. Results were expressed 
graphically as the mean and s.e. mean of the responses obtained. For statistical 
analysis of results the pECgg values were compared using Student's t-test and a value 
of p<0.05 considered to be significant.
2.3.3.4. Desensitisation Studies
UTP, ATP-y-S and AMPCPP were used in an attempt to desensitize the receptors in 
the muscularis mucosae. A lOOpM concentration of each agonist was administered 
repeatedly over 90 minutes with a contact time of 5 minutes followed by washout of 
the agonist, and a time of 1 0  minutes before readdition of the agonist to allow the 
tension to return to baseline values. The agonists were tested on separate tissues, and 
the percentage contraction for each dose of agonist was determined as a percentage 
relative to the initial dose of the agonist given. Cross-desensitisation between 
AMPCPP and UTP or ATP-y-S was also investigated. A lOOjxM concentration of 
UTP or ATP-y-S (control response) was first administered followed after 10 minutes 
by the addition of the desensitising dose of AMPCPP (lOOpM) for 5 minutes, after 
which the tissue was again challenged with UTP, ATP-y-S or AMPCPP (lOOpM). 
The percentage contraction for UTP, ATP-y-S or AMPCPP was determined relative 
to the control response. Results were expressed graphically as the mean and s.e.
mean of the responses obtained. For statistical analysis of the results, in the case of 
desensitisation to the same agonist tension in grams to each dose of agonist were 
compared against the initial dose given using analysis of variance followed by 
Dunnett's two-tailed test and a value of p<0.05 considered to be significant, whereas 
in the case of cross-desensitisation per cent contractions to each dose of agonist were 
compared against the initial dose given using Student's t-test and a value of p<0.05 
considered to be significant.
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2.3.3.S. Studies With Atropine
Atropine was used to determine if  AMPCPP was acting to elicit contractions via an 
action at prejunctional P2x-purinoceptors to induce the release of acetylcholine. A 
lOOpM concentration of AMPCPP was applied to the tissues with a contact time of 
approximately 1 minute, a washout period of 30 seconds, followed by the addition of 
atropine (IpM). Atropine was left in contact with tissue for 15 minutes, before re- 
challenging with AMPCPP (lOOpM). Tissues from 4 animals were used. 
Contractions to AMPCPP were expressed as percentage contraction to the mean of 
the three doses of carbachol (lOOpM) given before the administration of any other 
drug, and statistical analysis was carried out on percentage contractions induced by 
AMPCPP before and after incubation with atropine (IpM) by the use of Student's t- 
test, and a value of p<0.05 considered to be significant.
2.4. DEGRADATION STUDIES IN THE RAT DUODENUM MUSCULARIS 
MUCOSAE
The degradation of ATP, UTP, 2-MeSATP, AMPCPP and ATP-y-S by the 
muscularis mucosae was investigated in the presence and absence of suramin 
(ImM). The muscularis mucosae was dissected, mounted in 4ml organ baths and 
allowed to equilibrate for 45 minutes with regular washings as described previously. 
Suramin (ImM) or water (40jxl) was then added to the organ baths and incubated for 
1 hour, with regular washes and readministration of the suramin. ATP, UTP, 
2-MeSATP, AMPCPP or ATP-y-S (lOOpM) were then added to the organ baths and 
150pl aliquots were then taken at 0, 5, 10, 15 and 20 minute time points, stored at 
-20°C, and analysed by h.p.l.c. at a later date. Percentage degradation of the 
nucleotides were compared at the 5 minute time points in the presence and absence
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of suramin using Student's t-test, and a value of p<0.05 considered to be significant.
To check for leakage of enzymes, tissues Avhich had been washed and incubated with 
suramin (ImM) or water (40pl) as above, were then incubated for a further 45 
minutes with no washes, the tissues were removed, the nucleotide (ATP or UTP) 
added to the buffer which had contained the tissue and samples taken for analysis at 
0 and 20 minutes. Statistical analysis was carried out on the 20 minute time point 
samples using Student's t-test, and a value of p<0.05 considered to be significant. 
H.p.l.c. analysis was carried out using a Perkin Elmer Integral 4000 h.p.l.c. with an 
Apex n  5pm ODS Cjg column eluted with O.IM KH2PO4  / 8 mM 
tetrabutylammonium hydrogen sulphate (pH6.0) (solvent A) and a 60:40 mixture of 
solvent A and acetonitrile (pH6.73) (solvent B), using a non-linear gradient (0-2.5 
min 0% B, 2.5-5 min 0-20% B, 5-10 min 20-40% B, 10-13 min 40-100% B, 13-18 
min 100% B), at a flow rate of 1.3ml/min. This gradient gave good separation of the 
nucleotides and their catabolites (see Figures 6 -8 .), for which retention times are 
given in Table 5. The purines were detected by U.V. absorbence at 259nm and 
quantified from the height of their absorbence peaks, which was linearly related to 
the concentration.
2.4.1. Enzymic Synthesis of 2-Methylthioadenosine 5’-monophosphate and 
2-Methylthioadenosine
2-Methylthioadenosine 5'-monophosphate (2-MeSAMP) and 2-methylthioadenosine 
were synthesised for use as h.p.l.c. standards, so as to enable their identification as 
possible degradation products of 2-MeSATP, via enzymic dephosphorylation of 
2-MeSATP. For the synthesis of 2-MeSAMP, to 50 units of apyrase in tris buffer 
(15mM pH6.5) was added lOOpM 2-MeSATP for 3 minutes at 30^C. For the
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Figure 6. Separation of ATP and UTP, and their corresponding breakdown products
using h.p.l.c.
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Figure 7. Separation of 2-MeSATP and AMPCPP and their corresponding
breakdown products using h.p.Lc.
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Figure 8. Separation of ATP-y-S and ADP using kp.l.c.
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approximately a 10-20 per cent impurity of ATP-y-S as obtained from the supplier. 
Injection of sample is shown by (I).
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Table 5. H.p.l.c. retention times for purine and pyrimidines.
Purine/Pyrimidine Retention Time (minutes)
ATP 11.3
ADP 9.2
AMP 7.3
Adenosine 7.0
Inosine 2.7
UTP 10.0
UDP 7.0
UMP 1.9
Uridine 2.6
2-MeSATP 15.0
2-MeSADP 14.1
2-MeSAMP 12.7
2-MeSadenosine 10.6
AMPCPP 7.9
AMPCP 10.7
ATP-y-S 12.7
Table showing the h,p.l.c. retention times of purines and pyrimidines. Suramin had a 
retention time of 17.5 minutes, and did not affect retention times for any of the 
nucleosides or nucleotides.
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synthesis of 2-methylthioadenosine, to 300 units of alkaline phosphatase in tris 
buffer (15mM pH8.0) was added lOOpM 2-MeSATP for 10 minutes at 37°C. These 
standards were immediately analysed by h.p.l.c. following enzymic synthesis.
To try and synthesize 2-methyithioinosine, to lOOpM 2-MeSATP, 300 units of 
alkaline phosphatase and 300 units of adenosine deaminase in tris buffer (15mM 
pH8.0) were added for 20 minutes at 25°C, then immediately analysed by h.p.l.c. 
However, on h.p.l.c analysis this sample corresponded to a peak identical to that of 
2 -methylthioadenosine, indicating that 2 -methylthioadenosine was not deaminated to 
2-methylthioinosine by adenosine deaminase. In addition, h.p.l.c. analysis of 
incubation buffer containing 2-MeSATP and its dephosphorylation products revealed 
only four peaks, which appear to correspond to 2-MeSATP, 2-MeSADP, 2-MeSAMP 
and 2 -methylthioadenosine.
2.5. MATERIALS
ATP, ADP, UTP, UDP, AMP, UMP, AMPCPP, AMPCP, GTP, inosine, adenosine, 
uridine, carbachol, indomethacin, alkaline phosphatase, adenosine deaminase, 
apyrase, arachidonic acid and tetrabut>dammonium hydrogen sulphate, were 
obtained from Sigma Chemical Co., (U.K.), 2-MeSATP and 2-MeSADP were 
obtained from Research Biochemicals, (U.K.), ATP-y-S was obtained from 
Boehringer Mannheim, (U.K.) and buffer salts and solvents were of analytical or 
h p.l.c. grade and were obtained from BDH, (U.K.). Suramin was a generous gift 
from Bayer, (U.K). Gas cylinders containing 95% O2  / 5% CO2 were obtained from 
BDH Ltd, (U.K.). The Techsphere 5pm ODS C g^ column was obtained from 
H.P.L.C. Technology Ltd., (U.K.) and the Apex II 5pm ODS Cjg column was 
obtained from Jones Chromatography Ltd., (U.K.).
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Stock solutions of all nucleosides and nucleotides were made up in water. As these 
compounds are known to be hydroscopic the final concentration of the drug was 
confirmed by measuring the u.v. absorbence of the stock solution together with the 
extinction coefficients for each compound at its optimum wavelength (optimal 
wavelength and extinction coefficients are shown in Table 6 ). Indomethacin was 
initially dissolved in ethanol and made up in 1/19 v/v ethanol/phosphate buffer. The 
pH of this solution was approximately 7.4 and the indomethacin should therefore be 
stable for 24 hours (Cuny et al., 1982), but a fresh solution was prepared for 
immediate use before each experiment. Arachidonic acid was freshly made up in 
O.IM Na2 C0 g before the experiment. The solvents used for preparing the 
indomethacin had no effect on the responses of the tissues at the concentrations 
finally used. Suramin and all other drugs were made up in water.
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Table 6 . Optimum wavelength and extinction coefficients for purine and 
pyrimidines.
Purine/Pyrimidine Optimum wavelength Extinction coefficient at their
(nm) optimal wavelength at pH6-7
(Ex 10'^M‘lcm'I)
Adenosine 259 14.9
AMP 259 15.3
ADP 259 15.4
ATP 259 15.4
Inosine 259 7.1
Uridine 262 1 0 . 0
UMP 262 1 0 . 0
UDP 262 1 0 . 0
UTP 262 1 0 .0
AMPCP 259 15.4
AMPCPP 259 15.4
2-MeSADP 273 14.5
2-MeSATP 273 14.5
ATP-y-S 259 15.4
Table showing the optimum wavelength for absorbence of purines and pyrimidines 
and their respective extinction coefficients.
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CHAPTER 3: RESULTS
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3.1. RAT COLON MÜSCÜLARIS MUCOSAE
The results obtained for the various pharmacological studies carried out on the rat 
colon muscularis mucosae are given below.
3.1.1. Desensitisation Of P2 -Purinoceptors
ATP, UTP and adenosine each contracted the rat colon muscularis mucosae in a 
concentration-dependent manner, although maximal responses were not obtained for 
ATP and UTP even at concentration of 300pM. ATP was approximately 4 times 
more potent than UTP, and adenosine was of similar potency to ATP but at higher 
concentrations produced a smaller response than ATP (Figure 9).
Pretreatment with ATP (200pM) reduced responses to ATP and to UTP, increasing 
the EC30  values for these agonists approximately 10 fold and 3 fold respectively, 
although this increase failed to reach statistical significance for UTP (Figure 10). 
Pretreatment with UTP (200|xM) also reduced responses to both ATP and UTP, 
increasing the EC30 values for these agonists by 3 fold and 11 fold respectively, 
although this increase failed to reach statistical significance for ATP (Figure 11). 
Pretreatment with ATP (200pM) caused a very small (less than 2 fold) increase in 
the EC30  value to adenosine, which was not statistically significant (p>0.05) (Figure 
10). Pretreatment with UTP (200pM) did not affect the concentration-response curve 
to adenosine (Figure 11). Pretreatment with adenosine (200pM) did not affect the 
concentration-response curve to ATP or UTP, but did reduce responses to adenosine, 
increasing the EC30 value approximately 4 fold, although this was not statistically 
significant (Figure 12). Pretreatment with 2-MeSATP (200pM) greatly reduced the 
response to both ATP and UTP, increasing the EC30 values for these agonists 38 and 
21 fold respectively (Figure 13). The responses to adenosine were not affected
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Figure 9. Contractile effects of adenosine, ATP and UTP on the rat colon muscularis 
mucosae.
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1 00 . 1 1 1 0 0 1 0 0 0
Agonist concentration (|iM)
Contraction of the rat colon muscularis mucosae by ATP (■), UTP ( • )  or adenosine 
(A), expressed as a percentage of the contraction induced by carbachol (50pM). 
Each point is the mean of four determinations, and vertical bars show s.e, mean.
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Figure 10. Effect of desensitisation by ATP on contractile responses to ATP, UTP
and adenosine of the rat colon muscularis mucosae.
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Contraction of the rat colon muscularis mucosae by (a) ATP, (b) UTP or (c) 
adenosine in the absence (closed symbols) or presence (open symbols) of 
desensitisation by ATP (200pM). Contraction is expressed as a percentage of the 
contraction induced by carbachol (50pM). Each point is the mean of four 
determinations, and vertical bars show s.e. mean.
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Figure 11. Effect of desensitisation by UTP on contractile responses to ATP, UTP
and adenosine of the rat colon muscularis mucosae.
80-,
6 0 -
§
% 4 0 -I
o 2 0 -
1 0 0 01 1 0 1 0 00 . 1
ATP concentration (|xM)
60-,
g
1 01 1 0 0 1 0 0 00 . 1
UTP concentration (|liM)
60-1
I 4 0 -
Io
U
1 0 1 0 00 . 1 1 1000
Adenosine concentration (|iM)
Contraction of the rat colon muscularis mucosae by (a) ATP, (b) UTP or (c) 
adenosine in the absence (closed symbols) or presence (open symbols) of 
desensitisation by UTP (200pM). Contraction is expressed as a percentage of the 
contraction induced by carbachol (50pM). Each point is the mean of four 
determinations, and vertical bars show s.e. mean.
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Figure 12. Effect of desensitisation by adenosine on contractile responses to ATP,
UTP and adenosine of the rat colon muscularis mucosae.
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Contraction of the rat colon muscularis mucosae by (a) ATP, (b) UTP or (c) 
adenosine in the absence (closed symbols) or presence (open symbols) of 
desensitisation by adenosine (200pM). Contraction is expressed as a percentage of 
the contraction induced by carbachol (50pM). Each point is the mean of four 
determinations, and vertical bars show s.e. mean.
133
Figure 13. Effect of desensitisation by 2-MeSATP on contractile responses to ATP,
UTP and adenosine of the rat colon muscularis mucosae.
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Contraction of the rat colon muscularis mucosae by (a) ATP, (b) UTP or (c) 
adenosine in the absence (closed symbols) or presence (open symbols) of 
desensitisation by 2-MeSATP (200pM). Contraction is expressed as a percentage of 
the contraction induced by carbachol (50pM). Each point is the mean of four 
determinations, and vertical bars show s.e. mean.
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Figure 14. Effect of desensitisation by AMPCPP on contractile responses to ATP,
UTP and adenosine of the rat colon muscularis mucosae.
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Contraction of the rat colon muscularis mucosae by (a) ATP, (b) UTP or (c) 
adenosine in the absence (closed symbols) or presence (open symbols) of 
desensitisation by AMPCPP (200pM). Contraction is expressed as a percentage of 
the contraction induced by carbachol (50pM). Each point is the mean of four 
determinations, and vertical bars show s.e. mean.
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by pretreatment with 2-MeSATP (200pM) (Figure 13). Pretreatment of the tissues 
with AMPCPP (200pM) did not significantly affect the concentration-response 
curves to any of the agonists (Figure 14). ECgg values (mean pECgg ± s.e. mean) for 
ATP, UTP and adenosine in the presence and absence of desensitisation are given in 
Table 7.
3.1.2. Effect Of Suramin
Pretreatment with suramin (lOOpM) shifted the contraction concentration-response 
curve for ATP and UTP to the right to a similar extent, and this shift was statistically 
significant in each case (p<0.01). The mean pECgo value for ATP was shifted from 
4.64 + 0.40 (EC30  = 23pM) to 3.44 + 0.43 (EC3 0  = 360pM) with a dose ratio of 16, 
whereas the mean PEC30  value for UTP was shifted from 4.03 + 0.61 (EC3 0  = 
93pM) to 2.92 + 0.28 (EC30 = 1200pM) with a dose ratio of 13 (Figure 15).
3.1.3. Ontogeny To Adenosine 5’-Triphosphate And Uridine 5'-Triphosphate
Carbachol (50pM) induced contraction of the rat colon muscularis at each age 
tested, and the contraction in g (mean + s.e. mean) increased with age in the 
following manner; 2 days, 0.02 ±0.01; 5 days, 0.04 ± 0.01 and adult, 2.15 ± 0.30. 
ATP and UTP each contracted neonatal (2 and 5 day old) rat colon muscularis 
mucosae in a concentration-dependent manner, and at each of these ages ATP and 
UTP showed a similar potency relative to each other in eliciting contraction. The 
mean PEC30 value for ATP and UTP were 3.83 ± 0.20 (EC30 = 150pM) and 3.59 ±  
0.39 (EC30 = 260pM) at 2  days, and 5.65 ± 0 . 2 0  (EC30 = 2.2p,M) and 5.52 ± 0.17 
(EC30  = 3.0pM) at 5 days (Figure 16). Representative traces showing contraction 
induced by ATP and UTP in neonatal (2 and 5 day) and adult rat colon muscularis
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Figure 15. Effect of suramin on contractile responses to ATP and UTP of the rat 
colon muscularis mucosae.
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Contraction of the rat colon muscularis mucosae by (a) ATP and (b) UTP in the 
absence (closed symbols) or presence of suramin (lOOpM) (open symbols). 
Contraction is expressed as a percentage of the contraction induced by carbachol 
(50pM). Each point is the mean of four determinations, and the vertical bars show 
s.e. mean.
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Figure 16. Contractile effects of ATP and UTP on neonatal and adult rat colon 
muscularis mucosae.
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Ontogeny of contractile responses to ATP (H) and UTP ( • )  in the rat colon 
muscularis mucosae, (a) 2 Day old, (b) 5 day old and (c) 60 day olds (adult). Adults 
shown in (c) are from Figure 15 and used for comparison. Contraction is expressed 
as a percentage of the contraction induced by carbachol (50pM). Each point is the 
mean of four determinations, and the vertical bars show s.e. mean.
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Figure 17. Representative traces showing contractile responses to ATP and UTP in
neonatal (2 and 5 day old) and adult rat colon muscularis mucosae.
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Representative traces showing contractions to ATP (lOOpM) and UTP (lOOpM) in 
(a) 2 day old, (b) 5 day old and (c) adult rat colon muscularis mucosae.
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mucosae are shown in Figure 17.
3.2. RAT WHOLE DUODENUM
The results obtained for the various pharmacological studies carried out on the rat 
whole duodenum are given below.
3.2.1. Relaxant Responses
2-MeSATP, ATP, ADP, AMPCPP, ATP-y-S and GTP each relaxed the rat duodenum 
in a concentration-dependent manner with mean pEC$o values of 6.72 + 0.19 (EC50  
= 0.2pM), 5.93 ± 0.03 (EC50 = 1.2pM), 5.87 + 0.15 (EC50 = 1.4pM), 5.42 ± 0.02 
(EC50 = 3.8pM), 5.43 ± 0.17 (EC50 = 3.7pM) and 4.09 ± 0.32 (EC50 = 82pM) 
respectively. UDP and UTP (>30pM) only caused veiy small and inconsistent 
relaxations, and no EC50  value could be obtained. The agonist potency order for 
relaxation was 2-MeSATP>ATP=ADP>AMPCPP=ATP-y-S»GTP»UTP=UpP 
(Figure 18; see Figure 20a for representative traces).
3.2.2. Contractile Responses
UDP, UTP and ATP-y-S each contracted the rat duodenum in a concentration- 
dependent manner, whereas the other agonists used (2-MeSATP, ATP, ADP, 
AMPCPP and GTP, at concentrations of up to 300pM) did not. At concentrations of 
up to 300pM (UDP and UTP) and 267pM (ATP-y-S) maximal responses were not 
obtained. The agonist potency order for contracting the duodenum was ATP-y-S> 
UTP>UDP, with mean pEC$o values of 4.76 + 0.06 (EC50 = 17pM), 4.26 + 0.16 
(EC50 = 55pM), and 3.57 + 0.07 (EC50 ^ 270pM) respectively (Figure 19). The
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Figure 18. Relaxant effects of nucleotides on the rat duodenum.
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Relaxation of the rat duodenum by (a) 2-MeSATP (B), ATP ( • )  or AMPCPP (A) 
and (b) ADP (B), ATP-y-S (A), GTP (V), UTP ( • )  or UDP (♦), expressed as per 
cent reversal of the contraction induced by carbachol (0.1 pM). ATP is shown as a 
broken line in (b) for comparison. Each point is the mean of four determinations, and 
the vertical bars show s.e. mean.
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Figure 19. Contractile effects of nucleotides on the rat duodenum.
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Contraction of the rat duodenum by ATP-y-S (A), UTP ( • ) ,  UDP (▼) or ATP (■), 
expressed as a percentage of the contraction induced by carbachol (0.1 pM). Each 
point is the mean of four determinations, and the vertical bars show s.e. mean.
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Figure 20. Representative traces showing responses to nucleotides in the rat
duodenum.
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Representative traces showing responses to nucleotides in the rat duodenum, (a) Effect of 
ATP (lOpM), ATP (lOpM) in the presence of suramin (ImM) (ATP+S), UTP (lOOpM) or 
ATP-y-S (8.9pM), following contraction with carbachol (CCh) (0.1 pM). (b) Effect of UTP, 
UTP in the presence of suramin (ImM) (UTP+S), ATP, ATP+S, ATP-y-S (267 or 26.7pM), 
AMPCPP or 2-MeSATP. All drugs are at a concentration of 300pM unless otherwise 
indicated, and vertical arrows indicate administration of dmg. The trace in (a) showing 
relaxation to ATP shows the method of quantification of relaxation, and the trace in (b) 
showing contraction to UTP shows the method of quantification of contraction in the 
presence of spontaneous activity (see section 2.3.1.1.).
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contractile responses to UDP, UTP and to ATP-y-S consisted of an increase in both 
the basal tone and the spontaneous activity of contractions at concentrations up to 
300pM (UDP and UTP) and 26.7pM (ATP-y-S), whereas at higher concentrations 
the increase in spontaneous activity was not so marked (see Figure 20b for 
representative traces).
Pretreatment with indomethacin (25pM for 45 minutes) had no effect on significant 
difference on contractions induced by UTP, resulting in mean pEC$o value of 4.12 + 
0.14 (EC50 = 76pM) in the presence of indomethacin (Figure 2 1 ).
No desensitisation was observed to ATP-y-S or UTP (lOOpM) when contractions 
were induced by these agonists repeatedly over a period of 90 minutes (Figure 22).
3.2.3. Effect Of Suramin On Relaxant Responses
Pretreatment with suramin (lOOpM and ImM for 1 hour) shifted the relaxation 
concentration-response curve for ATP to the right, and this shift was statistically 
significant in each case (p<0.01), resulting in mean pEC^o values of 5.27 + 0.06 
(EC50 = 5.4pM) and 4.86 + 0.14 (EC50 = 14pM) and a dose ratio of 4.5 and 1 2  
respectively. The maximal responses to ATP were also depressed in the presence of 
ImM but not lOOpM suramin (Figure 23a). In the presence of lOOjxM and ImM 
suramin no contractions to ATP were observed. Pretreatment with suramin (ImM) 
also shifted the relaxation concentration-response curve for ATP-y-S to the right, and 
this shift was statistically significant (p<0 .0 1 ), resulting in a mean pEC$o value of 
4.43 + 0.09 (EC50 = 37pM) and a dose ratio of 10  (Figure 23b).
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Figure 21. Effect of indomethacin on contractile responses to ETTP of the rat
duodenum.
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Contraction of the rat duodenum by UTP in the absence (closed symbols) or 
presence (open symbols) of indomethacin (25pM). Contraction is expressed as a 
percentage of the contraction induced by carbachol (0.1 pM). Each point is the mean 
of four determinations, and the vertical bars show s.e. mean.
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Figure 22. Histograms showing contraction of the rat duodenum in response to
repeated doses of ATP-y-S and UTP.
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Contraction of the rat duodenum in response to repeated doses of (a) ATP-y-S 
(lOOpM) and (b) UTP (lOOpM), expressed as the percentage of response to the 
initial dose (control dose) of the agonist administered. Each column is the mean of 
four determinations, and the vertical bars show s.e. mean. No values were 
significantly different from control values (p>0.05) (Dunnetf s two-tailed test).
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Figure 23. Effect of suramin on relaxant responses to ATP and ATP-y-S of the rat
duodenum.
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Relaxation of the rat duodenum by (a) ATP and (b) ATP-y-S in the absence (H) or 
presence of suramin (lOOpM) ( • )  or (ImM) (A). Relaxation is expressed as per cent 
reversal of the contraction induced by carbachol (0.1 pM). Each point is the mean of 
four determinations, and the vertical bars show s.e. mean.
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3.2.4. Effect Of Suramin On Contractile Responses
Contractions to ATP-y-S were abolished in the presence of ImM suramin (Figure 
24b). In contrast, pretreatment with suramin (lOOpM and ImM) had little effect on 
the contractions to UTP (Figure 24a). Even with ImM suramin there was less than a 
2  fold shift to the right of the concentration-response curve (mean pEC^ Q value of 
4.03 + 0.19; EC50 = 94pM), and this shift was not statistically significant (p>0.05). 
In the presence of suramin (lOOpM and ImM) the UTP-induced contractions were 
less sustained and fell off more rapidly, and the spontaneous contractions were 
suppressed (see Figure 20b for representative traces).
3.2.5. Responses To Purified Adenosine 5’-f?-(3-Thiotriphosphate)
ATP-y-S as obtained from the suppliers contained approximately 11% ADP. After 
enzymic treatment with alkaline phosphatase and adenosine deaminase this ADP 
impurity was degraded to inosine, whereas the ATP-y-S was not degraded (Figure 
25). Inosine was inactive at concentrations of up to lOOpM for both relaxation and 
contraction (results not shown). After enzymic degradation of the ADP impurity, 
relaxations to ATP-y-S were slightly reduced, resulting in approximately a 2 fold 
shift in the concentration-response curve, with a decrease in the pEC^o value from 
5.77 + 0 . 1 0  (EC50 = 1.7pM) to 5.43 + 0.17 (EC50 ^ 3.7pM), whereas contractions 
were slightly enhanced, resulting in approximately a 2  fold shift in the concentration- 
response curve, with an increase in the pEC^o value from 4.48 ± 0.09 (EC50 = 
34pM) to 4.76 + 0.06 (EC50 = 17pM) respectively (Figure 26). However, these shifts 
were not statistically significant (p>0.05).
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Figure 24. Effect of suramin on contractile responses to UTP and ATP-y-S of the rat
duodenum.
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Contraction of the rat duodenum by (a) UTP and (b) ATP-y-S in the absence (H) or 
presence of suramin (lOOpM) ( • )  or (ImM) (À). Contraction is expressed as a 
percentage of the contraction induced by carbachol (0.1 pM). Each point is the mean 
of four determinations, and the vertical bars show s.e. mean.
150
Figure 25. H.p.l.c. trace showing impurities of ATP-y-S as obtained from the 
supplier and after enzymic treatment.
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H.p.I.c. trace of (a) ATP-y-S as obtained from the supplier or (b) after enzymic 
treatment. The presence of ATP-y-S ( • ) ,  ADP (■) and inosine (T) before and/or 
after enzymic treatment is shown. Injection of sample is shown by (I).
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Figure 26. Relaxant and contractile effects of ATP-y-S as obtained from the supplier
and following enzymic treatment on the rat duodenum.
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Relaxation (a) and contraction (b) of the rat duodenum by ATP-y-S as obtained from 
the supplier (open symbols) or following enzymic treatment (closed symbols). 
Relaxation is expressed as per cent reversal of the contraction induced by carbachol 
(0.1 pM), and contraction is expressed as a percentage of the contraction induced by 
carbachol (0.1 pM). Each point is the mean of four determinations, and the vertical 
bars show s.e. mean.
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3.3. RAT DUODENUM LONGITUDINAL MUSCLE
The results obtained for the various pharmacological studies carried out on the rat 
duodenum longitudinal muscle follow.
3.3.1. Response To Nucleotides
2-MeSATP, ATP, ATP-y-S and AMPCPP each relaxed the longitudinal muscle in a 
concentration-dependent manner with mean pEC$Q values of 5.96 + 0 . 1 1  (EC50 =
l.lpM), 5.51 ± 0.29 (EC50 -  B.lpM), 5.49 ± 0.04 (EC50  = 3.2pM) and 5.21 ± 0.09 
(EC50 = 6.2pM) respectively. UDP and UTP were inactive. The agonist potency 
order for relaxation was 2-MeSATP>ATP=ATP-y-S>AMPCPP (Figure 27). Relaxant 
responses to the agonists were reversible and occurred immediately upon their 
administration reaching a maximum response after 10-15 seconds. The responses 
were therefore qualitatively similar to those seen in the whole duodenum (see Figure 
28 for representative traces). In addition, the relaxation concentration-response 
curves to 2-MeSATP and ATP on the longitudinal muscle appear to be biphasic, 
whereas those to AMPCPP and ATP-y-S are not. The longitudinal muscle contracted 
very weakly to high concentrations of ATP-y-S (100 and SOOpM), achieving 
approximately 10 and 25% respectively of the response to carbachol (Figure 29). 
These contractile responses were qualitatively similar to those seen in the whole 
duodenum (see Figure 30 for representative traces). The agonists ATP, UTP, ADP, 
UDP 2-MeSATP, AMPCPP and AMPCP at concentrations of 300pM did not 
contract the longitudinal muscle (data not shown).
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Figure 27. Relaxant effects of nucleotides on the rat duodenum longitudinal muscle.
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Relaxation of the rat duodenum longitudinal muscle by 2-MeSATP ( • ) ,  ATP (O), 
ATP-y-S (A), AMPCPP (T), UTP (V) or UDP (H), expressed as per cent reversal of 
the contraction induced by carbachol (0.3pM). Each point is the mean of at least four 
determinations, and the vertical bars show s.e. mean.
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Figure 28. Representative traces showing relaxant responses to nucleotides of the rat
duodenum longitudinal muscle.
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Representative traces showing relaxant responses to nucleotides of the rat duodenum 
longitudinal muscle. Effect of ATP (0.3pM), ATP (30pM) in the presence of 
suramin (ImM) (ATP+S), 2-MeSATP (IpM) or UTP (lOOpM), following 
contraction with carbachol (CCh) (0.3pM). Vertical arrows show administration of 
drug.
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Figure 29. Effect of suramin on contractile responses to ATP-y-S of the rat
duodenum longitudinal muscle.
1 0 0 -,
i
Ë
o
2 5 -
10 100
ATP-y-S concentration (|xM)
1000
Contraction of the rat duodenum longitudinal muscle by ATP-y-S in the absence 
(closed symbols) or presence (open symbols) of suramin (ImM). Contraction is 
expressed as a percentage of the contraction induced by carbachol (lOpM). Each 
point is the mean of four determinations, and the vertical bars show s.e. mean.
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Figure 30. Representative traces showing contractile responses to nucleotides of the
rat duodenum longitudinal muscle.
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Representative traces showing contractile responses to nucleotides of the rat 
duodenum longitudinal muscle. Effect of ATP-y-S, ATP-y-S in the presence of 
suramin (ImM) (ATP-y-S+S), ATP, UTP, 2-MeSATP or AMPCPP. All drugs were 
at a concentration of 300pM, and vertical arrows indicate administration of drug.
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3.3.2. Effect Of Suramin
Pretreatment with suramin (ImM) shifted the relaxation concentration-response 
curve for ATP to the right, and this shift was statistically significant (p<0.001) 
resulting in a mean pEC^ Q values of 3.90 + 0 . 2 0  (EC50  = 130pM), and a dose ratio of 
42 (Figure 31). In the presence of suramin (ImM) contractions to ATP-y-S were 
almost abolished (Figure 29). No contractions were observed to the other agonists 
(ATP, UTP, ADP, UDP 2-MeSATP, AMPCPP and AMPCP) (300pM) in the 
presence of suramin (ImM) (data not shown).
3.4. RAT DUODENUM MUSCULARIS MUCOSAE
The results obtained for the various pharmacological studies carried out on the rat 
duodenum muscularis mucosae follow.
3.4.1. Response To Nucleotides
ATP-y-S, AMPCP, AMPCPP, ATP, UTP, ADP and UDP each contracted the 
muscularis mucosae in a concentration-dependent manner with mean pEC$o values 
of 5.11 ± 0 . 1 2  (EC5 0  = 7.8pM), 5.00 ± 0 . 1 1  (EC50 = lOpM), 4.84 ± 0 . 1 2  (EC50 = 
15pM), 4.67 ± 0.16 (EC50 = 21pM), 4.59 ± 0.13 (EC50 = 26pM), 4.70 ± 0.17 (EC50  
= 20pM) and 4.76 ± 0.35 (EC50 = 17jliM ) respectively. However, the curves were not 
sigmoidal in shape being incomplete at concentrations of 300jiM. 2-MeSATP also 
contracted the muscularis mucosae, but at 300pM only achieved 35%, and no EC50  
value could be obtained. The agonist potency order for contraction was ATP-y-S> 
AMPCP>AMPCPP=ATP=UTP=ADP=UDP»2-MeSATP (Figure 32). Contractile
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Figure 31. Effect of suramin on relaxant responses to ATP of the rat duodenum
longitudinal muscle.
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Relaxation of the rat duodenum longitudinal muscle by ATP in the absence (closed 
symbols) or presence of suramin (ImM) (open symbols), expressed as per cent 
reversal of the contraction induced by carbachol (O.BpM). Each point is the mean of 
at least four determinations, and the vertical bars show s.e. mean.
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responses to all agonists were sustained and declined slowly, reaching a maximum 
after approximately 30-45 seconds (see Figure 33 for representative traces). The 
muscularis mucosae did not relax to any of the agonists (ATP-y-S, AMPCP, 
AMPCPP, ATP, UTP, ADP, UDP and 2-MeSATP) at concentrations of 300pM (data 
not shown).
3.4.2. Effect Of Suramin
Pretreatment with suramin (ImM) shifted the contraction concentration-response 
curve for AMPCPP to the right and this shift was statistically significant (p<0.001), 
resulting in a mean pEC^g value of 3.31 + 0 . 1 2  (EC50  = 490pM) and a dose ratio of 
33 (Figure 34a). In contrast, pretreatment with suramin (ImM) did not significantly 
shift the contraction concentration-response curves to ATP, UTP or ATP-y-S, 
resulting in mean pEC^g values of 4.90 + 0.18 (EC$g = 13pM), 4.25 + 0.13 (ECgg = 
56pM) and 4.74 + 0.20 (EC^g = 18pM) respectively in the presence of suramin 
(Figure 34b-d).
3.4.3. Desensitisation Of The Rat Duodenum Muscularis Mucosae
Desensitisation was observed to AMPCPP (lOOpM), as subsequent contractions were 
significantly different from the response to the first dose of agonist (Figure 35a). In 
contrast no statistically significant desensitisation was observed to UTP or ATP-y-S 
(lOOpM) when repeatedly administered over 90 minutes (Figure 35a). Cross­
desensitisation between AMPCPP and UTP or ATP-y-S (lOOjiM) was not observed, 
as pretreatment with AMPCPP did not significantly reduce contractions induced by 
UTP or ATP-y-S (Figure 35b).
160
Figure 32. Contractile effects of nucleotides on the rat duodenum muscularis
mucosae.
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Contraction of the rat duodenum muscularis mucosae by (a) ATP-y-S (®), AMPCPP 
(■) or 2-MeSATP (A), (b) ATP (O) or UTP (■), and (c) AMPCP ( • ) ,  ADP (A) or 
UDP (■), expressed as a percentage of the contraction induced by carbachol 
(lOOpM). The results are shown as three separate figures for clarity. Each point is 
the mean of at least four determinations, and the vertical bars show s.e. mean.
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Figure 33. Representative traces showing contractile responses to nucleotides of the
rat duodenum muscularis mucosae.
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Representative traces showing contractile responses to nucleotides of the rat 
duodenum muscularis mucosae. Effect of ATP-y-S, ATP, UTP, 2-MeSATP, 
AMPCPP or AMPCPP in the presence of suramin (ImM) (AMPCPP+S). All drugs 
were at a concentration of 300pM, and vertical arrows indicate administration of 
drug.
162
Figure 34. Effect of suramin on contractile responses to nucleotides of the rat
duodenum muscularis mucosae.
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Contraction of the rat duodenum muscularis mucosae by (a) AMPCPP, (b) ATP, (c) 
UTP or (d) ATP-y-S in the absence (closed symbols) or presence of suramin (ImM) 
(open symbols). Contraction is expressed as a percentage of the contraction induced 
by carbachol (lOOpM). Each point is the mean of at least four determinations, and 
the vertical bars show s.e. mean.
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Figure 35. Histograms showing contraction of the rat duodenum muscularis
mucosae in response to repeated doses of agonists.
2 3 4 5 6
Exposure to agonist
Control After AMPCPP
Exposure to agonist
Contraction of the rat duodenum muscularis mucosae in response to repeated doses 
of agonist (lOOpM), expressed as the percentage of response to the initial dose 
(control dose) of the agonist administered, (a) Shows contraction to repeated 
administration of the same agonist and (b) shows contraction following exposure to a 
desensitising dose of AMPCPP. AMPCPP is shown as solid columns, ATP-y-S as 
open columns and UTP as shaded columns. Each column is the mean of four 
determinations, and the vertical bars show s.e. mean. Values significantly different 
from control values are indicated by * p<0,05 and ** p<0.01. !
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3.4.4. Studies With Atropine
There was no statistical difference for contractions to AMPCPP (lOOpM) (n=4), in 
the absence (71 + 4.9 per cent contraction) or presence (71 + 10.8 per cent 
contraction) of atropine (IpM). Contraction (mean and s.e. mean) is expressed as a 
percentage of the contraction induced by carbachol (lOOpM).
3.5. DEGRADATION STUDIES ON THE RAT DUODENUM MUSCULARIS 
MUCOSAE
ATP (lOOpM) was rapidly degraded by the muscularis mucosae to ADP, AMP and 
inosine with no adenosine being detected, and around 25% of the ATP remained 
after 5 minutes (Figure 36a). A similar rate of degradation was seen for UTP 
(lOOpM), with UDP, UMP and uridine being formed (Figure 37a), and for 
2-MeSATP (lOOpM), with 2-MeSADP, 2-MeSAMP and 2-methylthioadenosine 
being formed (Figure 38a). In contrast, ATP-y-S (lOOpM) was degraded much more 
slowly than ATP, around 60% of ATP-y-S remaining after 5 minutes, with ADP, 
AMP and inosine being formed (Figure 39a). AMPCPP was also degraded at a 
slower rate than ATP, around 55% remaining after 5 minutes, with AMPCP being 
formed (Figure 40a). ATP, UTP and 2-MeSATP were almost completely degraded 
after 20 minutes, whereas for ATP-y-S and AMPCPP around 40 and 45% 
respectively remained (Figures 36b-40b.). Suramin (ImM) did not significantly 
affect the rate or pattern of degradation of the nucleotides compared at 5 minutes, 
apart from AMPCPP which was degraded more slowly in the presence of suramin 
(p<0.01) (Figure 40b).
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ATP (lOOjxM) and UTP (lOOpM) were also degraded by the buffer in which the 
muscularis mucosae had previously been incubated for 45 minutes, however, their 
rate of degradation was significantly slower (p<0.01) with around 25% remaining 
after 20 minutes. In the presence of suramin (ImM) the rate of degradation of ATP 
and UTP by the incubation buffer was significantly slower (p<0.01) than in the 
absence of suramin with around 75% remaining after 20 minutes. In the presence or 
absence of suramin (ImM) the degradation products detected for ATP were ADP, 
AMP and inosine (Figure 41a), and for UTP were UDP, UMP and uridine (Figure 
41b).
166
Figure 36. Metabolism of ATP by rat duodenum muscularis mucosae.
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Degradation by the rat duodenum muscularis mucosae of ATP (lOOjiM) ( • ) ,  to ADP 
(□), AMP (A) and inosine (V). (a) Is in the absence and (b) is in the presence of 
suramin (ImM). Each point is the mean of three determinations, and the vertical bars 
show s.e. mean.
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Figure 37. Metabolism of UTP by rat duodenum muscularis mucosae.
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Degradation by the rat duodenum muscularis mucosae of UTP (lOOjxM) ( • ) ,  to UDP 
(□), UMP (A) and uridine (V). (a) Is in the absence and (b) is in the presence of 
suramin (ImM). Each point is the mean of three determinations, and the vertical bars 
show s.e. mean.
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Figure 38. Metabolism of 2-MeSATP by rat duodenum muscularis mucosae.
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Degradation by the rat duodenum muscularis mucosae of 2-MeSATP (lOOfxM) ( • ) ,  
to 2-MeSADP (□), 2-MeSAMP (A) and 2-methylthioadenosine (V). (a) Is in the 
absence and (b) is in the presence of suramin (ImM). Each point is the mean of three 
determinations, and the vertical bars show s.e. mean.
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Figure 39. Metabolism of ATP-y-S by rat duodenum muscularis mucosae.
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Degradation by the rat duodenum muscularis mucosae of ATP-y-S (100|iM) ( • ) ,  to 
ADP (□), AMP (A) and inosine (V). (a) Is in the absence and (b) is in the presence 
of suramin (ImM). Each point is the mean of three determinations, and the vertical 
bars show s.e. mean.
170
Figure 40. Metabolism of AMPCPP by rat duodenum muscularis mucosae.
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Degradation by the rat duodenum muscularis mucosae of AMPCPP (lOOjiM) ( • ) ,  to 
AMPCP (□). (a) Is in the absence and (b) is in the presence of suramin (ImM). Each 
point is the mean of three determinations, and the vertical bars show s.e. mean.
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Figure 41. Histograms showing degradation of ATP and UTP after 20 minutes by 
buffer in which the rat duodenum muscularis mucosae had been previously 
incubated for 45 minutes.
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The results shown are the concentrations remaining from an initial concentration of 
lOOjxM (a) ATP or (b) UTP. (a) Concentration of ATP, ADP, AMP and inosine, and 
(b) concentration of UTP, UDP, UMP and uridine. Solid columns are in the absence 
and open columns in the presence of suramin (ImM). Each column is the mean of 
three determinations, and the vertical bars show s.e. mean. Values in the presence of 
suramin significantly different from control values are indicated by * p<0.05, ** 
p<0.01 and *** p<0.001 (Students t-test).
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CHAPTER 4: DISCUSSION
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4.1. RAT COLON MÜSCULARIS MUCOSAE
It has been shown that the rat colon muscularis mucosae contracts to nucleotides 
with an agonist potency order of 2-MeSATP>ATP>AMPCPP, and the receptor 
mediating contraction has therefore been characterised as a P2Y-purinoceptor (Bailey 
& Hourani, 1990). However, the results of this thesis show that UTP, like ATP, 
contracts the rat colon muscularis mucosae and is approximately four times less 
potent than ATP itself, which indicates that UTP is somewhat more potent here than 
in other tissues, such as the guinea-pig taenia caeci (Brown & Bumstock, 1981) 
which have been classified as containing P2Y-purinoceptors. In addition, 2-MeSATP 
does not achieve the same maximal response as ATP in the rat colon muscularis 
mucosae (Bailey & Hourani, 1990), in contrast to the guinea-pig taenia caeci 
(Satchell & Maguire, 1975). In some tissues an overall agonist potency order of 
2-MeSATP>ATP=UTP has been seen, where 2-MeSATP is a potent agonist biit has 
a lower maximal response than ATP, and until recently often been classed as 
containing a P2Y-Hke receptor. It is now recognised that these tissues contain a 
mixed population of P2U and P2Y subtypes which mediate the same functional 
response leading to an observed agonist potency order not characteristic of either 
single subtype (O’Connor et al., 1991). The rat colon muscularis mucosae could 
therefore contain a mixture of P2Y- and P2(j-purinoceptors, with 2-MeSATP acting 
on the former, UTP on the latter and ATP on both. Alternatively, this tissue could 
contain pyrimidinoceptors (Seifert & Schultz, 1989) on which only UTP acts, 
together with P2Y-purinoceptors which respond to 2-MeSATP and ATP.
Although P2Y-purinoceptors generally do not readily undergo marked desensitisation 
in tissues such as the guinea-pig taenia caeci and rabbit portal vein (Bumstock & 
Kennedy, 1985), desensitisation of P2Y-purinoceptors mediating relaxation has been
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reported in some tissues such as the rabbit and cat colon (Crema et aL, 1982; 
Hedlund et al., 1983) and p2Y-purinoceptor regulated PLC in turkey erythrocytes 
(Martin & Harden, 1989). Furthermore, in a number of blood vessels desensitisation 
has been used to discriminate between the contractile responses to ATP and UTP, 
providing some support for the existence of pyrimidinoceptors. For example, in the 
smooth muscle of the rat tail and femoral arteries and dog saphenous vein, 
contractions induced by ATP but not by UTP are desensitized by AMPCPP. 
Furthermore, ATP and UTP desensitized responses to themselves but not to each 
other, which has been taken to indicate that ATP and UTP elicit contraction via a 
P2X‘Purinoceptor and a pyrimidinoceptor respectively (Saïag et al., 1987; 1990). In 
the absence of any antagonist known to be selective for P2 -purinoceptors and 
pyrimidinoceptors, desensitisation was used to investigate the receptors involved in 
contraction of the rat colon muscularis mucosae, in the hope that a contractile 
response might prove easier to manipulate in this way than the relaxations observed 
in most smooth muscle preparations containing receptors of this type.
Desensitisation of the rat colon muscularis mucosae was achieved with ATP, UTP, 
2-MeSATP and adenosine, but not with AMPCPP. The failure of this agonist to 
cause any desensitisation probably reflects its low potency in this tissue (Bailey & 
Hourani, 1990), and is further evidence that ATP does not contract via P2X" 
purinoceptors here as these receptors are veiy readily desensitized by AMPCPP in 
tissues such as the guinea-pig urinaiy bladder and vas deferens (Kasakov & 
Bumstock, 1983; Meldmm & Bumstock, 1983; Bumstock & Kennedy, 1985). 
2-MeSATP was the most effective desensitising agonist, again probably reflecting its 
high potency in this tissue (Bailey & Hourani, 1990). In each case the contractile 
effect of the desensitising dose of agonist used was similar except for 2-MeSATP 
which caused a smaller contraction than the other agonists, so the ability to cause
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desensitisation was not simply related to the size of the contraction and therefore 
fatigue of the tissue. The desensitisation also demonstrated some degree of receptor 
selectivity, as responses to ATP and UTP were not reduced by desensitisation with 
adenosine and responses to adenosine were not decreased by desensitisation with 
UTP or 2-MeSATP and were only slightly decreased, at low adenosine 
concentrations, by desensitisation with ATP. As part of the desensitisation protocol, 
ATP was left in contact with the tissue for 5 minutes and it has been shown that 
during this time and under these conditions ATP is significantly degraded and 
adenosine is produced (Bailey & Hourani, 1990). Indeed use of the antagonist, 
suramin, revealed that contractions induced by high concentrations of ATP had a 
minor component which was due to interaction with A | receptors (Bailey et al., 
1992). The effect of desensitisation with ATP in reducing the effects of low 
concentrations of adenosine is therefore most likely to be due to desensitisation of 
the Aj receptor by the adenosine produced.
The lack of cross-desensitisation between adenosine and any of the nucleotides 
therefore suggests that any reduction in responses was not due to tissue fatigue, but 
was occurring at some process closer to the receptor interaction. However, there was 
cross-desensitisation between ATP and UTP, which suggests in this tissue ATP and 
UTP are interacting with the same receptor, and there is therefore no evidence for a 
separate pyrimidinoceptor. To investigate the possibility that the effects of ATP and 
UTP may be mediated via nucleotide receptors as proposed by O'Connor et al.
(1991), 2-MeSATP which is a potent agonist at P2Y-p^rinoceptors but is inactive at 
P2U’purinoceptors was used. 2-MeSATP proved however to be the most effective 
desensitising agonist, inhibiting not only responses to ATP but also those to UTP, 
which does not support the existence of P2U receptors.
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It is of course possible that the cross-desensitisation observed between the 
nucleotides but not with adenosine may be due to all the nucleotides causing 
contraction via the same second messenger pathways (e.g. PLC activation), which 
may be different from that used by the A% receptor. In this case the desensitisation 
may not be a true effect at the receptors, but may instead reflect an alteration in the 
function of this pathway. In support of this, P2xj-purinoceptors have also been shown 
to undergo desensitisation in some tissues such as bovine aortic endothelial cells, in 
which desensitisation of the P2xj-purinoceptor in response to UTP and of the P2y~ 
purinoceptors in response to 2-MeSATP has been reported. However, in bovine 
aortic endothelial cells, where desensitisation of the P2Y receptor does not affect the 
P2XJ receptor, desensitisation of the P2U receptor causes heterologous desensitisation 
of the P2Y receptor by a PKC dependent mechanism (Wilkinson et al., 1994b). 
However, it is unknown how adenosine or the nucleotides cause contraction of the 
rat colon muscularis mucosae, or how the process of desensitisation occurs and so 
these questions remain unanswered in this tissue.
Suramin has been shown to be a non-selective antagonist at P2X and P2Y- 
purinoceptors (Dunn & Blakely, 1988; Den Hertog et al., 1989; Hoyle et al., 1990; 
Leff et al., 1990), and at P2u-purinoceptors in some tissues such as bovine aortic 
endothelial cells (Wilkinson et al., 1993), bovine aortic collateral arteries (Wilkinson 
et al., 1994a) and rat aorta (Dainty et al., 1994), but not in others such as PC 12 cells 
(Murrin & Boarder, 1991) and canine tracheal epithelial cells (Dainty et al., 1994). 
However, the results presented here show that in the rat colon muscularis mucosae 
suramin antagonised responses to both ATP and UTP, and taken together with the 
desensitisation data, does not provide evidence for a suramin-insensitive P2U" 
purinoceptor in this tissue.
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It has been shown that contractile responses to adenosine and ATP are present in 
neonatal ( 2  day old) to adult rat colon muscularis mucosae, and whilst initially weak, 
develop rapidly and are at least as equal to those seen in the adult by 15 days. 
AMPCPP has also been shown to induce contractions in 2 day old tissue onwards, 
and as AMPCPP has been shown to be less potent than ATP at all ages (2, 5, 10, 15 
and 25 day old and adult), this suggests an involvement of a P2Y"purinoceptor. 
However, while the potency of ATP did not significantly decrease after day 10 that 
for AMPCPP decreased, and it is therefore possible that changes in ectonucleotidase 
activity may play a role in modulating the potency of ATP (Hourani, et al., 1993b). 
The results of this thesis show that in neonatal (2 and 5 day old) and adult rat colon 
muscularis mucosae UTP has a similar relative potency to ATP. This probably 
indicates that they are acting at the same receptor which is present from day 2 , 
although could also be interpreted as indicating two receptors which develop equally 
in respect to the potency of ATP and UTP.
In conclusion, the data presented here does not support the existence of either 
pyrimidinoceptors or P2xj-purinoceptors on the rat colon muscularis mucosae, but 
instead suggest that ATP, UTP and 2-MeSATP all act at the same receptor. There 
seems no reason at the present time to call this receptor anything other than a P2Y- 
purinoceptor, although it may not be identical to P2 Y"Purinoceptors found in other 
tissues, such as the guinea-pig taenia caeci, at which UTP is considerably less potent.
4.2. RAT WHOLE DUODENUM
It has been shown that relaxation of the rat duodenum is mediated via a P2Y- 
purinoceptor with an agonist potency order of 2-MeSATP>ATP>AMPCPP (Nicholls 
et al., 1990; Hourani et al., 1991), and the results of this thesis show an agonist
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potency order of 2-MeSATP>ATP=ADP>AMPCPP=ATP-Y-S»GTP»UTP=UDP, 
which is consistent with this conclusion. In contrast, UDP and UTP which were 
almost inactive in relaxing precontracted duodenum, brought about a marked 
contraction of this tissue. It has been shown that the rat duodenum in response to 
ATP undergoes a transient relaxation followed by a rebound contraction which 
appears to be mediated via prostaglandin synthesis as this rebound contraction is 
abolished by indomethacin (Manzini et al., 1985). In the present study no consistent 
rebound contractions were observed to ATP, with consistent contractions following 
relaxation only being seen for UTP. In addition, in the study by Manzini et al. (1985) 
a higher concentration of ImM ATP was used, although in a further study rebound 
contractions were reported to occur in response to lOOpM but not lOpM ATP 
(Manzini et al., 1986). In addition, rebound contractions to ATP (0.1-30pM) in the 
rat duodenum were not remarked on by Hourani et al. (1991). As indomethacin did 
not block contractions to UTP, but did those to arachidonic acid, contractions 
induced by UTP were not mediated by prostaglandins. ATP-y-S, in addition to 
relaxing the duodenum, also caused marked contraction of this tissue, and was thus 
more potent than either of the pyrimidine nucleotides. As no contraction was 
observed in response to AMPCPP, which is a potent agonist at P2x-purinoceptors, or 
to 2-MeSATP, a potent agonist at P2Y-purinoceptors, contraction of the rat 
duodenum does not appear to be mediated by a purinoceptor of the P2X or P2Y 
subtypes.
The agonist potency order at the P2U receptor is UTP=ATP=ATP-y-S>ADP> 
2-MeSATP>AMPCPP (Dubyak, 1991; O'Connor et al., 1991; O'Connor, 1992; 
Dubyak & El-Moatassim, 1993; Fredholm et al., 1994), and a number of tissues have 
been shown to contain P2U receptors (Demolle et al., 1988; Fine et al., 1989; 
Davidson et al., 1990; Brown et al., 1991; Motte et al., 1993b; Wilkinson et al..
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1993; 1994a, b; Purkiss et al., 1994). However, as ATP does not cause contraction in 
the rat duodenum, these results indicate that these contractions are not mediated by 
P2U receptors as defined in previous literature. Although the relaxations induced by 
ATP could possibly mask any contractions, ATP-y-S clearly caused contraction in 
spite of being a potent relaxant agonist, and suramin (ImM), which inhibited ATP- 
induced relaxations, did not reveal any contractile response.
Pyrimidinoceptors, which respond to uracil nucleotides instead of adenine 
nucleotides (Seifert & Schultz, 1989), have been proposed to exist in a number of 
blood vessels (Saïag et al., 1987; 1990; Von Kügelgen et al., 1987; Von Kügelgen & 
Starke, 1990). This has been proposed largely on the basis that desensitisation with 
ATP analogues reduces subsequent responses to ATP but not to UTP, and whilst 
desensitisation with ATP and UTP reduces subsequent responses to themselves, 
cross-desensitisation is not observed, indicating that ATP and UTP act at different 
receptors to elicit vasoconstriction. In the rat duodenum, however, desensitisation 
was not observed to either ATP-y-S or UTP, so this approach could not be used to 
investigate whether these agonists acted at a common receptor.
The non-selective P2 antagonist suramin shifted the ATP relaxation concentration- 
response curve to the right, as expected for a P2Y"purinoceptor. In contrast, suramin 
did not affect the UTP contraction concentration-response curve. This indicates that 
the receptor at which UTP is acting to elicit contraction is not blocked by suramin, 
and further supports the suggestion that it is not of the P2X or ?2Y subtypes. 
However, suramin completely abolished the contractions to ATP-y-S, and this could 
suggest that in addition to a suramin-insensitive pyrimidinoceptor, there is a further 
suramin-sensitive receptor causing contraction of the rat duodenum, which can be 
activated only by the purine nucleotide ATP-y-S, and not by the other nucleotides
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tested. In support of the suggestion of a pyrimidinoceptor, UDP, which is a potent 
agonist at the proposed pyrimidinoceptors in the rabbit ear artery (Von Kügelgen et 
al., 1987), basilar artery (Von Kügelgen & Starke, 1990) and rat C6-2B glioma cells 
(Lazarowski & Harden, 1994), as well as at the cloned pyrimidinoceptor (Communi 
et al., 1995a), was also a potent agonist in eliciting contraction in the rat duodenum.
The rat duodenum has been shown to rapidly and sequentially degrade ATP to ADP, 
AMP, adenosine and inosine by the presence of ectonucleotidases (Nicholls et al., 
1992b). Therefore an alternative explanation for the differential antagonism of UTP 
and ATP-y-S by suramin, is that there could be one receptor at which both UTP and 
ATP-y-S act, and the effect of suramin on contractions could be explained in terms 
of its action as an ectonucleotidase inhibitor (Hourani & Chown, 1989; Bailey & 
Hourani, 1994; Crack et al., 1994). Degradation by ectonucleotidases has been 
shown to lead to decreased potency of ATP and some of its analogues in some 
tissues, and ATP-y-S has been shown to be relatively resistant to ectonucleotidase 
activity, unlike UTP, which is rapidly degraded (Welford et al., 1987). Thus the dual 
effect of suramin in inhibiting ectonucleotidase activity and antagonising the 
receptor could result in differential inhibition of the agonists. The effect on ATP-y-S 
would be simple antagonism, whereas in the case of UTP the enhanced potency due 
to inhibition of ectonucleotidases would oppose any shift in its observed 
concentration-response curve. Indeed, a similar mechanism has been proposed 
recently to explain variable effects of suramin against agonists degraded at different 
rates in the rabbit ear artery (Crack et ah, 1994).
A complication which should be borne in mind when ATP-y-S is used is the presence 
of ADP as an impurity in the ATP-y-S as obtained from the supplier. As ADP is a 
potent P2Y-purinoceptor agonist but has little activity at P2u-purinoceptors, this
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could affect the observed potency of ATP-y-S. In addition, ADP is readily 
dephosphorylated by ectonucleotidases to its corresponding nucleoside adenosine 
(Welford et al., 1986; 1987; Nicholls et al., 1992b), which can then act at P%- 
purinoceptors (Bailey & Hourani, 1990; 1992; Slakey et al., 1990).
The data presented here therefore indicates that in the rat whole duodenum in 
addition to P2y-purinoceptors causing relaxation, there are receptors causing 
contraction at which UTP and ATP-y-S act and do not appear to be either P2X" or 
P2Y-purinoceptors. Because of the differential inhibition by suramin of these 
agonists, these results could be interpreted as indicating the presence of a suramin- 
insensitive pyrimidinoceptor as well as a suramin-sensitive receptor for ATP-y-S. An 
alternative explanation for the differential effects of suramin, however, is that its 
actions as an antagonist are compromised in the case of rapidly degraded nucleotides 
such as UTP by its action as an ectonucleotidase inhibitor.
4.3. RAT DUODENUM LONGITUDINAL MUSCLE
The rat duodenum longitudinal muscle relaxed to a series of purine nucleotides with 
an agonist potency order of 2-MeSATP>ATP=ATP-y-S>AMPCPP, while the 
pyrimidine nucleotides UTP and UDP were inactive in eliciting relaxation. In 
addition, suramin antagonised the relaxant response to ATP on the longitudinal 
muscle, significantly shifting its relaxation concentration-response curve to the right. 
In contrast, when examined for a relaxant response to a series of nucleotides, the rat 
duodenum muscularis mucosae was unresponsive. The results of this thesis thus 
clearly show that it is the longitudinal muscle which contains the P2Y"purinoceptor 
previously demonstrated in the rat whole duodenum as the potency order and the 
qualitative nature of the response are similar (Nicholls et al., 1990; Hourani et al..
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1991; Windscheif et al., 1995). However, AMPCPP is rather more potent in the rat 
duodenum longitudinal muscle than might be expected from its reported lack of 
activity at P2Y-p^noceptors cloned from chick or turkey brain, rat or mouse 
insulinoma cells and bovine endothelium (Webb et al., 1993; Filtz et al., 1994; 
Henderson et al., 1995; Tokuyama et al., 1995). This could be a consequence of its 
resistance to breakdown, as previously proposed for the observed differences in 
agonist potency orders obtained for P2x-purinoceptors in pharmacological studies in 
isolated tissues compared to the cloned P2x-P^rinoceptors (Kennedy & Leff, 1995), 
or could indicate that the P2Y-purinoceptor on smooth muscle is of a different 
subtype.
The relaxation concentration-response curves to 2-MeSATP and ATP on the 
longitudinal muscle appear to be biphasic, whereas those to AMPCPP and ATP-y-S 
are not. This could imply that 2-MeSATP and ATP are acting via two receptors to 
cause relaxation, and the fact that the more stable compounds ATP-y-S and 
AMPCPP are monophasic suggest that this second receptor could be a Pj- 
purinoceptor, as it has been shown that the longitudinal muscle relaxes to adenosine 
via A | and A2B receptors (Nicholls et al., 1995). However, 2-methylthioadenosine 
which is ultimately formed from the dephosphorylation of 2-MeSATP by 
ectonucleotidases (Welford et al., 1986; 1987), is only a weak agonist at P%- 
purinoceptors in the taenia caeci (Satchell & Maguire, 1975), and the effects of ATP 
were largely inhibited by suramin, with no hint that this antagonism was only 
blocking one component of the action of ATP. In addition, in the whole duodenum 
the relaxant responses to 2-MeSATP and ATP, as well as those to AMPCPP are not 
inhibited by 8 -SPT (Hourani et al., 1991). It therefore seems unlikely that ATP and 
2-MeSATP are acting whether directly or indirectly at a Pj-purinoceptor in the rat 
duodenum longitudinal muscle, but the nature of this second site is unknown.
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The results of this thesis thus clearly show that rat duodenum longitudinal muscle 
contains a P2Y"Purinoceptor which mediates relaxation. However, the results also 
suggest the possibility of the presence of a second site which mediates relaxation in 
response to ATP and 2-MeSATP.
Further work into this second site mediating relaxation of the rat duodenum 
longitudinal muscle might be done by the use of Pj-purinoceptor antagonists to 
determine if this second site is in fact a Pj-purinoceptor. In the taenia caeci, based on 
studies with DIDS and PPADS, it has been proposed that in addition to a relaxation- 
mediating P2Y-purinoceptor there is an additional relaxation-mediating P2- 
purinoceptor which does not fit into any of the presently recognised subtypes 
(Windscheif et al., 1994; Dudeck et al., 1995; Windscheif et al., 1995). DIDS and 
PPADS might therefore be of use in investigating the relaxation-mediating receptors 
in the rat duodenum longitudinal muscle.
4.4. RAT DUODENUM MUSCULARIS MUCOSAE
The rat duodenum muscularis mucosae contracted with an agonist potency order of 
ATP-y-S>AMPCP>AMPCPP=ATP=UTP=ADP=UDP»2-MeSATP, which is not 
characteristic of any one P2 -purinoceptor subtype. However, this is in contrast to the 
rat whole duodenum which was found to contract to ATP-y-S, UTP and UDP, but not 
to ATP, ADP, AMPCPP or 2-MeSATP (see section 4.2.). The fact that ATP 
contracted the muscularis mucosae whereas no contractions were observed in the 
whole duodenum is presumably because in the unseparated tissue these contractions 
are counteracted by the strong relaxations of the longitudinal muscle. In addition, the 
longitudinal muscle only contracted weakly to high concentrations of ATP-y-S which 
may reflect the presence of a small amount of the muscularis mucosae left attached
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to the longitudinal muscle during the dissection.
The ?2x  subtype is characterised by a contractile response and an agonist potency 
order in smooth muscle of AMPCPP>ATP=2-MeSATP (Bumstock & Kennedy, 
1985), although this does not reflect the true potency order at the cloned P2X 
subtypes (Brake et al., 1994; Valera et al., 1994; Chen et al., 1995, Evans et al., 
1995). Suramin is also an antagonist (Hoyle et al., 1990; Leff et al., 1990), and rapid 
desensitisation is observed (Kasakov & Bumstock, 1983; Meldmm & Bumstock, 
1983). In the rat duodenum muscularis mucosae AMPCPP was much more potent 
than 2-MeSATP in eliciting contraction suggesting the presence of a P2X- 
purinoceptor. In addition, suramin significantly shifted the contraction 
concentration-response curve of AMPCPP to the right, and desensitisation to 
AMPCPP was observed. Taken together, this would suggest that there is a P2X- 
purinoceptor in the rat duodenum muscularis mucosae at which AMPCPP is able to 
elicit contraction. However, the data also indicates the presence of an additional 
contraction-mediating receptor in the rat duodenum muscularis mucosae, probably of 
the P2XJ subtype.
The P2XJ receptor has been characterised as a receptor linked to PLC and at which 
the agonist potency order is UTP=ATP=ATP-y-S»2-MeSATP=AMPCPP 
(O’Connor et al., 1991; O'Connor, 1992; Dubyak & El-Moatassim, 1993; Fredholm 
et al., 1994). The agonist potency order for contraction of the rat duodenum 
muscularis mucosae suggests an action at a P2U receptor, as ATP was equipotent 
with UTP, and 2-MeSATP is only weakly active. The high potency of AMPCPP may 
be due to the presence of the P2X receptor, and this may also explain why ATP-y-S 
has a higher potency than would be expected for a P2U receptor, as it is also a potent 
P2X receptor agonist. The lack of antagonism by suramin is also consistent with this
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suggestion, as there appear to be subclasses of the P2U subtype based on sensitivity 
to suramin (Murrin & Boarder, 1991; Wilkinson et al., 1993; 1994a; Dainty et al., 
1994). In the rat duodenum muscularis mucosae it was found that suramin did not 
antagonise the responses to ATP, UTP or ATP-y-S, which implies that contraction to 
all three of these agonists is mediated via a suramin-insensitive P2U receptor. In the 
rat duodenum muscularis mucosae responses to AMPCPP were readily desensitized 
unlike those to UTP and ATP-y-S, and no cross-desensitisation between AMPCPP 
and ATP-y-S or UTP was observed. This further supports the proposal that UTP and 
ATP-y-S are acting via a receptor different from that at which AMPCPP acts.
The data presented here therefore indicates that the rat duodenum muscularis 
mucosae contains two receptors which both mediate contraction. One of these is 
suramin-sensitive at which AMPCPP is a potent agonist readily causing 
desensitisation, suggesting it is probably a P2x-purinoceptor. The other is suramin- 
insensitive at which ATP and UTP show equal potency, and at which ATP-y-S also 
acts, suggesting it is probably a P2u-punnoceptor.
4.4.1. Degradation Studies In The Rat Duodenum Muscularis Mucosae
In the rat whole duodenum, contractions to ATP-y-S but not those to UTP were 
abolished in the presence of suramin, suggesting that UTP and ATP-y-S act via 
different receptors. However, the results for the rat duodenum muscularis mucosae 
suggest that UTP and ATP-y-S act via a common receptor, and as the use of suramin 
as a P2 antagonist can also be complicated by its ability to inhibit ectonucleotidases 
(Hourani & Chown, 1989; Bailey & Hourani, 1994; Crack et al., 1994), it is possible 
that this differential antagonism in the whole duodenum was instead due to 
concomitant inhibition by suramin of the breakdown of UTP but not of ATP-y-S.
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Therefore the rate and pattern of degradation of some nucleotides and the effect of 
suramin was investigated to see if this could account for the differential antagonism 
observed in the muscularis mucosae.
The rat whole duodenum has been shown to dephosphoiylate ATP rapidly via 
ectonucleotidases, with inosine rather than adenosine being formed as the ultimate 
product due to the presence of adenosine deaminase extracellularly on the duodenum 
(Franco ef a/., 1988; Nicholls el aL, 1992b). In the rat duodenum muscularis 
mucosae it was also found that inosine rather than adenosine was the major 
breakdown product of ATP. ATP, UTP and 2-MeSATP were all rapidly degraded at 
similar rates ultimately to inosine, uridine and 2 -methylthioadenosine respectively. 
ATP-y-S and AMPCPP were both degraded more slowly and at much the same rate, 
ultimately to inosine and AMPCP respectively. A similar rate and pattern of 
degradation was seen in the absence and presence of suramin for all of these 
agonists, apart from AMPCPP which was dephosphorylated significantly slower at 5 
minutes in the presence of suramin. Although it has been shown in other tissues that 
the lack of antagonist action of suramin can be explained by its action as an 
ectonucleotidase inhibitor (Crack et aL, 1994), in the rat duodenum muscularis 
mucosae however this does not appear to be the case. The contraction concentration- 
response curve to AMPCPP was shifted by suramin, whereas the contraction 
concentration-response curve to ATP-y-S was not, while suramin inhibited the 
breakdown of AMPCPP but not that of ATP-y-S. It is therefore hard to explain the 
lack of effects of suramin on the response to ATP-y-S simply in terms of suramin 
slowing removal of the agonist by inhibiting ectonucleotidases. However, it is 
possible that the nature of the product formed as a result of the degradation of 
AMPCPP and ATP-y-S may complicate this interpretation, as the product of 
degradation of AMPCPP, AMPCP, was also a potent contractile agonist, whereas the
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ultimate product of ATP-y-S was the inactive inosine, and therefore 
dephosphorylation may not affect the observed action of AMPCPP as greatly as that 
of ATP-y-S. However, as ATP-y-S was degraded significantly more slowly than ATP, 
the fact that suramin had exactly the same effect on each of these agonists argues 
against a 'self cancelling' effect of suramin as an antagonist and an ectonucleotidase 
inhibitor. In this context it is worth noting that as 2-MeSATP was degraded at a 
similar rate as for ATP and UTP, its low potency in the muscularis mucosae cannot 
be due to the action of ectonucleotidases. As it was only possible to detect the 
concentration of nucleotides remaining and their breakdown products in the bulk 
phase (the organ bath buffer), the rate of degradation measured was certainly an 
underestimate of the rate of degradation occurring in the biophase (the vicinity of the 
receptor) due to lack of equilibration between the bulk phase and the biophase 
(Kennedy & Leff, 1995). However, the relative rates of degradation of the various 
nucleotides measured here should be a true reflection of their relative rates of 
degradation in the biophase, although it is possible that diffusion into the biophase 
may be different for different agonists.
Degradation of ATP by buffer in which the rat duodenum muscularis mucosae had 
previously been incubated with for 45 minutes was significantly slower than in the 
presence of the tissue, and also showed a different proportion of breakdown 
products. More ATP, ADP and AMP, but less inosine was observed in incubation 
buffer, although there was still no adenosine detected. A similar rate of degradation 
was seen for UTP, but with UTP, UDP, UMP and uridine being detected. In 
incubation buffer in the presence of suramin there was clearly ectonucleotidase 
inhibition with the majority of the nucleotide remaining as ATP or UTP, and very 
little ADP, AMP and inosine or UDP, UMP and uridine being seen respectively. This 
inhibition of ATP and UTP degradation by suramin of buffer in which the tissue had
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been incubated and then removed, but not in which the tissue was present, 
presumably reflects the relative concentrations of ectonucleotidases present. As 
5'-nucleotidase (Meghji, 1993; Ziganshin et aL, 1994a) and adenosine deaminase 
(Franco et aL, 1986; 1988) have been shown to be membrane bound, the results 
presented here suggest that the breakdown in the incubation buffer may be due to 
small pieces of tissues which had been fragmented into the medium. In the presence 
of the rat whole duodenum degradation of ATP has been observed by organ bath 
medium in which tissues had been incubated for 45 minutes (Nicholls et aL, 1992b). 
However, whilst in the presence of the whole duodenum inosine is the end product 
of degradation, in buffer in which the duodenum had been incubated for 45 minutes 
and then removed AMP was the end product of degradation. This indicates that the 
enzymes responsible are not purely membrane bound ectoenzymes but also soluble 
enzymes which had leaked into the medium. However, degradation of AMP to 
adenosine appears to be due solely to an ecto-5'-nucleotidase (Nicholls et al., 1992b).
In conclusion, the data presented here shows that the rat duodenum muscularis 
mucosae is able to rapidly dephosphorylate adenine and uracil nucleotides, via 
ectonucleotidases and adenosine deaminase, although in the rat duodenum 
muscularis mucosae this does not appear to complicate interpretation of the results, 
as has been the case in other tissues such as the rabbit ear artery (Leff et aL, 1990; 
Crack et aL, 1994).
4.5. CONCLUSION AND FURTHER WORK
It is thus apparent from the work of this thesis that in addition to receptors at which 
adenine nucleotides act in the rat colon and duodenum, there are also receptors at 
which the pyrimidine nucleotide UTP can act to bring about the same functional
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response. The data presented here indicates that the receptors at which UTP acts are 
the same P2-purinoceptors at which ATP acts, rather than specific 
pyrimidinoceptors. This is in agreement with present literature, as pyrimidinoceptors 
have been proposed to exist in a number of blood vessels such as the rabbit ear artery 
(Von Kügelgen et a l, 1987), rat tail and femoral arteries and dog saphenous vein 
(Saïag et al., 1987; 1990), and neuronal tissues such as the rat superior cervical 
ganglion (Connolly, 1994) and rat C6-2B glioma cells (Lazarowski & Harden, 1994). 
However, with the recent cloning of a pyrimidinoceptor which was demonstrated to 
be present in human placenta (Communi et al., 1995a), the identification of further 
receptors of this type should be aided. The data presented here indicate that the 
receptor at which both ATP and UTP act in the rat colon muscularis mucosae is 
probably of the P2Y subtype, whilst in the rat duodenum muscularis mucosae is 
probably of the P2U subtype. However, the presence of coexisting P2Y and P2U 
subtypes with UTP acting only on the later cannot be ruled out in the rat colon 
muscularis mucosae, and if this is the case, might suggest a role of the P2U subtype 
in enabling regulation of gut motility by UTP. In contrast, the results of this thesis 
show that there is a mixed population of P2X- and P2xj-purinoceptors in the rat 
duodenum muscularis mucosae, which indicates that ATP can potentially mediate 
contraction via two mechanisms, a significance of which might be that whereas the 
P2X“Purinoceptor underwent desensitisation the P2U"Parinoceptor did not.
A marked difference between responses induced by ATP and UTP in both the rat 
colon and duodenum was that whilst both nucleotides contracted the muscularis 
mucosae, only ATP relaxed the rat duodenum longitudinal muscle. The results show 
that relaxation of the rat duodenum longitudinal muscle was by a P2Y"Purinoceptor, 
and in the case of the rat colon longitudinal muscle, it has also been shown that ATP 
relaxes this tissue by acting at a P2Y-purinoceptor (Bailey & Hourani, 1992). This
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therefore illustrates a differential location of the P2 -purinoceptors mediating 
contraction and relaxation of the rat colon and duodenum. A similar differential 
location of Pj-purinoceptors has been shown in the rat colon and duodenum. In the 
rat duodenum, an Aj and an A2 receptor which both mediate relaxation are located 
on the longitudinal muscle, and an A2  receptor mediating contraction is located on 
the muscularis mucosae (Nicholls et al., 1995), whereas in the rat colon, an A% 
receptor mediating relaxation is located on the longitudinal muscle (Bailey & 
Hourani, 1992) and an A2 receptor mediating contraction is located on the 
muscularis mucosae (Bailey et al., 1992). This therefore suggests that the outer 
longitudinal muscle and the muscularis mucosae (inner longitudinal muscle) of the 
rat colon and duodenum have an opposing action in regulating gut function in 
response to purines.
To date, a number of pharmacological studies have been carried out to investigate 
the purinoceptors in the different tissues of the gastrointestinal tract, and although 
the overall knowledge is incomplete, it is clear from these studies that there are 
differences in the location and subtypes of purinoceptors present. For example, the 
cat colon circular muscle has been shown to contain a P2x-p^rinoceptor which 
mediates contraction and a P2Y- and a Pj-purinoceptor which mediate relaxation 
(Venkova et al., 1994). This is in contrast to the rat colon muscularis mucosae which 
contains only contraction-mediating purinoceptors (A2 and P2Y subtypes), and the rat 
colon longitudinal muscle which contains only relaxation-mediating purinoceptors 
(A] and P2Y subtypes). In addition, it has been demonstrated that the guinea-pig 
ileum longitudinal muscle contains a P2Y“purinoceptor which mediates contraction 
(Kennedy & Humphrey, 1994), which is in marked contrast to the longitudinal 
muscle of the rat colon and rat duodenum which contain a relaxation-mediating P2Y- 
purinoceptor. Furthermore, in the rabbit colon muscularis mucosae it has been shown
191
that ATP, ADP, AMP and adenosine cause considerably larger contractions of 
muscularis mucosae from the proximal colon than of that from either the mid and the 
distal region, and that whist in all three regions of the muscularis mucosae a relative 
potency of ATP=ADP>AMP>adenosine is observed, contractions to adenosine are 
only observed in the proximal region (Percy et a l, 1992). However, further work is 
required to investigate the different tissues of the gastrointestinal tract (and the 
separate muscle layers) in a variety of species, before a complete knowledge of the 
purinoceptors present and the response they mediate will be obtained.
A similarity between the P2Y"purinoceptor in the rat duodenum longitudinal muscle 
(data presented here) and the rat colon longitudinal muscle (Bailey & Hourani, 
1992), is that AMPCPP is rather more potent here than might be expected from its 
reported lack of activity at P2 Y-pwinoceptors cloned from chick or turkey brain, rat 
or mouse insulinoma cells and bovine endothelial cells (Webb et al., 1993; Filtz et 
al., 1994; Henderson et al., 1995; Tokuyama et a l, 1995). As previously mentioned, 
this could be a consequence of resistance to breakdown of AMPCPP, and this has 
been proposed for the observed differences in agonist potency orders obtained for 
P2x-purinoceptors in pharmacological studies in isolated tissues compared to the 
cloned P2x-punnoceptors (Kennedy & Leff, 1995). In addition, in the rat colon 
longitudinal muscle ectonucleotidase activity was suggested to explain a lack of 
potency of 2-MeSATP (Bailey & Hourani, 1992). However, as well as the rat 
duodenum longitudinal muscle, AMPCPP is an agonist at the relaxation-mediating 
P2 Y"Purinoceptors on smooth muscles such as the guinea-pig taenia caeci (Satchell 
& Maguire, 1975) and rat colon longitudinal muscle, and taken together this might 
alternatively indicate that the P2Y-purinoceptors on visceral smooth muscle are of a 
different subtype to those that have been cloned. In addition, in the rat whole 
duodenum in which there are present both the opposing relaxation-mediating
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(longitudinal muscle) and contraction-mediating (muscularis mucosae) ?2 - 
purinoceptors, relaxant responses to ATP predominate (via the P2Y~purinoceptor), 
whilst UTP which is inactive at the P2Y“purinoceptor induces contraction (via the 
P2U"purinoceptor). A P2X”Purinoceptor is present on the rat duodenum muscularis 
mucosae and it would therefore not be unreasonable to expect AMPCPP to elicit 
contraction in the whole duodenum. However, AMPCPP was observed to induce 
relaxation and not contraction of the whole duodenum indicating a predominant 
effect at the P2Y-purinoceptor. If the P2Y-purinoceptor in the rat duodenum 
represents a P2Y subtype at which AMPCPP is a relatively potent agonist, this may 
explain its action in relaxing rather than contracting the whole duodenum. However, 
as the nucleotides were administered into the organ bath buffer and the location of 
the P2Y-ptu"inoceptor is on the longitudinal muscle (the outer muscle layer) and the 
P2x-purinoceptor on the muscularis mucosae (the inner muscle layer), diffusion into 
the tissue may have had an influence on responses seen in the whole tissue compared 
to when the muscularis mucosae and longitudinal muscle were separated. However, 
although this is unlikely to account for the higher potency of AMPCPP at the P2Y- 
purinoceptor compared to the cloned P2Y-ptirinoceptors, it does illustrate observed 
differences between what is seen in pharmacological studies with whole tissues and 
when they are separated into individual muscle layers.
The control of gastro-intestinal motility and secretion relies upon many functionally 
and anatomically discrete populations of intrinsic neurones. The smooth muscle is 
controlled by two main functional classes of enteric neurones, those that are 
excitatory motor neurones and those that are inhibitory motor neurones. As well as 
purines a number of other substances are present within enteric neurones, and these 
include acetylcholine, a wide variety of neuropeptides (e.g. substance P and VIP), 
amino acids (e.g. GABA and 5-HT) and NO, which can contribute to excitatory and
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inhibitory transmission of gut smooth muscle (Bumstock & Kennedy, 1992). The 
control of the gastrointestinal tract is therefore not solely by purines, but as purines 
can modulate the release of some of these substance by acting at prejunctional P%- 
and P2 -purinoceptors as well as having a direct postjunctional effect, they are 
obviously of importance in the overall regulation of gastrointestinal motility, as are 
the other substances. In contrast, little is known about the storage and regulation of 
release of pyrimidine nucleotides. It is known that they are synthesised via de novo 
synthesis and salvage pathways in the body to meet metabolic needs (Traut, 1994), 
and uracil nucleotides such as UTP have been shown to be stored in platelet granules 
where they are released upon platelet activation, and in adrenal medullary 
chromaffin granules (Goetz et al., 1971). They are also present in appreciable 
amounts in the liver, brain, kidney, various blood cells and to a lesser extent in 
skeletal muscle (Keppler et ah, 1970; Traut, 1994). However, the presence of 
receptors at which uracil nucleotides can act does support the idea that they are 
important extracellular signalling compounds.
Ideally, selective antagonists and the cloning of the receptors on the different muscle 
layers in the rat colon and duodenum would be employed to further investigate the 
receptors present. However, in the absence of this, one approach to further 
investigate the receptor(s) involved might be the use of electrophysical studies. This 
would certainly confinn if  a P2x-punnoceptor (ion channel) was involved in 
mediating contraction for either the colon or duodenum muscularis mucosae.
It has been demonstrated in a number of tissues which contain both P2Y- and P2U- 
purinoceptors that there are differences in their signal transduction mechanisms. The 
dissociation and culturing of the smooth muscle cells of the rat colon and duodenum, 
as has been performed in other visceral smooth muscles such as the rat vas deferens
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(Friel et al., 1988), might therefore be another approach by which to investigate the 
receptor(s) in the colon and duodenum. For example, in rat C6  glioma cells, it has 
been shown that the P2u-purinoceptor is coupled to PLC by a pertussis toxin- 
insensitive Gp protein which mediates stimulation of phosphoinositide hydrolysis, 
whereas the P2Y-purinoceptor is linked to adenylyl cyclase by a pertussis toxin- 
sensitive Gi protein which mediates inhibition of cAMP (Lin & Chuang, 1994). In 
bovine aortic endothelial cells, P2Y- and P2xj-purinoceptor mobilisation of the 
second messenger inositol 1,4,5-trisphosphate has been shown to be by different 
routes. It was shown that stimulation of inositol 1,4,5-trisphosphate was more 
sustained in response to UTP than to 2-MeSATP, and whereas the response to UTP 
was attenuated by pertussis toxin, the response to 2-MeSATP was unaffected. In 
addition, activation of PKC with tetradodecanoyl phorbol acetate (TPA) inhibited 
responses to 2-MeSATP, but had no effect on the response to UTP, and the PKC 
inhibitor RO 31-8220 enhanced responses to 2-MeSATP but had no effect on 
responses to UTP (Purkiss et al., 1994). The use of similar experiments, particularly 
in the rat colon muscularis mucosae, might therefore resolve the receptor(s) present 
by allowing a study of the second messengers involved in response to 2-MeSATP 
and to UTP.
A potential problem in isolated tissues is the presence of ectonucleotidases, and the 
development of selective ectonucleotidase inhibitors would be of value in the study 
of the receptors present. Ectonucleotidases are Ca^  ^and Mg2+-dependent enzymes 
and it has been shown in the rat vagus nerve, that removal of Ca^+ and Mg^+ ions 
from the buffer inhibits ectonucleotidase activity (Trezise et al., 1993; 1994). 
However, in smooth muscle preparations contractions to ATP are dependent on 
extracellular Ca^+ and it would therefore not be practical to remove Ca^  ^ from the 
buffer. Recently an analogue of ATP, FPL 67156, has been reported to be a selective
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inhibitor of ecto-ATPase in the rabbit ear artery (Crack et al., 1995), but is not yet 
commercially available. However, an investigation into the ectonucleotidases present 
on the rat duodenum longitudinal muscle, as well as a further more in-depth 
investigation into the stereoselectivity of the ectonucleotidases present on the rat 
duodenum muscularis mucosae would be of interest, not only in terms of potential 
differences between the two muscle layers, but also in relation to differences 
between the ectonucleotidases in tissues of the gastrointestinal tract and other 
visceral and vascular smooth muscles.
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